SEQUENCE ENCODING MAMMALIAN SULFONYLUREA RECEPTOR AND METHOD OF DETECTING PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA OF INFANCY

Abstract: The present invention is directed to a method of detecting persistent hyperinsulinemic hypoglycemia of infancy comprising obtaining a sample comprising patient nucleic acids from a patient tissue sample; amplifying sulfonylurea receptor specific nucleic acids from said patient nucleic acids to produce a test fragment; obtaining a sample comprising control nucleic acids from a control tissue sample; amplifying control nucleic acids encoding wild type sulfonylurea receptor to produce a control fragment; comparing the test fragment with the control fragment to detect the presence of a sequence difference in the test fragment, wherein a difference in said test fragment indicates persistent hyperinsulinemic hypoglycemia of infancy. A diagnostic kit and primers for the detection of persistent hyperinsulinemic hypoglycemia of infancy are also within the scope of the present invention.

Description: SEQUENCE ENCODING MAMMALIAN SULFONYLUREA RECEPTOR AND METHOD OF DETECTING PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA OF INFANCY REFERENCE TO RELATED APPLICATIONS This application is a continuation-in-part of U.S. patent application Serial No. 08/226,972, filed April 13, 1994, the disclosure of which is hereby incorporated by reference in its entirety. REFERENCE TO GOVERNMENT GRANTS This work was supported in part by research grants from the National Institutes of Health, grant number NIH R01DK41898 and R01DK44311. The United States Government may have certain rights in this invention. BACKGROUND OF THE INVENTION Sulfonylureas are oral hypoglycemics widely used in the treatment of Non-Insulin Dependent Diabetes Mellitus (NIDDM) . They enter the bloodstream, bind with high affinit to a pancreatic β-cell plasma membrane protein termed the sulfonylurea receptor, and stimulate insulin release. The mechanism of stimulation is thought to be through inhibition of an ATP-sensitive K+ channel (K ATP ) , a key protein which sets the /S-cell resting membrane potential (Ashcroft, et al. Cell . Signal . 1990, 2, 197-214, all references cited herein are incorporated by reference in their entirety) . A reduction in potassium outflow causes depolarization of the plasma membrane, activation of L-type voltage-dependent calcium channels (VDCCs) , and increased cytosolic calcium. This triggers insulin release by as yet unknown mechanisms (Rajan, et al. Diabetes Care 1990, 13 , 340-363). In NIDDM patients on sulfonylureas, the consequent reduction in blood glucose to more normal levels is thought to be critical in controlling the disease (Gerich, J.E. New Engl . J. Med . 1989 321 , 1231-1245) . The biochemistry of the sulfonylurea receptor (SUR) (Ashcroft et al Biochem . Biophys Acta 1992, 1175 , 45-49 and Panten et al. Horm . Metab . Res . 1992, 24 , 549-554) is consistent with the electrophysiology of the /3-cell K ATP channel. The endogenous regulators of channel activity include cytosolic nucleotides (ATP and Mg-ADP) and possibly phosphorylation. In the absence of cytosolic nucleotides, sulfonylureas weakly inhibit channel activity (Schwanstecher et al. Br. J. Pharmacol 1992, 107 , 87-94). When channels are activated by Mg-ADP, inhibition by ATP is strongly promoted by the presence of sulfonylureas. These results are interpreted as evidence that simultaneous occupancy of two nucleotide binding sites is required for effective channel inhibition by the sulfonylureas. The reported allosteric interactions correlate well with evidence that the brain receptor has two nucleotide binding sites (de Weille, et al. J. Biol . Chem 1992, 267, 4557-4563) physically located on the same polypeptide chain as the sulfonylurea binding site (Bernardi et al. Biochemistry 1992, 31 , 6328-6332). One binding site appears to be specific for ATP, and is proposed to be the same site at which micromolar concentrations of ATP inhibit the K ATP channel. A second site has high affinity for Mg-ADP, with occupancy at this site promoting channel opening. Absolute concentrations of ATP and ADP in the cell are thought to regulate channel activity in a straightforward fashion (Hopkins et al. J. Membrane Biol . 1992, 129 , 287- 295) . High ATP concentrations as a result of high serum glucose levels close the channel, stimulating insulin secretion. Reduced glucose levels increase intracellular ADP concentrations, and thereby increase the open channel probability, and decrease insulin secretion. Although sulfonylureas, particularly tolbuta ide and more potent second generation drugs like glyburide and glipizide, are considered to be relatively specific inhibitors of the K ATP channel, the exact relationship between the sulfonylurea receptor and the K ATP channel is not clear (Nichols et al. Am . J . Physiol . 1991, 261 , H1675-H1686, Takano et al. Progress in Neurobiology 1993, 41 , 21-30, and Edwards et al. Annu. Rev. Pharmacol . Toxicol . 1993, 33 , 597- 637) . In the insulin-secreting CRI-G1 cell line, the addition of glyburide, or tolbutamide to inside-out plasma membrane patches inhibits the K ATP channel (Khan et al. Proc. R . Soc . Lond . B . 1993, 253 , 225-231), intimating direct interactions between sulfonylureas and the channel protein. In another insulin secreting cell line, CRI-D11 cells, however, the loss of sulfonylurea binding sites with the retention of K ATP activity suggests these two activities may uncouple and reside on separate, transiently bound subunits (Khan et al. Proc . R . Soc. Lond. B . 1993, 253 , 225-231). Similarly, in other cell and tissue types, sulfonylurea binding and channel activity may be uncoupled (Ashford et al Br. J. Pharmac. 1990, 101 , 531-540). A technique is not currently available to assess whether K ATP activity resides within the same polypeptide containing the putative nucleotide and sulfonylurea binding sites, or on separate loosely, or tightly bound subunits. A previous attempt to purify the receptor from hamster insulin-secreting tumor (HIT) cells was limited by the low abundance of the receptor and the presence of a more abundant co-purifying protein. Aguilar-Bryan, L. , et al . , JBC, 1990, 265 , 8218. The sulfonylurea receptor is the target for drugs used in the treatment of type II diabetes (non-insulin diabetes mellitus) . This association has suggested it plays a role in the regulation of insulin secretion by glucose and makes the sulfonylurea receptor a potential diabetes candidate gene. Persistent hyperinsulinemic hypoglycemia of infanc (PHHI) is an autosomal recessive disorder of glucose homeostasis characterized by unregulated secretion of insuli and profound hypoglycemia. A. Aynsley-Green et al., Arch . Dis . Child. 1981, 56, 496. The pathophysiolσgy of this disease remains obscure, but in vitro studies suggest a defect of glucose-regulated insulin secretion in pancreatic islet /3-cells. Aynsley-Green et al., supra . , N. Kaiser et al., Diabetologia 1990, 33 , 482. The incidence of PHHI has been estimated at 1/50,000 live births in a randomly mating population. G.J. Bruining, Curr. Opin . Pediatr. 1990, 2, 758. However, in a Saudi Arabian population in which 51% of births occurred to parents who were first or second cousins, the incidence has been established as 1/2675 live births. P.M. Mathew et al., Clin . Pediatr. 1988, 27, 148. Recently, the PHHI gene was assigned to chromosome llpl415.1 by linkage analysis. B. Glaser et al., Nature Genet . 1994, 7, 185 and P.M. Thomas, G.J. Cote, D.M. Hallman, P.M. Mathew, Am . J. Hum . Genet . 1995, 56, 416-421. Candidate genes for this disorder include those involved in the β-cell glucose sensing mechanism and insulin secretion. Localization of PHHI to chromosome lip excluded previously mapped genes involved in 3-cell function. Considered as a candidate was the newly cloned high-affinity SUR gene, a member of the ATP-binding cassette superfamily, and a putative subunit of the modulator of insulin secretion, the / 3-cell ATP-sensitive potassium channel (K ATP ) . S.J. Ashcroft and F. M. Ashcroft, Biochimica et Biophyεica Acta , 1992, 1175 , 45; U. Panten, M. Schwanstecher, and C. Schwanstecher, Horm . Metab . Res . 1992, 24 , 549. The methods of the present invention map the sulfonylurea receptor to the same chromosomal location as PHHI and provide evidence that mutations in the sulfonylurea receptor are the cause of PHHI. Accordingly, there remains a need to identify sulfonylurea receptor and sequences encoding sulfonylurea receptor which will provide: 1. a correlation between sulfonylurea receptor and one or more forms of diabetes, 2. a sequence to purify human sulfonylurea receptors, 3. an isolated sulfonylurea receptor, prepared by recombinant methods, 4. polyclonal and monoclonal antibodies and methods of preparing the same against sulfonylurea receptor, 5. information as to whether this receptor-ion channel family involves multi-subunits within each channel for channel activity, 6. gene therapy such that sequences which encode mutant sulfonylurea receptors are replaced by wild type sulfonylurea receptor sequences, 7. a method of screening to identify drugs which react with and bind to the sulfonylurea receptor, 8. non-human transgenic animals to study diabetes and PHHI, and the physiologic effects of varying levels of sulfonylurea receptor, by using an inducible promoter to regulate the expression of the sulfonylurea receptor, for example, and 9. probes, including PCR probes, for diagnosing conditions associated with the expression of a specific sulfonylurea receptor allele. The present invention reveals that the sequence encoding the mammalian sulfonylurea receptor maps to the sequence encoding persistent hyperinsulinemic hypoglycemia o infancy. SUMMARY OF THE INVENTION The present invention provides sequences encoding a sulfonylurea receptor. Nucleic acid sequences, SEQ ID NO: 1 4, 6, 26, 27, 32, 33, 35, and 36 are cDNA sequences to which the present invention is directed. The nucleic acid sequences, SEQ ID NOS: 2 and 3, may be added to the 5' end SEQ ID NO: 1 to furnish a sequence encoding a sulfonylurea receptor. SEQ ID NOS: 32, 33, 35 and 36 are rodent sequence (SEQ ID NOS: 32 and 33 - rat, SEQ ID NOS: 34 and 35 - hamster) encoding sulfonylurea receptor which functionally bind sulfonylurea. SEQ ID NOS: 26 and 27 are human sequence which encode sulfonylurea receptor. SEQ ID NOS: 27, 33, and 36 set forth DNA sequences translated into amino acid sequences, which set forth below the DNA sequence. A further aspect of the present invention provides sulfonylurea receptor polypeptides and/or proteins. SEQ ID NOS: 4, 5, 6, 7, 26, and 28 are novel polypeptides of the invention produced from nucleotide sequences encoding rat (SEQ ID NOS: 4, 5, and 34), hamster (SEQ ID NOS: 6, 7, and 37) , and human (SEQ ID NOS: 26 and 28) sulfonylurea receptor, respectively. Also within the scope of the present invention is a purified sulfonylurea receptor. The present invention also provides nucleic acid sequences encoding a sulfonylurea receptor, expression vectors comprising a nucleic acid sequence encoding a sulfonylurea receptor, transformed host cells capable of expressing a nucleic acid sequence encoding a sulfonylurea receptor, cell cultures capable of expressing a sulfonylurea receptor, and protein preparations comprising a sulfonylurea receptor. A method of detecting persistent hyperinsulinemic hypoglycemia of infancy comprising obtaining a sample comprising patient nucleic acids from a patient tissue sample; amplifying sulfonylurea receptor specific nucleic acids from said patient nucleic acids to produce a test fragment; obtaining a sample comprising control nucleic acids from a control tissue sample; amplifying control nucleic acids encoding wild type sulfonylurea receptor to produce a control fragment; comparing the test fragment with the control fragment to detect the presence of a sequence difference in the test fragment, wherein a difference in said test fragment indicates persistent hyperinsulinemic hypoglycemia of infancy is also an embodiment of the present invention. Other methods of the present invention include a method of detecting persistent hyperinsulinemic hypoglycemia of infancy comprising obtaining a sample comprising patient mRNA from a patient tissue sample; reverse transcribing said mRNA into cDNA to produce patient cDNA; amplifying sulfonylurea receptor specific cDNA from said patient cDNA to produce amplified patient cDNA; obtaining a sample comprising control nucleic acids from a control tissue sample; amplifying control DNA encoding wild type sulfonylurea receptor to produce control cDNA; digesting said test fragment and said control fragment with a selected endonuclease; and comparing the test fragment to the control fragment, wherein said test fragment indicates persistent hyperinsulinemic hypoglycemia of infancy. Another embodiment of the present invention is a diagnostic kit for detecting persistent hyperinsulinemic hypoglycemia of infancy comprising in one or more containers a pair of primers, wherein one primer within said pair is complementary to a region of the sulfonylurea receptor, wherein one of said pair of primers is selected from the group consisting of SEQ ID NOS: 16-24, a probe specific to the amplified product, and a means for visualizing amplified DNA, such as and not limited to fluorescent stain, P, and biotin, and optionally including one or more size markers, positive and negative controls, and restriction endonucleases. Still another embodiment of the present invention includes the primer sequences identified in SEQ ID NOS: 16- 24. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 displays characteristics of the purified HIT cell receptor. The radiolabeled receptor (lanes 1 and 3 cleaved with endoglycosidase F/N-glycosidase F (endo F) , increases the mobility of the protein by approximately 3 kDa (lane 2) . Subsequent partial V8 protease digestion (lanes 4 and 6) yielded radiolabeled fragments that also shift mobility with endo F treatment (lane 5) . Each of these species has the same N-terminal sequence (left side of figure) , except that receptor deglycosylation results in an Asp at residue 9. Figure 2A shows that antibodies against residues 10-20 specifically recognize the 140 kDa polypeptide. Purified 140 kDa polypeptide was electrophoresed on a single lane of a 6% SDS gel and transferred to Immobilon P. The Immobilon P was placed in a miniblotter and the lanes incubated as follows: Lane 1 - Preimmune serum. Lane 2 - Immune serum. Lane 3 -Immune serum + immunogen. Lane 4 - immune serum + irrelevant MAP peptide. The filter was further incubated with a second antibody (goat anti-rabbit conjugated to alkaline phosphatase) and developed with the appropriate substrates. Figure 2B displays antibodies which recognize a polypeptide with the appropriate mobility shift following Endo F treatment. Purified receptor (lane 1) was incubated for 30 min at 37 °C in the presence (lane 2) , or absence (lane 3) of endoglycosidase F/N-glycosidase F, incubated with first (anti-MAP 10-20) and second antibody, and developed with substrate. The bottom panel shows the autoradiogram of the immunoblot in the top panel. Figure 2C shows antibodies which immunoprecipitate the photolabeled 140 kDa receptor. HIT cell membranes were incubated with 125I- labeled iodoglyburide, photolabeled, solubilized with 1% digitonin, centrifuged at 100,000 x g and the supernatant (lane 1) incubated with preimmune serum (lane 2) , immune serum (lane 3), immune serum + anti-MAP 10-20 (lane 4) and immune serum + irrelevant MAP peptide (lane 5) . Samples were co-incubated with protein A-Sepharose, the beads washed with buffer, heated in the presence of pH 9 sample buffer, electrophoresed on a 6% polyacrylamide SDS gel, and an autoradiogram prepared. Results using antibodies against receptor residues 1-8 were the same as those using antibodies against residues 10-20. Multiple antigenic peptides (MAPS) were synthesized (Posnett et al. J. Biol . Chem . 1988 263:1719-1725) and polyclonal antibodies generated in rabbits produced by standard methods (Antibodies: A Laboratory Manual Cold Spring Harbor Laboratory 1988) . Interdermal injections of 1 mg of antigen were spaced 2-3 weeks apart, and contained complete, or incomplete Freund's adjuvant Figure 3 shows the nucleotide sequence of cDNAs encoding the high affinity sulfonylurea receptors from rat and hamster together with the deduced amino acid sequences. DNA sequencing was performed by the dideoxy chain terminatio method with S-labeled nucleotides. Numbers on the left of each column indicate the nucleotide positions; numbers on th right of each column indicate the amino acid positions. The amino acid sequence of four peptides determined by chemical methods are marked in bold italics. The putative ATP-bindin domains are shown underlined and the Walker (Walker et al. EMBO Jour. 1982 1:945-951) "A" and "B" consensus sequences are boxed in dotted lines. The Walker A sequence, GXXGXGK (SEQ ID NO: 14) and B sequence, X 1 X 1 X 1 D (SEQ ID NO: 15) (wher X is a hydrophobic amino acid) are part of a common nucleotide binding fold found in a number of nucleotide binding proteins. The G residues in the A sequence interact with a phosphate in the nucleotide. Possible sites of phosphorylation by protein kinase A (closed diamonds) and C (open diamonds) are indicated. Potential transmembrane spanning helices assigned using the algorithm of Eisenberg e al. (Eisenberg, et al. J. Mol . Biol . 1984 179:125) are boxed The nucleotide sequence and first row of amino acid sequence are for the rat; the amino acid sequence differences are given in the second row for the hamster. A consensus poly A addition site is indicate in bold at the 3' end of the cDNA. Abbreviations for the amino acid residues are: A, ala; C, cys; D, asp; E, glu; F, phe; G, gly; H, his; I, ile; K, lys; L, leu; M, met; N, asn; P, pro; Q, gin; R, arg; S, ser, T, thr; V, val; W, trp; and Y, tyr. Figure 4 displays the deduced amino acid sequence of the sulfonylurea receptor aligned with the amino acid sequence of a MRP, multidrug resistance-associated protein, (dvhuar) . The alignment was generated with PILEUP from the Genetics Computer Group package (Madison, WI) (Genetics Computer Group Program Manual for the GCG Package Version 7 1991) using a modification of the algorithm of Feng and Doolittle (Feng, et al. J. Mol . Evol . 1987 25:351). Figure 5 exhibits the sequence comparison of nucleotide binding folds. The alignment was generated using the PILEUP program as described in Figure 4. The Walker A and B consensus sites are given in boldface. Upper case letters indicate a match to the consensus sequence generated using the pretty program (Genetics Computer Group, Madison, WI) . Figure 6 is a northern blot of total RNA from α- and /3-cell lines hybridized with a 2.2 kb EcoRI-Xhol fragment of the sulfonylurea receptor. Approximately 10 μg of RNA from (A) αTC-6 cells, (B) HIT cells, (C) RIN cells and (D) mouse liver was analyzed using standard procedures (Ausubel et al. Current Protocols in Mol . Biol . 1994). The estimated size of the major component is approximately 5000 nucleotides. Figure 7 displays a hydrophobicity profile of the Rat Sulfonylurea receptor. Hydrophobicity values were determined according to Kyte and Doolittle (Kyte et al. J. Mol . Biol . 1982 157:105-132) for ll-residue peptides and are plotted versus the amino acid number. The bars marked A and B are over the Walker A and B consensus sequences Walker et al. EMBO Jour . 1982 1:945-951). Figure 8 shows a schematic model of the high affinity sulfonylurea receptor. The Walker A and B sites are marked within the two nucleotide binding folds. Based on the hydrophobicity and hydrophobic moment data there are nine transmembrane spanning domains before the first nucleotide binding fold and four transmembrane spanning domains between the two folds. The branched structure at the N-terminus of the mature receptor symbolizes glycosylation. Figure 9A reveals the results of in vitro translation of mRNA transcribed from the rat sulfonylurea cDNA. The cDNA was subcloned into pGEM4 (Promega, Inc., Madison, WI) and transcribed using the SP6 promoter and SP6 RNA polymerase following the manufacturer's directions. RNA was translated in rabbit reticulocyte lysate (Promega, Inc.) following the manufacturer's recommendations for S- methionine. Lane 1 is the HIT cell photolabeled receptor as a marker, lane 2 is the in vitro translation product resulting from addition of receptor mRNA and lane 3 is the result of no added RNA. The arrow marks the 140 kDa protein Figure 9B displays a gel of the results of immunoprecipitation of the RIN cell sulfonylurea receptors with polyclonal antibodies directed against a nucleotide binding fold domain (NBF) . Lane 1; 140 and 150 kDa receptor from soluble RIN cell membrane proteins, lane 2; immunoprecipitation with preimmune serum, lane 3; immune serum from rabbit immunized with NBF2, lane 4; immune serum NBF2 fusion protein. Sulfonylurea receptor cDNA regions encoding the NBF2 domain was subcloned in frame into pMALc and expression of the proteins fused with maltose binding protein induced in E. coli . Fusion proteins were purified b electrophoresis and electroelution, and 200μg amounts, with complete, or incomplete Freund's adjuvant, injected interdermally into rabbits using a standard 2-3 week regimen of bleeding and boosting. Figure 10 displays the genomic organization and cDNA sequence of the human sulfonylurea receptor (SUR) homologue in the second nucleotide binding fragment region (NBF-2) . The sequence encoding NBF-2 is located within SEQ ID NO: 26, nucleic acid positions 524 to 1048. Solid rectangles represent exons which are labeled a-φ for identification. The numbers between rectangles represent intronic sizes. Primers used in mutational analysis are diagrammed and listed in SEQ ID NOS: 16-24. Figure 11A-D display the exon mutation in the SUR NBF-2. Figures 11A is a schematic representation of NBF-2 exons β, X, S illustrating the normal (upper) and mutant (lower) RNA splicing patterns. Figure 11B displays the sequence of a pancreatic cDNA product, from an affected chil of Family 6, demonstrating the exon skipping event. Skippin of exon X results in a 109 bp deletion in the mRNA transcript, a frame shift and inclusion of a premature stop codon. Single upper case letters represent amino acids. Figure 11C shows the sequence of genomic DNA from the affected patient in Figure 11B which reveals a G to A point mutation at the 3' end of the exon, which exon is excised in mRNA, as compared to a normal sample of genomic DNA. Exonic sequence is in upper case and intronic sequence in lower case letters. Figure 11D shows Mspl restriction enzyme analysis of PCR-amplified genomic DNA from members of Family 6, indicating affected individuals. The G to A mutation destroyed a restriction site for Mspl (C/CGG) . Normal PCR product is digested into 304 bp, 85 bp, and 38 bp fragments, while that containing the mutation is digested into 304 bp and 123 bp fragments. MW is 100 bp ladder (GIBCO-BRL, Gaithersburg, Maryland) , UC is an uncut sample, C is a control PCR reaction lacking template. Figure 12A-D reveal a mutation in the intron preceding NBF-2 exon a , which activates cryptic 3' splice site usage. Figure 12A displays the sequence of genomic DNA from an affected member of Family 4 which revealed a G to A mutation in the splice site preceding the first exon of the NBF-2. Figure 12B shows Weil restriction enzyme analysis of genomic DNA from members of Family 4, indicating affected individuals. The G to A mutation destroys a restriction site for Weil (CC/(G/C)GG) . Normal PCR product is digested into 71 bp and 75 bp fragments, while that containing the mutant sequence is not cut. By previous haplotype analysis, the unaffected sibling in this family had two wild type alleles, P.M. Thomas, G.J. Cote, D.M. Hall an, P.M. Mathew, Am. J. Hum . Genet . , supra . Figure 12C illustrates the constructs used to examine RNA processing of exons within NBF-2. Solid rectangles and thin lines represent human SUR gene exonic and intronic sequences, respectively. The unmarked solid rectangle represents a portion of the exon which is 5' to exon α of the NBF-2 region. That labeled RSV represents the enhancer and promoter isolated from the rous sarcoma virus long terminal repeat. The thick line represents an intronic sequence derived from vector and the human metallothionine IIA gene, which also contains polyadenylation signals. Normal and mutant RNA splicing patterns, including the location of the three cryptic splice sites, are diagrammed in the lower portion. The open triangle marks the position of the mutated base within the splice site. Figure 12D shows PCR amplification across splice site of normal (N) and mutant (M) cDNA transcripts, isolated 48 hours after transfection with the splicing constructs. Subcloning and sequencing of these products revealed their identity as diagrammed in Figure 12C. The control (C) represents cDNA amplified from untransfected cells. DETAILED DESCRIPTION OF THE INVENTION The present invention is directed to the nucleic acid and protein sequences encoding a sulfonylurea receptor. The present invention provides a nucleotide sequence of a sulfonylurea receptor, Figure 3, and SEQ ID NOS: 1, 4, 6, 33, and 36. Novel polypeptide sequences, SEQ ID NOS: 4, 5, 6, 7, 34, and 37 coding for a sulfonylurea receptor are also included in the present invention. SEQ ID NOS: 26, 27, and 28 provide the nucleic acid and amino acid sequences of the last 11 exons of the 3' end of human sulfonylurea receptor, hereinafter referred to, together with the rodent sequences for sulfonylurea receptor, as sequence for the sulfonylurea receptor. SEQ ID NO: 1 provides the cDNA sequence of a rodent sulfonylurea receptor. SEQ ID NOS: 26 and 27 provide the human genomic DNA sequence of sulfonylurea receptor. Nuclei acids within in the scope of the present invention include cDNA, RNA, genomic DNA, sequences within these larger sequences, antisense oligonucleotides. Sequences encoding the sulfonylurea receptor also include amino acid, polypeptide, and protein sequences. Variations in the nucleic acid and polypeptide sequences of the present invention are within the scope of the present invention and include N terminal and C terminal extensions, transcription and translation modifications, and modifications in the cDNA sequence to facilitate and improve transcription and translation efficiency. In addition, mismatches within the sequences identified herein, which achieve the methods of th invention, such that the mismatched sequences are substantially complementary to the sulfonylurea receptor sequences identified, are also considered within the scope of the present invention. Mismatches which permit substantial 5 complementarity to the sulfonylurea receptor sequences, such as similarity in residues in hydrophobicity, will be known to those of skill in the art once armed with the present disclosure. In addition, the sequences of the present invention may be natural or synthetic. 0 SEQ ID NOS: 2 and 3 are rat and hamster sequences, respectively, which may be added to SEQ ID NO: 1 at the 5' end preceding the coding region of the sulfonylurea gene. The cDNA and amino acid sequences identified in Figure 3 indicate several amino acid residue differences 15 between rat and hamster sulfonylurea receptor. These differences are indicated in the corresponding nucleic acid sequence of SEQ ID NO: 1 by an "N" in the positions which result in different amino acids. Accordingly, "N" appears in SEQ ID NO: 1, at nucleic acid positions 586, 752, 802, 842, 20 1204, 1318, 1518, 1711, 2000, 2009, 2245, 2275, 2278, 2280, 2281, 2288, 2305, 2383, 2384, 2518, 2540, 2548, 2848, 2850, 2913, 3173, 3208, 3230, 3463, 3601, 3751, 4442. "N" may be any nucleic acid residue which provides an amino acid which results in a sulfonylurea receptor. For example, SEQ ID NOS: 25 4 and 6 provide cDNAs of rat and hamster, respectively, where N of SEQ ID NO: 1 is identified as a particular nucleic acid such that a corresponding amino acid may be provided in the protein. In addition, an Asparagine is inserted in the hamster sequence at amino acid position 740 and a threonine 30. is deleted in the hamster sequence at amino acid position 831. The N positions indicated for SEQ ID NO: 1 result in differences in the rat and hamster sequences provided in SEQ ID NOS: 4 and 5 (rat) , 6 and 7 (hamster) at amino acid positions 196 - Val, Ile; 251 - Gly, Ala; 268 - Leu, Val; 281 35 - Gin, Pro; 300 - Val, Ile; 402 - Leu, Met; 440 - Ala, Thr; 491 - Tyr, His; 506 - He, Met; 516 - Asn, Ser; 524 - Lys, Val; 571 - Phe, Leu; 667 - Thr, Ala; 670 - Thr, Met; 749 - Arg, 750 - Gly; 759 - Gly, 760 - Ser; 760 - Arg, 761 - Trp; 761 - Phe, 762 - Leu; 763 - Cys, 764 - Tyr; 769 - Cys, 770 - Arg; 795 - Lys, 796 - Pro; (two series of numbers appear due to the asparagine deletion in the hamster sequence, the hamster codon is represented by the second number) 840 - Arg Gly; 847 - Thr, Arg; 850 - Ile, Phe; 950 - Pro, Ser; 971 - Asp, Glu; 1058 - Ala, Asp; 1070 - Val, Leu; 1077 - Ala, Val; 1155 - Ala, Thr; 1201 - Leu, Val; 1251 - Arg, Cys; and 1481 Lys, Thr. In addition, the hamster sequence has an Asn insert at position 741 and a Thr deletion at position 831. A purified sulfonylurea receptor is also provided by the present invention. The purified sulfonylurea recepto may have an amino acid sequence as provided by SEQ ID NOS: 4 5, 6, 7, 34, and 37. A purified sulfonylurea receptor havin the amino acid sequence of SEQ ID NO: 28 is also within the scope of the present invention. The present invention is directed to sulfonylurea receptor sequences obtained from mammals from the Order Rodentia, including and not limited to hamsters, rats, and mice; Order Logomorpha, such as rabbits; more particularly the Order Carnivora, including Felines (cats) and Canines (dogs); even more particularly the Order Artiodactyla, Bovines (cows) and Suines (pigs) ; and the Order Perissodactyla, including Equines (horses) ; and most particularly the Order Primates, Ceboids and Simoids (monkeys) and Anthropoids (humans and apes) . The mammals of most preferred embodiments are humans. There are several transfection techniques by which a sulfonylurea receptor may be obtained. An appropriate RNA may be hybridized to a cDNA to obtain a sulfonylurea recepto nucleic acid sequence. A nucleic acid sequence encoding sulfonylurea receptor may be inserted into cells and the corresponding protein immunoprecipitated with an antibody. Labeled drugs known to bind sulfonylurea receptor protein ma be added to cell culture to label the receptor. The drug labeling procedure may involve modifying cells such that the cell culture provides conditions similar to β cells, cells where sulfonylurea receptors naturally appear; and the sulfonylurea receptor may be part of a larger multisubunit ATP receptor channel, which may not be provided by the cells in culture. Generally, the sequences of the invention may be produced in host cells transformed with an expression vector comprising a nucleic acid sequence encoding the sulfonylurea receptor. The transformed cells are cultured under conditions whereby the nucleic acid sequence coding for the sulfonylurea receptor is expressed. After a suitable amount of time for the protein to accumulate, the protein is purified from the transformed cells. A gene coding for sulfonylurea receptor may be obtained from a cDNA library. Suitable libraries can be obtained from commercial sources such as Clontech, Palo Alto, CA. Libraries may also be prepared using the following non- limiting examples hamster insulin-secreting tumor (HIT) , mouse αTC-6, and rat insulinoma (RIN) cells. Positive clones are then subjected to DNA sequencing to determine the presence of a DNA sequence coding for sulfonylurea receptor. DNA sequencing is accomplished using the chain termination method of Sanger et al . , Proc . Nat 'l . Acad . Sci, U .S .A . , 1977, 74 , 5463. The DNA sequence encoding sulfonylurea receptor is then inserted into an expression vector for later expression in a host cell. Expression vectors and host cells are selected to form an expression system capable of synthesizing sulfonylurea receptor. Vectors including and not limited to baculovirus vectors may be used in the present invention. Host cells suitable for use in the invention include prokaryotic and eukaryotic cells that can be transformed to stably contain and express sulfonylurea receptor. For example, nucleic acid coding for the recombinant protein may be expressed in prokaryotic or eukaryotic host cells, including the most commonly used bacterial host cell for the production of recombinant proteins, E . coli . Other microbial strains may also be used, however, such as Bacillus subtilis , and other enterobacteriaceae such as Salmonella typhimurium or Serratia marcescens, various species of Pseudomonas, or other bacterial strains. Commonly used eukaryotic systems include yeast, such as Saccharomyces cerevisiae ; insect cells, such as Spodoptera frugiperda ; chicken cells, such as E3C/0 and SL- 29; mammalian cells, such as HeLa, Chinese hamster ovary cells (CHO), COS-7 or MDCK cells and the like. The foregoin list is illustrative only and is not intended in any way to limit the types of host cells suitable for expression of the nucleic acid sequences of the invention. As used herein, expression vectors refer to any type of vector that can be manipulated to contain a nucleic acid sequence coding for sulfonylurea receptor, such as plasmid expression vectors and viral vectors. The selection of the expression vector is based on compatibility with the desired host cell such that expression of the nucleic acid encoding sulfonylurea receptor results. Plasmid expression vectors comprise a nucleic acid sequence of the invention operably linked with at least one expression control element such as a promoter. In general, plasmid vectors contain replicon and control sequences derived from species compatible with the host cell. To facilitate selection of plasmids containing nucleic acid sequences of the invention, plasmid vectors may also contain a selectable marker such as a gene coding for antibiotic resistance. Suitable examples include the genes coding for ampicillin, tetracycline, chloramphenicol or kanamycin resistance. Suitable expression vectors, promoters, enhancers, and other expression control elements are known in the art and may be found in Sambrook et al., Molecular Cloning: A Laboratory Manual , second edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989) , incorporate herein by reference in its entirety. Transformed host cells containing a DNA sequence encoding sulfonylurea receptor may then be grown in an appropriate medium for the host. The cells are then grown until product accumulation reaches desired levels at which time the cells are then harvested and the protein product purified in accordance with conventional techniques. Suitable purification methods include, but are not limited to, SDS PAGE electrophoresis, phenylboronate-agarose, reactive green 19-agarose, concanavalin A sepharose, ion exchange chromatography, affinity chromatography, electrophoresis, dialysis and other methods of purification known in the art. Protein preparations, of purified or unpurified sulfonylurea receptor produced by host cells, are accordingly produced which comprise sulfonylurea receptor and other material such as host cell components and/or cell medium, depending on the degree of purification of the protein. Antibodies, including and not limited to monoclonal, polyclonal, and chimeric, prepared and used against a sulfonylurea receptor are also within the scope of the present invention, and may be prepared by methods known to those of skill in the art such as and not limited to the methods of Kohler and Milstein, Nature , 256: 495-497 (1975), incorporated herein by reference in its entirety. The invention also includes a transgenic non-human animal, including and not limited to mammals, such as and not limited to a mouse, rat, or hamster, whose germ cells and somatic cells contain a sequence encoding a sulfonylurea receptor introduced into the animal or an ancestor of the animal. The sequence may be wild-type or mutant and may be introduced into the animal at the embryonic or adult stage. The sequence is incorporated into the genome of an animal such that it is chromosomally incorporated into an activated state. Embryo cells may be transfected with the gene as it occurs naturally, and transgenic animals are selected in which the gene has integrated into the chromosome at a locus which results in activation. Other activation methods include modifying the gene or its control sequences prior to introduction into the embryo. The embryo may be transfected using a vector containing the gene. In addition, a transgenic non-human animal may be engineered wherein the sulfonylurea receptor is suppressed. For purposes of the present invention, suppression of the sulfonylurea receptor includes, and is not limited to strategies which cause the sulfonylurea receptor not to be expressed. Such strategies may include and are not limited to inhibition of protein synthesis, pre-mRNA processing, or DNA replication. Each of the above strategies may be accomplished by antisense inhibition of sulfonylurea recepto gene expression. Many techniques for transfering antisense sequences into cells are known to those of skill, including and not limited to microinjection, viral-mediated transfer, somatic cell transformation, transgene integration, and the like, as set forth in Pinkert, Carl, Transgenic Animal Technology, 1994, Academic Press, Inc., San Diego, CA, incorporated herein by reference in its entirety. Further, a transgenic non-human animal may be prepared such that the sulfonylurea receptor gene is knocked out. For purposes of the present invention, a knock out includes and is not limited to disruption or rendering null the sulfonylurea receptor gene. A knock out may be accomplished, for example, with antisense sequences for the sulfonylurea receptor mutating the sequence for the sulfonylurea receptor. The sulfonylurea receptor gene may b knocked out by injection of an antisense sequence for all or part of the sulfonylurea receptor sequence such as an antisense sequence for all or part of SEQ ID NO: 27. Once the sulfonylurea receptor has been rendered null, correlatio of the sulfonylurea receptor to persistent hyperinsulinemic hypoglycemia of infancy may be tested. Sequences encoding mutations affecting the sulfonylurea receptor may be inserte to test alterations in glucose homeostasis. Also in transgenic non-human animals, the sulfonylurea receptor may be replaced by preparing a construct having an insulin promoter ligated to the sulfonylurea receptor gene. This experiment permits testing of mutant sulfonylurea receptors directly in the pancreas of the transgenic animal. Transgenic non-human animals may also be useful for testing nucleic acid changes to identify nucleotides which are responsible for ADP and ATP modulation of the sulfonylurea receptor resulting in an increase or decrease in glucose sensitivity of insulin release. The present invention is also directed to gene therapy wherein a mutant sulfonylurea receptor is replaced by a wild type sulonylurea receptor. A resulting transgenic non-human animal thus comprises a recombinant sulfonylurea receptor. In addition, gene therapy techniques may be used for individuals with persistent hyperinsulinemic hypoglycemia of infancy. For purposes of the present invention, gene therapy refers to the transfer and stable insertion of new genetic information into cells for the therapeutic treatment of diseases or disorders. The foreign gene is transferred into a cell that proliferates to spread the new gene throughout the cell population. Known methods of gene transfer include microinjection, electroporation, liposomes, chromosome transfer, transfection techniques, calcium-precipitation transfection techniques, and the like. Numerous techniques are known in the art for the introduction of foreign genes into cells and may be used to construct the recombinant cells for purposes of gene therapy, in accordance with this embodiment of the invention. The technique used should provide for the stable transfer of the heterologous gene sequence to the stem cell, so that the heterologous gene sequence is heritable and expressible by stem cell progeny, and so that the necessary development and physiological functions of the recipient cells are not disrupted. Techniques which may be used include but are not limited to chromosome transfer (e.g., cell fusion, chromosome-mediated gene transfer, micro cell-mediated gene transfer), physical methods (e.g., transfection, spheroplast fusion, microinjection, electroporation, liposome carrier) , viral vector transfer (e.g., recombinant DNA viruses, recombinant RNA viruses) and the like (described in Cline, M. J. , 1985, Pharmac. Ther. 29:69-92, incorporated herein by reference in its entirety) . The term "purified", when used to describe the state of nucleic acid sequences of the invention, refers to nucleic acid sequences substantially free of nucleic acid no coding for sulfonylurea receptor or other materials normally associated with nucleic acid in non-recombinant cells, i.e., in its "native state." The term "purified" or "in purified form" when used to describe the state of a sulfonylurea receptor, protein, polypeptide, or amino acid sequence, refers to sulfonylurea receptor sequences free, to at least some degree, of cellula material or other material normally associated with it in it native state. Preferably the sequence has a purity (homogeneity) of at least about 25% to about 100%. More preferably the purity is at least about 50%. To begin to elucidate the relationship between the sulfonylurea receptor and K ATP , the iodinated derivative of glyburide was used to identify, and subsequently to purify and obtain N-terminal amino acid sequence from the 140 kDa high affinity, hamster insulin-secreting tumor (HIT) cell sulfonylurea receptor. The peptide sequence data was used t clone full length cDNAs encoding the rat and hamster /3-cell proteins of the present invention. Another embodiment of the present invention is a method of detecting persistent hyperinsulinemic hypoglycemia of infancy comprising obtaining a sample comprising patient nucleic acids from a patient tissue sample; amplifying sulfonylurea receptor specific nucleic acids from said patient nucleic acids to produce a test fragment; obtaining sample comprising control nucleic acids from a control tissu sample; amplifying control nucleic acids encoding wild type sulfonylurea receptor to produce a control fragment; comparing the test fragment with the control fragment to detect the presence of a sequence difference in the test fragment, wherein a difference in said test fragment indicates persistent hyperinsulinemic hypoglycemia of infancy is also an embodiment of the present invention. Persistent hyperinsulinemic hypoglycemia of infancy (PHHI) is an autosomal recessive disorder which results in unregulated insulin secretion. The present invention revealed several different mutations in the sulfonylurea receptor in individuals with PHHI. These mutations include nucleic acid transition and restriction fragment length polymorphism, both defined herein as sequence differences. The nucleic acid sequence transition may be a G to A transition at nucleic acid position 750 in SEQ ID NO: 26 which results in PHHI. This transition was found to occur in nine affected children in nine different families of the families studied. The pancreatic cDNA from a child with this transition involved skipping an exon. Exon X of Figure 10 was skipped resulting in an mRNA transcript having a 109 bp deletion, a frame shift, and the inclusion of a premature stop codon. This deletion may be seen by performing rtPCR on the child's mRNA. Amplification of SEQ ID NO: 26 resulted in a 427 base pair product for the normal as well as for the mutant genomic DNA. Digesting the normal and mutant products with Mspl , however, resulted in three fragments (304 bp, 85 bp, and 38 bp) for the normal gene and two fragments (304 bp and 123 bp) for the mutant gene of affected children. Another mutation involves a G to A transition in intron 11 of the human sulfonylurea receptor which gives rise to PHHI. The transition site corresponds to position 27 of SEQ ID NO: 29. The G to A transition destroys a restriction site for Neil. Both normal and mutant PCR products resulted in 146 bp. Digestion with WciJ resulted in two fragments (71 bp and 75 bp) fragments for normal individuals, while the mutant sequence was not be cut by Neil and thus remained at 146 bp. A method of detecting persistent hyperinsulinemic hypoglycemia of infancy comprising obtaining a sample comprising patient genomic DNA from a patient tissue sample; amplifying sulfonylurea receptor specific DNA from said patient genomic DNA to produce a test fragment; obtaining a sample comprising control nucleic acids from a control tissu sample; amplifying control DNA encoding wild type sulfonylurea receptor to produce a control fragment; comparing the test fragment with the control fragment to detect a test fragment having G to A transition at nucleic acid position 750 of SEQ ID NO: 26, or a G to A transition a nucleic acid position 27 of SEQ ID NO: 29, wherein said test fragment indicates persistent hyperinsulinemic hypoglycemia of infancy is also an embodiment of the present invention. Also within the scope of the present invention is a method of detecting persistent hyperinsulinemic hypoglycemia of infancy comprising obtaining a sample comprising patient mRNA from a patient tissue sample; reverse transcribing said mRNA into cDNA to produce patient cDNA; amplifying sulfonylurea receptor specific cDNA from said patient cDNA t produce a test fragment; obtaining a sample comprising control nucleic acids froma control tissue sample; amplifyin control DNA encoding wild type sulfonylurea receptor to produce a control fragment; digesting said test fragment and said control fragment with an endonuclease selected from the group consisting of WciJ and Mspl; and comparing the test fragment with the control fragment to detect a restriction fragment length polymorphism, wherein said restriction fragment length polymorphism indicates persistent hyperinsulinemic hypoglycemia of infancy. The restriction fragment polymorphisms include test fragments of about 304 bp and about 123 bp as a result of Mspl restriction and a test fragment of about 146 bp as a result of WciJ restriction. The test fragments thus indicat persistent hyperinsulinemic hypoglycemia of infancy. In accordance with methods of the present invention, methods of detecting PHHI in a patient are provided comprising obtaining a patient tissue sample for testing. The tissue sample may be solid or liquid, a body fluid sample such as and not limited to blood, serum, saliva sputum, mucus, bone marrow, urine, lymph, and a tear; and feces. In addition, a tissue sample such as pancreatic tissue may be provided for the detection of PHHI in accordance with the present invention. A test fragment is defined herein as an amplified sample comprising sulfonylurea receptor specific nucleic acids from a patient suspected of having PHHI. A control fragment is an amplified sample comprising normal or wild type sulfonylurea receptor specific nucleic acids from an individual not suspected of having PHHI. The method of amplifying nucleic acids may be the polymerase chain reaction using a pair of primers wherein at least one primer within the pair is selected from the group consisting of SEQ ID NO: 16-24. When the polymerase chain reaction is the amplification method of choice, a pair of primers may be used such that one primer of the pair is selected from the group consisting of SEQ ID NOS: 17, 18, 21, and 23 and the second primer of the pair is selected from the group consisting of SEQ ID NOS: 16, 19, 20, 22, and 24. Nucleic acids, such as DNA (such as and not limited to genomic DNA and cDNA) and/or RNA (such as and not limited to mRNA) , are obtained from the patient sample. Preferably RNA is obtained. A whole blood gradient may be performed to isolate nucleated cells and total RNA is extracted such as by the RNazole B method (Tel-Test Inc., Friendswood, Texas) or by modification of any methods known in the art such as described in Sambrook et al . , Molecular Cloning: A Laboratory Manual , 1989, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, incorporated herein by reference in its entirety. Nucleic acid extraction is followed by amplification of the same by any technique known in the art. The amplification step includes the use of at least one primer sequence which is complementary to a portion of sulfonylurea receptor specific expressed nucleic acids or sequences. Primer sequences useful in the amplification methods include and are not limited to SEQ ID NOS: 16-24, which may be used in the amplification methods. Any primer sequence of about 10 nucleotides to about 35 nucleotides, more preferably about 15 nucleotides to about 30 nucleotides even more preferably about 17 nucleotides to about 25 nucleotides may be useful in the amplification step of the methods of the present invention. In addition, mismatches within the sequences identified above, which achieve the methods of the invention, such that the mismatched sequences are substantially complementary and thus hybridizable to the sequence sought to be identified, are also considered within the scope of the disclosure. Mismatches which permit substantial similarity to SEQ ID NOS: 16-24, such as and not limited to sequences with similar hydrophobicity and hydrophilicity, will be known to those of skill in the art once armed with the present disclosure. The primers may als be unmodified or modified. Primers may be prepared by any method known in the art such as by standard phosphoramidite chemistry. See Sambrook et al . , supra . The method of amplifying nucleic acids may be the polymerase chain reaction using a pair of primers wherein at least one primer within the pair is selected from the group consisting of SEQ ID NO: 16-24. When the polymerase chain reaction is the amplification method of choice, a pair of primers may be used such that one primer of the pair is selected from the group consisting of SEQ ID NOS: 16-24. Primers used in mutational analysis were SEQ ID NO: 16: CACGCTCAGGTTCTGGAT; SEQ ID NO: 17: TCAACTGGATGGTGAGGA; SEQ ID NO: 18: 5' TGACATCGCCAAACTGC; SEQ ID NO: 19: TCCTGGCAGTGCCTTCA; SEQ ID NO: 20: TCCTCTCAGGGTCCAGGTTA; SEQ ID NO: 21: ACAAGGAGCCTGGGGAT; SEQ ID NO: 22: TGCATGGGTCCCAGTGA; SEQ ID NO: 23: TTGACCATTCACCACATTGGTGTGC; and SEQ ID NO: 24: ACCATCGACCAGCACATC When an amplification method includes the use of two primers, a first primer and a second primer, such as in the polymerase chain reaction, the first primer may be selected from the group consisting of SEQUENCE ID NOS: 17, 18, 21, and 23; and the second primer may be selected from the group consisting of SEQUENCE ID NOS: 16, 19, 20, 22, an 24. Any primer pairs which transcribe nucleic acids toward each other and which are specific for sulfonylurea receptor may be used in accordance with the methods of the present invention. Total extraction of RNA is preferably carried out. As used herein, the term "amplification" refers to template-dependent processes and vector-mediated propagation which result in an increase in the concentration of a specific nucleic acid molecule relative to its initial concentration, or in an increase in the concentration of a detectable signal. As used herein, the term template-dependent process is intended to refer to a process that involves the template-dependent extension of a primer molecule. The term template dependent process refers to nucleic acid synthesis of an RNA or DNA molecule wherein the sequence of the newly synthesized strand of nucleic acid is dictated by the well-known rules of complementary base pairing (see, for example, Watson, J. D. et al., In: Molecular Biology of the Gene, 4th Ed., W. A. Benjamin, Inc., Menlo Park, Calif. (1987)). Typically, vector mediated methodologies involve the introduction of the nucleic acid fragment into a DNA or RNA vector, the clonal amplification of the vector, and the recovery of the amplified nucleic acid fragment. Examples of such methodologies are provided by Cohen et al. (U.S. Pat. No. 4,237,224), Maniatis, T. et al., Molecular Cloning (A Laboratory Manual) , Cold Spring Harbor Laboratory, 1982. A number of template dependent processes are available to amplify the target sequences of interest present in a sample. One of the best known amplification methods is the polymerase chain reaction (PCR) which is described in detail in U.S. Patents 4,683,195, 4,683,202 and 4,800,159, and in Innis et al . , PCR Protocols , Academic Press, Inc., San Diego CA, 1990, each of which is incorporated herein by reference in its entirety. Briefly, in PCR, two primer sequences are prepared which are complementary to regions on opposite complementary strands of the target sequence. An excess of deoxynucleoside triphosphates are added to a reaction mixture along with a DNA polymerase (e.g., Tag polymerase) . If the target sequence is present in a sample, the primers will bind to the target and the polymerase will cause the primers to be extended along the target sequence b adding on nucleotides. By raising and lowering the temperature of the reaction mixture, the extended primers will dissociate from the target to form reaction products, excess primers will bind to the target and to the reaction products and the process is repeated. Preferably a reverse transcriptase PCR amplification procedure may be performed i order to quantify the amount of mRNA amplified. Polymerase chain reaction methodologies are well known in the art. Another method for amplification is the ligase chain reaction (referred to as LCR) , disclosed in EPA No. 320,308, incorporated herein by reference in its entirety. In LCR, two complementary probe pairs are prepared, and in the presence of the target sequence, each pair will bind to opposite complementary strands of the target such that they abut. In the presence of a ligase, the two probe pairs will link to form a single unit. By temperature cycling, as in PCR, bound ligated units dissociate from the target and then serve as "target sequences" for ligation of excess probe pairs. U.S. Patent 4,883,750, incorporated herein by reference in its entirety, describes an alternative method o amplification similar to LCR for binding probe pairs to a target sequence. Qbeta Replicase, described in PCT Application No. PCT/US87/00880, incorporated herein by reference in its entirety, may also be used as still another amplification method in the present invention. In this method, a replicative sequence of RNA which has a region complementary to that of a target is added to a sample in the presence of an RNA polymerase. The polymerase will copy the replicative sequence which can then be detected. An isothermal amplification method, in which restriction endonucleases and ligases are used to achieve th amplification of target molecules that contain nucleotide 5'-[ alpha -thio]triphosphates in one strand of a restriction site (Walker, G. T. , et al . , Proc . Natl . Acad, Sci . (U . S .A . ) 1992, 69:392-396, incorporated herein by reference in its entirety) , may also be useful in the amplification of nucleic acids in the present invention. Strand Displacement Amplification (SDA) is another method of carrying out isothermal amplification of nucleic acids which involves multiple rounds of strand displacement and synthesis, i.e. nick translation. A similar method, called Repair Chain Reaction (RCR) is another method of amplification which may be useful in the present invention and which involves annealing several probes throughout a region targeted for amplification, followed by a repair reaction in which only two of the four bases are present. The other two bases can be added as biotinylated derivatives for easy detection. A similar approach is used in SDA. Sulfonylurea receptor specific nucleic acids can also be detected using a cyclic probe reaction (CPR) . In CPR, a probe having a 3' and 5' sequences of non-sulfonylurea receptor specific DNA and middle sequence of sulfonylurea receptor specific RNA is hybridized to DNA which is present in a sample. Upon hybridization, the reaction is treated with RNaseH, and the products of the probe identified as distinctive products, generate a signal which is released after digestion. The original template is annealed to another cycling probe and the reaction is repeated. Thus, CPR involves amplifying a signal generated by hybridization of a probe to a sulfonylurea receptor specific expressed nucleic acid. Still other amplification methods described in GB Application No. 2 202 328, and in PCT Application No. PCT/US89/01025, each of which is incorporated by reference in its entirety, may be used in accordance with the present invention. In the former application, "modified" primers are used in a PCR like, template and enzyme dependent synthesis. The primers may be modified by labelling with a capture moiety (e.g., biotin) and/or a detector moiety (e.g., enzyme) . In the latter application, an excess of labelled probes are added to a sample. In the presence of the target sequence, the probe binds and is cleaved catalytically. After cleavage, the target sequence is released intact to be bound by excess probe. Cleavage of the labelled probe signals the presence of the target sequence. Other nucleic acid amplification procedures include transcription-based amplification systems (TAS) (Kwoh D., et al . , Proc . Natl . Acad . Sci . (U. S .A . ) 1989, 86:1173, Gingeras T. R. , et al . , PCT Application WO 88/10315, each of which is incorporated herein by reference in its entirety) , including nucleic acid sequence based amplification (NASBA) and 3SR. In NASBA, the nucleic acids can be prepared for amplificatio by standard phenol/chloroform extraction, heat denaturation of a clinical sample, treatment with lysis buffer and minispin columns for isolation of DNA and RNA or guanidiniu chloride extraction of RNA. These amplification techniques involve annealing a primer which has sulfonylurea receptor specific sequences. Following polymerization, DNA/RNA hybrids are digested with RNase H while double stranded DNA molecules are heat denatured again. In either case the single stranded DNA is made fully double stranded by additio of second sulfonylurea receptor specific primer, followed by polymerization. The double stranded DNA molecules are then multiply transcribed by a polymerase such as T7 or SP6. In an isothermal cyclic reaction, the RNAs are reverse transcribed into double stranded DNA, and transcribed once against with a polymerase such as T7 or SP6. The resulting products, whether truncated or complete, indicate sulfonylurea receptor specific sequences. Davey, C. , et al . , European Patent Application Publication No. 329,822, incorporated herein by reference in its entirety, disclose a nucleic acid amplification process involving cyclically synthesizing single-stranded RNA ("ssRNA") , ssDNA, and double-stranded DNA ("dsDNA") which ma be used in accordance with the present invention. The ssRN is a first template for a first primer oligonucleotide, which is elongated by reverse transcriptase (RNA-dependent DNA polymerase) . The RNA is then removed from resulting DNA:RNA duplex by the action of ribonuclease H (RNase H, an RNase specific for RNA in a duplex with either DNA or RNA) . The resultant ssDNA is a second template for a second primer, which also includes the sequences of an RNA polymerase promoter (exemplified by T7 RNA polymerase) 5' to its homology to its template. This primer is then extended by DNA polymerase (exemplified by the large "Klenow" fragment of E. coli DNA polymerase I) , resulting as a double-stranded DNA ("dsDNA") molecule, having a sequence identical to that of the original RNA between the primers and having additionally, at one end, a promoter sequence. This promoter sequence can be used by the appropriate RNA polymerase to make many RNA copies of the DNA. These copies can then re-enter the cycle leading to very swift amplification. With proper choice of enzymes, this amplification can be done isothermally without addition of enzymes at each cycle. Because of the cyclical nature of this process, the starting sequence can be chosen to be in the form of either DNA or RNA. Miller, H. I., et al . , PCT application WO 89/06700, incorporated herein by reference in its entirety, disclose a nucleic acid sequence amplification scheme based on the hybridization of a promoter/primer sequence to a target single-stranded DNA ("ssDNA") followed by transcription of many RNA copies of the sequence. This scheme is not cyclic; i.e. new templates are not produced from the resultant RNA transcripts. Other amplification methods include "race" disclosed by Frohman, M. A. , In: PCR Protocols : A Guide to Methods and Applications 1990, Academic Press, N.Y.) and "one-sided PCR" (Ohara, O. , et al . , Proc . Natl . Acad . Sci . (U.S .A. ) 1989, 86:5673-5677), all references herein incorporated by reference in their entirety. Methods based on ligation of two (or more) oligonucleotides in the presence of nucleic acid having the sequence of the resulting "di-oligonucleotide" , thereby amplifying the di-oligonucleotide (Wu, D. Y. et al . , Genomic 1989, 4:560, incorporated herein by reference in its entirety) , may also be used in the amplification step of the present invention. Test fragment and control fragment may be amplified by any amplification methods known to those of skill in the art, including and not limited to the amplification methods set forth above. For purposes of the present invention, amplification of sequences encoding patient and wild type sulfonylurea receptor includes amplification of a portion of a sequence such as and not limited to a portion of the sulfonylurea receptor sequence of SEQ ID NO: 26, such as sequence of a length of about 10 nucleotides to about 1,000 nucleotides, more preferably about 10 nucleotides to about 100 nucleotides, or having at least 10 nucleotides occurring anywhere within the SEQ ID NO: 26, where sequence difference are known to occur within sulfonylurea receptor test fragments. Thus, for example, a portion of the sequence encoding the second nucleotide binding fragment (NBF-2) region of sulfonylurea receptor of a patient sample and a control sample may be amplified to detect sequence differences between these two sequences. Following amplification of the test fragment and control fragment, comparison between the amplification products of the test fragment and control fragment is carrie out. Sequence differences such as and not limited to nuclei acid transition and restriction digest pattern alterations may be detected by comparison of the test fragment with the control fragment. Nucleic acid transition includes and is not limited to a G to A transition at nucleic acid position 750 of SEQ ID NO: 26. Another nucleic acid transition involves a G to A transition at nucleic acid position 27 of SEQ ID NO: 29. These nucleic acid transitions lead to restriction fragment length polymorphisms as exemplified by the altered results following Mspl and WciJ restriction digests set fort above. Accordingly, the restriction fragment length polymorphisms of test fragments may be compared to the restriction fragments of control fragments. Alternatively, the presence or absence of the amplification product may be detected. The nucleic acids are fragmented into varying sizes of discrete fragments. For example, DNA fragments may be separated according to molecular weight by methods such as and not limited to electrophoresis through an agarose gel matrix. The gels are then analyzed by Southern hybridization. Briefly, DNA in the gel is transferred to a hybridization substrate or matrix such as and not limited to a nitrocellulose sheet and a nylon membrane. A labelled probe encoding a sulfonylurea mutation is applied to the matrix under selected hybridization conditions so as to hybridize with complementary DNA localized on the matrix. The probe may be of a length capable of forming a stable duplex. The probe may have a size range of about 200 to about 10,000 nucleotides in length, preferably about 500 nucleotides in length, and more preferably about 2,454 nucleotides in length. The preferred sequence of the probe is set forth in SEQ ID NO: 30. Mismatches which permit substantial similarity to SEQ ID NO: 30, such as and not limited to sequences with similar hydrophobicity and hydrophilicity, will be known to those of skill in the art once armed with the present disclosure. Various labels for visualization or detection are known to those of skill in the art, such as and not limited to fluorescent staining, ethidium bromide staining for example, avidin/biotin, radioactive labeling such as P labeling, and the like. Preferably, the product, such as the PCR product, may be run on an agarose gel and visualized using a stain such as ethidium bromide. See Sambrook et al . , supra . The matrix may then be analyzed by autoradiography to locate particular fragments which hybridize to the probe. Yet another alternative is the sequencing of the test fragment and the control fragment to identify sequence differences. Methods of nucleic acid sequencing are known to those of skill in the art, including and not limited to the methods of Maxam and Gilbert, Proc . Natl . Acad . Sci . , USA 1977, 74 , 560 564 and Sanger, Proc . Natl . Acad . Sci . , USA 1977, 74 , 5463- 5467. A diagnostic kit for detecting PHHI comprising in one or more containers at least one primer which is complementary to a sulfonylurea receptor sequence and a mean for visualizing amplified DNA is also within the scope of th present invention. Alternatively, the kit may comprise two primers. In either case, the primers may be selected from the group consisting of SEQ ID NOS: 16-24, for example. The diagnostic kit may comprise a pair of primers wherein one primer within said pair is complementary to a region of the sulfonylurea receptor gene, wherein one of said pair of primers is selected from the group consisting of SEQ ID NO: 16-24, a probe specific to the amplified product, and a mean for visualizing amplified DNA, and optionally including one or more size markers, and positive and negative controls. The diagnostic kit of the present invention may comprise one or more of a fluorescent dye such as ethidium bromide stain, 32P, and biotin, as a means for visuali.zi.ng or detecting amplified DNA. Optionally the kit may include one or more size markers, positive and negative controls, restriction enzymes such as and not limited to Mspl and/or Neil, and/or probe specific to the amplified product. The following examples are illustrative but are not meant to be limiting of the invention. EXAMPLES Purification and Partial Characterization of the 140 kDa Receptor: HIT cell membranes were photolabeled using a radioiodinated derivative of the second generation hypoglycemic drug, glyburide, according to the methods of Nelson, D.A. , et al . , JBC, 1992, 267:14928, Aguilar-Bryan, L. , et al . , JBC, 1992, 267:14934, and Aguilar-Bryan, L. , et al . , JBC, 1990, 265:8218, the disclosures of which are hereb incorporated by reference in its entirety. Glyburide (Kramer et al. FEBS Lett . 1988 229:355- 359) and an iodinated derivative of glyburide (Aguilar-Bryan et al. J. Biol . Chem . 1990 265:8218-8224) are known to photolabel a 140 kDa polypeptide. The pharmacological characteristics of the photolabeling, a kD in the low nanomolar range, and appropriate rank order of displacement with other insulin-releasing sulfonylureas, are those expected from studies on glyburide-induced insulin release from islets (Panten et al. Biochem . Pharm . 1989 38:1217-1229) and /3-cell lines (Schmid-Antomarchi et al. J. Biol . Chem . 1987 262:15840-15844) and inhibition of K ATP channel activity. Glyburide was purchased from Sigma (St. Louis, MO) and prepared in stock solutions of 10 mM in dimethyl sulfoxide. Radioligand stocks were prepared by diluting high pressure liquid chromatography-purified 5-[ ]iodo-2-hydroxyglyburide in dimethyl sulfoxide. Specific activity (cpm/mol) was measured on radioligand diluted 1/1000 into lOmM Tris, 100 mM NaCl, 2 mM EDTA, pH 7.4, and the absorbance determined at 2.5 nm intervals in a UV-VIS Gilford spectrophotometer. Dimethylsulfoxide was diluted 1/1000 into the same buffer, and the absorbance of the buffer without drug was subtracted at each wavelength to generate the final absorbance profile. HIT cells, passage 67-73, were seeded in roller bottles at 50 x 10 6 cells/bottle in 100 ml of Dulbecco's modified Eagle's medium plus 10% fetal bovine serum. Cells were fed with 200 ml of medium plus serum 4-5 times over a period of 2 weeks until the cells were confluent. After plating and each feeding, bottles were gassed with 5% C0 2 prior to capping. The cells in confluent roller bottles were washed with phosphate-buffered saline (0.14 M NaCl, 3 mM KCl, 2 mM KH 2 P0 , 1 mM Na 2 HP0 , pH 6.8) and then incubated at room temperature with 25 ml of phosphate-buffered saline plus 2 mM EDTA until cells detached from the sides of the bottles. Cells were pelleted at 900 xg for 10 minutes at 4 °C. All steps were carried out at 0-4 °C. Cell pellets were resuspended in 5 mM Tris, 2 mM EDTA, 0.1 mM PMSF, pH 7.4, using approximately 5 ml of buffer for each roller bottle. Cells were placed on ice for 40 minutes to allow swelling and then homogenized with 10 strokes of a motorized glass-Teflon homogenizer (500 rpm) . The homogenate was centrifuged at 1000 xg for 10 minutes to remove nuclei and cellular debris, and the supernatant transferred to 30 ml of Beckman polycarbonate, screw-cap ultracentrifuge tubes. Supernatants were centrifuged at 100,000 xg for 60 minutes i a Beckman 60 Ti rotor. The pellets were resuspended in membrane storage buffer (10 mM Tris, 100 mM NaCl, 2 mM EDTA, 20% glycerol, 0.1 mM PMSF, pH 7.4). 200 mg of membrane protein were typically obtained from 20 roller bottles. Membranes were stored at -80° C at 5 mg/ml protein in 10 mM Tris (pH 7.5), 0.1 M NaCl, 2 mM EDTA, 20% glycerol. To monitor receptor purification, an aliquot (5-20 ml) of th membranes was incubated with 1 nM [ I]-iodo-2- hydroxyglyburide for 15 minutes and the sample photolabeled. Binding of 5-[ 125I]-ιodo-2-hydroxyglyburιde (5-10 nM) to membranes was done for 30 minutes at 23 °C. Aliquots were pipetted onto parafilm and irradiated at 23 °C in a UV cross linker (Fisher Scientific) . The energy settings for the UV cross-linker were factory calibrated at 254 nm. For cross- linking at 312 nm, a conversion factor was estimated by determining the time required for the UV cross-linker to deliver a specific amount of energy with each set of bulbs, and then multiplying by the ratio of these times. All subsequent steps were performed at room temperature in the presence of 0.1 mM PMSF, 0.1 mM phenanthroline and 0.1 mM iodoacetamide. 20% (w/v) digitoni was freshly prepared by boiling in deionized water, then added to 200-400 mg thawed labeled membranes to a final concentration of 1%. Membranes were solubilized for 15 minutes then sedimented for 1 hr at 100,000 xg. The supernatant was divided into 4 ml aliquots and each aliquot was chromatographed over a 1 ml Concanavalin A-Sepharose column equilibrated with 25 mM Tris-HCI, pH 7.5,0.1 M NaCl, mM EDTA, 1% digitonin. The solution was cycled through the column twice before washing the column with 8 ml of the equilibration buffer. Retained protein was eluted with 4 ml of the same buffer containing 0.5 M methyl α-D- mannopyranoside. The eluted protein was stored at -80°C Three Con A eluates were combined, then cycled twice over a 1 ml column of reactive green 19-agarose equilibrated with 50 mM HEPES (pH 8.5), 2 mM EDTA, 0.2% digitonin. The column was washed with 8 ml of the equilibration buffer followed by 8 ml of the same buffer containing 0.4 M NaCl. The retained protein was eluted with 4 ml of the equilibration buffer containing 1.5 M NaCl. The two pooled eluates were diluted 1:1 with the HEPES equilibration buffer without NaCl and cycled twice over a 1 ml phenylboronate-10 agarose column. The column was washed with 8 ml of the HEPES buffer, followed by 2 ml of 0.1 M Tris-HCI, pH 7.5, 2 mM EDTA, 0.1% digitonin. Protein was eluted with 4 ml of 0.1 M Tris (pH 7.5), 2 mM EDTA, 0.1 % SDS. The protein was concentrated to 0.5 ml using a 100,000 MW cutoff Amicon filter, pretreated with 5% Tween-20, then loaded onto a single 5 cm wide lane of a 5.5% polyacrylamide SDS gel. After electrophoresis the gel was stained with Coomassie blue, destained, and the receptor band excised with a razor blade. The receptor was electroeluted into a 14,000 MW cutoff dialysis bag and concentrated by Amicon filtration. Table 1 summarizes the yields and fold-purification in the scheme developed for receptor purification. The amount of receptor, yields, and fold-purification reported after each step are based on the radioactivity, determined by γ counting, in the 140 kDa band after electrophoresis relative to the total protein loaded on a gel lane (as determined using the BioRad protein assay) . HIT cell membranes contain approximately 1.6 pmol of receptor per mg of membrane protein as determined by filtration binding (Aguilar-Bryan et al. J. Biol . Chem . 1990 265:8218-8224). TABLE 1 Purification of the High Affinity 140 kDa Sulfonylurea Receptor from HIT cells Step Total Volume Total Protei Receptor Receptor Purification Yield ml n pmol pmol/mg - fold % mg Crude 90 200 320 1.6 1 100 Membranes Supernatant 90 150 240 1.6 1 75 ConA- 48 10.2 80 7.8 4.9 25 Sepharose Reactive 16 1.8 56 31.1 19.5 18 Green 19-agarose Phenyl 4 0.56 45 80.4 50.4 14 boronate agarose SDS-PAGE 0.2 -0.002 8 4000 2507 2.5 electroelute For the autoradiogram depicted in Figure 1, 1-2 μg of purified, radiolabeled receptor was made 1% in β- octylglucoside and divided into 6 aliquots. Lane 1 containe receptor kept on ice. The receptor was incubated in the presence (lane 2) and absence (lane 3) of Endo F for 30 min at 37 °C. Aliquots of the samples for lanes 1-3 were furthe incubated with V8 protease (1 μg/10 μl) for 30 min at 37 °C, yielding two radiolabeled peptides of 66 and 49 kDa (lanes 4 and 6) , both of which are N-glycosylated as indicated by the mobility shift after endo F treatment (lane 5) . To obtain N terminal sequence from the intact receptor, 2 μg of protein was separated by electrophoresis on a single, 0.8 cm wide lane of a 5.5% gel. The receptor was transferred to ProBlot (Applied Biosystems) in 10 mM CAPS (pH 11) , 10% MeOH, the filter stained for 10-20 seconds with Coomassie blue, destained, the band excised and microsequenced. To prepare receptor fragments for microsequencing, 10 μg of purified receptor was cleaved with V8, electrophoresed on a single lane and the fragments from the partial digest transferred t ProBlot. Fragments were prepared and sequenced multiple times as indicated in the figure. Gels used in the - 38 - preparation of receptor and fragments for microsequencing were aged overnight, and the top tray buffer contained 0.1 mM thioglycolate. The purified receptor showed a small apparent molecular weight decrease (ΔM r ~3000) following treatment with Endoglycosidase F/N-glycosidase F (Endo F) and yielded two bands following limited cleavage with V8 protease (Figure 1) . Each of the major labeled proteolytic fragments, M r ~69 and 49 kDa, shift mobility after digestion with Endo F. Identical N-terminal sequence, 15-25 residues, were recovered from each of the major labeled peptides. No residue was obtained at residue 9 when the glycosylated peptides were sequenced; an aspartic acid was identified at residue 9 (see Figure 3) in the deglycosylated receptor indicating this is an N- glycosylated asparagine. In addition, N-terminal sequences were recovered on two unlabeled V8 peptides and a third minor labeled peptide. The results indicate there is an N-linked glycosyl group at residue nine in the mature receptor, suggesting that the N terminus is extracellular, and that the sulfonylurea labeling site is within the first 50 kDa of the receptor. Two multiple antipeptide antibodies (MAPs) , directed against residues 1 through 8 and 10 through 20 respectively, of Figure 3, both immunoprecipitate photolabeled 140 kDa receptors from HIT, mouse αTC-6, and rat insulinoma (RIN) cells. MAPs were prepared by synthetic protein sequencing (Perkin Elmer-ABI, 430 A Peptide Synthesizer, Foster City, CA) to obtain antibodies to M-P-L- A-F-C-G-T, residues 1-8 of SEQ ID NOS: 5 and 7. This process was repeated for residues 10-20 of SEQ ID NOS: 5 and 7, N-H- S-A-A-Y-R-V-D-Q-G. A purified sulfonylurea receptor protein was immunoprecipitated from HIT cells using the MAPs prepared as set forth above. HIT cell membranes were incubated with 5-[ 125I]ιodo- 2-hydroxyglyburide, photolabeled, solubilized with 1% digitonin, centrifuged at 100,000 xg and the supernatant incubated with 1/10 volume of preimmune serum, immune serum, immune serum + anti-MAP 10-20, or immune serum + irrelevant MAP peptide. 50 μl of protein A-Sepharose was added and the mixture was incubated for 2 hours at room temperature, the beads washed with buffer, heated in the presence of pH 9 sample buffer, eletrophoresed on a 6% polyacrylamide SDS gel and an autoradiogram prepared. The immunoprecipitation was competed using the immunizing peptide, but not the other MAPS (Figure 2) . The amino acid sequence is derived from the photolabeled protein and the N-terminal amino acid sequence is conserved between mouse, rat, and hamster. Isolation and Characterization of cDNA Clones: Degenerate PCR primers with flanking restriction sites were designed based on the sequence obtained from the labeled peptides. The primers used were as follows: primer 1 (SEQ ID NO: 10) : 5' GAGAGAAGCTT(T/C)TG(T/C)GG(T/C/G/A)GA(A/G)AA(T/C)CA-3' primer 2 (SEQ ID NO: 11) : 5' GAGAGAGAATTCC(T/C)Tβ(A/G)TC(T/C/G/A)AC(T/C/G/A)C(G/T) (A/G)TA-3 ' The bases in parenthesis indicate the degeneracy at that position. The sequence in bold was derived from the peptide sequence obtained from the N-terminus of the sulfonylurea receptor. The remaining 5' sequence was added to facilitate subcloning. Primer 1 has a Hindlll site at th 5' end; Primer 2 was engineered with an EcoRI site at the 5' end. These primers were used in a standard PCR reaction wit a random primed cDNA library, constructed in λZAPII using mouse α-cell poly A+ mRNA, as template. The following cycle times and temperatures were employed: 94 °C for 10 minutes; 85 °C for 3 minutes, [50 °C for 2 minutes, 72 °C for 5 minutes, 94 °C for 2 minutes,] 50 °C for 2 minutes, 72 °C fo 5 minutes. The bracketed conditions were cycled 30 times. From the N-terminal peptide sequence of the receptor a 47 base pair coding region was expected to be amplified plus th 20 base pairs added to the primers to facilitate cloning yielding an expected 67 base pair product. The 47 base pair coding region was predicted to have 14 base pairs that were not present in the primers. The PCR product obtained was approximately 67 base pairs and was restricted with EcoRI and Hindlll, subcloned into M13 and sequenced. The resulting sequence gave the expected 14 base pairs indicating the sequence was derived from the receptor. The 47 base pair oligonucleotide given below was synthesized based on the consensus sequence derived from nine M13 clones: 5' TTTTGCGGGACGGAGAATCACTCGGCCGCCTACCGCGTCGACCAAGG-3' (SEQ ID NO: 12) . This oligonucleotide was used to screen the random primed mouse TC-cell cDNA library. A 1.1 kb cDNA was cloned which encoded 28 amino acids obtained from peptide sequencing. This cDNA fragment was used to screen RIN and HIT cell cDNA λ libraries to obtain full sequence. The nucleotide sequence of a 4635 bp rat receptor cDNA is given in Figure 3. The open reading frame encodes a 1498 amino acid protein with a mass of 167,834 daltons, larger that predicted by SDS polyacrylamide gel electrophoresis. Aguilar-Bryan, L. , et al . , JBC, 1990, 265:8218. The amino acid sequence of the hamster receptor, immediately below the rat sequence in Figure 3, is approximately 98% identical. There is a single insertion of an asparagine at position 742 and a deletion of a threonine at position 831. The first difference between the hamster and rat sequences is in the same relative position, 21 residues C-terminal of the Walker consensus site, as the ΔF508 deletion seen in a common cystic fibrosis transconductance regulator (CFTR) mutation (Riordan et al. Science 1989 245:1066-1073). In addition to the insertion and deletion, the first nucleotide binding fold contains approximately a third (10/33) of all differences between the two species. The mature rat protein, defined by peptide sequencing, begins with a proline following the ethionine start site. In the RIN cell receptors the adjacent amino acid is a methionine. This is the initiating methionine based on the surrounding sequence which is a good fit to the consensus pattern for initiation, GCC(A/G)CCAUG(G) (SEQ ID NO: 13) (Kozak, M. Cell 1986 44 : 283 ) , including the strongly conserved A at position -3. However, in the mouse receptor, an additional 35 amino acids is found preceding this proline which cannot eliminate the possibility that some forms of th hamster and rat receptors have similar leader sequences. Confirming the chemical sequence, residue 9 in the mature proteins is an asparagine within a consensus glycosylation site. A Blast search of the National Center for Biotechnology Information (NCBI) nucleotide database with th receptor sequence produced matches with several members of the P-glycoprotein/multidrug resistance protein family. A similar search with the amino acid sequence indicated the sulfonylurea receptor is a member of the ATP-binding cassett superfamily with two putative nucleotide binding domains. The sulfonylurea receptor sequence revealed 29% similarity, to an ATP-binding cassette superfamily member, termed a multidrug resistance-associated protein (MRP) , isolated from a small cell lung carcinoma cell line (H69AR) selected with doxorubicin (Cole et al. Science 1992 258:1650-1654) see Figure 4. A cluster analysis of this molecule, dvhuar in th Protein Identification Resource (PIR) database, indicates it is related to the leishmania P-glycoprotein-related molecule (Lei/PgpA) , the CFTRs (human (Hum/CFTR) , bovine (Bov/CFTR) , mouse (Mus/CFTR) , and dogfish (Squ/CFTR) ) (Cole et al. Science 1992 258:1650-1654). A similar result was obtained for the sulfonylurea receptor with the additional inclusion of the Xenopuε CFTR indicating the receptor is a member of this cluster. The identification of the nucleotide binding domains goes beyond simply having Walker "A" and "B" consensus sequences. The receptor is similar to the 230-240 amino acid nucleotide binding domain(s) described by (Hyde e al. Nature 1990 346:362-365) and database searches find similarities to the nucleotide binding fold of ATP-binding proteins. The more conserved of the two receptor nucleotide binding folds, based on similarity with other ATP-binding proteins and the comparison of the rat and hamster sequences, is at the C-terminal end. An alignment of this region with four of the cystic fibrosis transconductance regulator (CFTRs) and multidrug resistance proteins (MRPs) with similarity to the sulfonylurea receptor are shown in Figure 5. RNA Analysis: Northern blot analysis of poly A+ mRNA isolated from RIN, HIT and αTC-6 cells, previously shown to have the high affinity receptor by drug binding and photolabeling studies (Aguilar-Bryan et al J. Cell . Biochem . Suppl . 1994 18A:133) each have an approximately 5000 nucleotide transcript, see Figure 6. A preliminary tissue distribution study shows the same size transcript is present in mouse brain and heart. Predicted Protein Structure: Sequence similarities indicate the sulfonylurea receptor has two potential ATP binding folds. The size and additional sequence similarities with P-glycoproteins and CFTRs suggest the receptor has a similar structure. Hydrophobicity (Figure 7) and hydrophobicity versus hydrophobic moment (Eisenberg et al. J. Mol . Biol . 1984 179:125) plots were used to generate a model for the receptor (Figure 8) . Two constraints were imposed on the model structure: the glycosylation site is on the external face of the membrane and both nucleotide binding domains are on the internal face. The 'classical' ATP-binding cassette superfamily model proposes duplication of a unit consisting of six transmembrane spanning helices followed by a nucleotide binding domain. The sulfonylurea receptor differs from this model and has at least nine potential transmembrane helices before the first nucleotide binding domain but only four between the two nucleotide binding domains (Figure 8) . The multidrug resistance-associated protein (MRP) is predicted to have 8 transmembrane spanning helices (Cole et al. Science 1992 258:1650-1654). Phosphorylation has been implicated in regulation of K ATP channel activity (Schwanstecher et al. J. Pharmacol . Exper. Ther. 1992 262:495-502) and has been proposed to change the affinity of the sulfonylurea receptor for various ligands. There are 21 potential phosphorylation sites in the receptor sequence; 3 protein Kinase A (pKA) sites and 18 protein kinase C (pKC) sites. The pKA site at 278 is predicted to be on the external face of the membrane, while those at positions 1363 and 1417 are in the second nucleotide binding fold. Four of the pKC sites (positions 151, 200, 304 and 1213) are predicted to be extracellular or in a membrane spanning helix. Seven of the remaining 14 are in the nucleotide binding folds (NBF) ; 4 in NBF-1, and 3 in NBF-2. One of the latter sites, Thr 1297 in the Walker A consensus site, is expected to alter nucleotide binding if it is accessible for phosphorylation. Functional Properties, In Vitro Translations: mRNA, transcribed by SP6 RNA polymerase from the rat cDNA subcloned into pGEM4, was translated in vitro . Approximately 0.5 μg of mRNA was heated to 70 °C for 10 minutes, immediately cooled on ice then added to rabbit reticulocyte lysate (Promega, Madison, WI) supplemented with ribonuclease inhibitor, an amino acid mixture, and [ S]methionine. The reaction mixture was incubated at 30 °C for 60 minutes then aliquots were subject to electrophoresis on SDS polyacrylamide gels using standard protocols. The gels were dried and autoradiographed. The resulting protein was approximately 137 kDa, indicating the receptor behaves anonymously on SDS polyacrylamide gels having a faster than expected mobility, see Figure 9a. A similar anomalous behavior has been reported for CFTRs (Gregory et al. Nature 1990 347:382-386). Anti-Nuclβotidβ Fold Antibodies Immunoprecipitate the Photolabeled 140 kDa Receptor: Antibodies were produced against two fusion proteins containing the two nucleotide binding folds. Fragments of the receptor cDNA were subcloned in frame into pMALc (New England BioLabs, Boston, MA) at the C-terminal end of the DNA encoding the maltose binding protein (MBP) . A plasmid expressing the first nucleotide binding fold fused to MBP was constructed by restricting pMALc with StuI and Sail and restricting the sulfonylurea receptor cDNA with PvuII plus Xhol. A unique 500 base pair fragment was gel purified from the receptor cDNA digest and subcloned into pMALc. The construction was verified by sequencing. The receptor segment expressed is leu708 to leu874. Expression was obtained in E. coli following transformation and induction by isopropylthiogalactoside per the manufacturer's directions. The expressed proteins were found to be in inclusion bodies which were solubilized in SDS and separated on SDS polyacrylamide gels, see Figure 9b. The fusion protein was electroeluted, concentrated, and used as an immunogen. The solubilized protein in 200 μg amounts, with complete, or incomplete Freund's adjuvant, was injected interdermally into rabbits using a standard 2-3 week regimen of bleeding and boosting. Injection of Xenop s Oocytes with Receptor mRNA: mRNA, approximately 50 ng, transcribed as described above, was injected into Xenopus oocytes. The injected oocytes were assayed for K+ channel activity after 1-5 days using both two-electrode and patch clamp methods. New K+ currents in the injected oocytes were not detected. Similarly, co-injection of mRNAs transcribed from cDNAs encoding two small inward rectifiers, ROMK1 (Ho et al. Nature 1993 362:31-38) or a brain homolog of IRK1 (Kelly et al. Biophysical J. 1994 66 (2) :A109) failed to confer sulfonylurea sensitivity on these K+ channels. The results suggest that the 140 kDa receptor does not have intrinsic K+ channel activity, or that Xenopus oocytes are not an adequate background for their expression. Transfection Experiments: The sulfonylurea receptor cDNA has been ligated into eukaryotic expression vectors containing SV40 virus, adenovirus and cytomegalovirus (CMV) promoters. These plasmids have been transfected into COS cells which do not have the high affinity sulfonylurea receptor as determined b filtration binding and photolabeling studies. To date experiments with the SV40 plasmid have shown that the transfected cells produce an mRNA of the appropriate size as determined by Northern blots with receptor cDNA. Metabolic labeling experiments with the SV40 plasmid where transfected and non-transfected cells were labeled with [ 35 S] methionine indicate that the transfected, but not the non-transfected cells, synthesize an appropriate sized protein which can be immunoprecipitated with the antinucleotide binding fold antibodies. The level of receptor synthesized by COS cells using this promoter has been low using SEQ ID NOS: 4 and 5. Expression levels are high using SEQ ID NOS: 32, 33, 35, and 36 from rat and hamster. Chromosomal localization of the Sulfonylurea Receptor Gene Chromosomal localization of the Sulfonylurea Receptor (SUR) gene to normal male human banded chromosomes was determined by utilization of the fluorescence in situ hybridization (FISH) technique by staining with 4,6- diamidino-2-phenylindole (DAPI) . A metaphase spread showed the two chromosome 11 homologues which map the SUR cDNA to llplδ.l. Overlapping human SUR cDNA plasmids "mid" and "3", totaling 3.8 kb, were labeled with biotin-14-dATP (GIBCO) an hybridized in situ to standard metaphase spreads from normal male peripheral blood lymphocytes, according to the methods of P. Lichter et al., Science 247, 64 (1990), the disclosure of which is hereby incorporated by reference in its entirety The biotin-labeled DNA was detected using Fluorescein-Avidin DCS (Vector Laboratories, Burlingame, California) . Chromosomes were identified by simultaneous DAPI staining, which produces a Q-banding pattern. Fifteen metaphases were analyzed. Digital images were obtained with a cooled charge- coupled device camera mounted on a standard epifluorescent microscope (Axioplan; Zeiss, Thronwood, New York) . Images were acquired using the software ISee (Inovision Co.) running on a Sun workstation. Fluorescein isothiocyanate and DAPI fluorescence were recorded separately as gray scale images and then merged using the software package NIH 1.55 (J.W. Ijdo, E.A. Lindsay, R.A. Wells, A. Baldini, Genomics 14, 1019 (1992)). Eighty-five per cent of metaphases analyzed showed specific hybridization signal on both chromatids of the two chromosomes 11 at llplδ.l. Partial cDNA clones, comprising 3.8 kb of coding sequence of the human homologue of SUR, were obtained from a human pancreatic cDNA library (provided by Graeme Bell, University of Chicago, and commercial libraries of Clontech, Palo Alto, CA and Invitrogen, San Diego, CA) . The library was produced in lambda gtlO phage (Bell RIN library) and screened with a 2294 bp hamster cDNA probe encoded by SEQ ID NO: 31. The protocol for making the library is provided by Sambrook et al. , supra . Poly A+ mRNA was isolated using an oligo dT column. Poly A+ mRNA was incubated with oligo dT and random hexamers plus reverse transcriptase (such as MMLV RT from Promega, Stratagene or NEBL) and dNTPs to produce single strand cDNA. The single strand cDNA is treated with E. coli DNA polymerase, RNAseH and dNTPs, then ligated to linkers that have EcoRI sites to produce double stranded DNA. The final product is restricted with EcoRI and ligated, using T4 DNA ligase, into lambda phage DNA that has been similarly restricted and dephosphorylated with alkaline phosphatase to prevent self ligation. The ligated product is packaged into phage using commercially available packaging extracts. Screening involved plating and hybridizing at 55°C or 65°C in 5X or 6X SSC (according to the methods of Sambrook, et al . ) . 55°C was used for cross species screens and 65°C was employed for the same species. Two washes were carried out at room temperature using 2X SSC, then one at the hybridization temperature of 65°C using 0.1X SSC. Hybridizations and washes were done at reduced stringency (55°C) using methods according to F.M. Ausubel et al.. Current Protocols in Molecular Biology (Greene Publishing Associates, Inc, New York, NY, 1989), Chap. 6, the disclosures of which are hereby incorporated by reference in their entirety. Subsequent screening was done at higher stringency (65°C) , using a human cDNA of SEQ ID NO: 29 obtained from the first screen as a probe. Characterization of these cDNA clones by sequence analysis revealed an overall homology of 95% with the rat SUR gene. A specific hybridization signal was detected at the band llplδ.l in 85% of metaphases on both chromatids of the two chromosomes 11. Detection of Sulfonylurea Receptor Mutations in PHHI Affected Individuals Mutational analysis was performed on samples from 16 affected progeny of nine consanguineous matings. In each case, diagnosis of PHHI was based on criteria established by A. Aynsley-Green et al., supra . , the disclosure of which is hereby incorporated by reference in its entirety. The parents in six families were first cousins, in two families second cousins, and in one family more distantly related. Eight families were of Saudi Arabian origin, recruited from the patient population of the Arabian American Oil Company Hospital Medical Services Organization, after institutional approval was received, and one was of Germanic origin. Family labels follow the form of Thomas et al., supra . Studies indicated that no major insertions or deletions of the SUR locus had occurred in three of the families. The first region evaluated, by direct sequence analysis, was the second nucleotide binding fold (NBF-2) of the human SUR homologue (Figure 10) . This is the most highl conserved region of the SUR gene, and in other superfamily members it, as well as NBF-1, has functional importance for control of channel activity through interaction with cytosolic nucleotides. S.C. Hyde, Wature 346, 362 (1990) and M.J. Weish, A.E. Smith, Cell 73, 1251 (1993). To obtain this genomic structure, a normal human lymphocyte genomic bacteriophage library (provided by Mary Beth Humphrey, Baylor College of Medicine) was screened, using standard methods according to F.M. Ausubel et al., supra . , with a human partial SUR cDNA probe of SEQ ID NO: 29 (cDNA probe, "3prime") . The human genomic library was made in lambda FIX using materials supplied by Stratagene, Inc. Briefly, genomic DNA was partially digested with Sau3A, the fragments were precipitated with ethanol, resuspended with precut lambda FIX DNA which has compatible ends, ligated with T4 DNA ligase and packaged and screened. Hybridizations and washes were done at reduced stringency (55°C) using methods according to F.M. Ausubel et al., Current Protocols in Molecular Biology (Greene Publishing Associates, Inc, New York, NY, 1989), Chap. 6, the disclosures of which are hereby incorporated by reference in their entirety. The library was screened with a 1.2 kb hamster cDNA probe of SEQ ID NO: 30, which spans the SUR NBF2 sequence. Subsequent screening was done at higher stringency (65°C) , using a human cDNA of SEQ ID NO: 29 obtained from the first screen as a probe. Screening involved plating and hybridizing at 55°C or 65°C in 5X or 6X SSC (according to the methods of Sambrook, et al . ) . 55°C was used for cross species screens and 65°C was employed for the same species. Two washes were carried out at room temperature using 2X SSC, then one at the hybridization temperature of 65°C using 0.1X SSC. Inserts in the bacteriophage clone λG4 were subcloned into pBluescript 11 (Stratagene, La Jolla, California) . Plasmids were purified using standard cesium chloride purified methods, restricted using the appropriate desired enzyme(s) . The fragments were purified by electrophoresis on low melt agarose and cut out of the gel. A l-to-5 microliter aliquot of the desired fragment and 1 microgram of the appropriately restricted plasmid carrying a selectable ampicillin resistance marker (such as pBluescript from Stratagene, Inc.) were melted at 65°C, mixed and diluted to 20 microliters with a buffer containing T4 DNA ligase and ATP, then incubated for 4-18 hours before transforming into E. coli and selecting on ampicillin plates. Exon-intron boundaries were defined by comparing the nucleotide sequences of the human SUR gene and cDNA, which were obtained using the dideoxy chain termination method (Sequenase; U.S. Biochemicals, Cleveland, Ohio). Because of the consanguineous matings and autosomal recessive inheritance pattern of this disorder, affected individuals are expected to be homozygous by descent at the disease gene locus. E.S. Lander and D. Botstein, Science 236, 1567 (1987) , the disclosure of which is hereby incorporated by reference in its entirety. Direct sequencing of a pancreatic cDNA product, isolated from an affected child of Family 6, revealed a 109 bp deletion within the NBF-2 region which corresponded to skipping of an exon resulting in a cDNA product of about 2190 bp in length using primers of SEQ ID NOS: 20 and 21 as compared to mRNA of about 2080 bp in length. The effects of this skipping event are severe and include production of a frameshift, premature truncation of the protein due to inclusion of a stop 24 codons later, and disruption of the NBF-2 (Figure 11A and 11B) . The splice sites of the skipped exon were evaluated at the genomic DNA level and a homozygous G to A point mutation, located within the 5' splice site at the last base of the skipped exon, was found (Figure 11C) . A recognition site for the restriction endonuclease MspJ is destroyed by this base change, providin a means to confirm and test for the presence of the mutation. mRNA was directly isolated using Oligotex (Qiagen Inc. , Studio City, California) from a fresh-frozen pancreatic tissue sample and reverse transcribed (RT) , using random primers (Invitrogen, San Diego, California) , with Superscript 11 (GIBCO-BRL) into cDNA. For cloning of the NBF-2 region, an initial PCR amplification with SEQ ID NOS: 23 (primer 22 (located 5' of 17)) and 19 (primer 29) was followed by a second amplification of a portion of the reaction with SEQ ID NOS: 16 (primer 17) and 19 (primer 29) using conditions described by P.M. Thomas, G.J. Cote, D.M. Hallman, P.M. Mathew, Am. J . Hum . Genet . , in press, supra . PCR products were amplified using hybridization at 60°C for 1 minute, elongated at 72°C for 1 minute and denatured at 93°C for 1 minute for thirty cycles. Hybridization may be carried out at temperatures of between about 55°C to about 65°C. The amplified product was cloned into pCR 11™ vector (Invitrogen, San Diego, CA) and sequenced, as above. pCR 11™ vector is set forth in Figure 13. The vector was purified using a standard cesium chloride method, restricted using the appropriate desired enzyme(s), the fragments were purified by electrophoresis on low melt agarose and cut out of the gel. A l-to-5 microliter aliquot of the desired fragment and 1 microgram of the appropriately restricted plasmid carrying a selectable ampicillin resistance marker (such as pBluescript from Stratagene, Inc.) were melted at 65°C, mixed and diluted to 20 microliters with a buffer containing T4 DNA ligase and ATP, then incubated for 4-18 hours before transforming into E. coli and selecting on ampicillin plates. For detection of the mutation in genomic fragments, 100 ng of genomic DNA was amplified using SEQ ID NOS: 18 and 20, primers 28 and 29B, as above except in the presence of PCR buffer N (Invitrogen, San Diego, CA) , and either directly PCR sequenced according to the methods of S. Khorana, R.F. Gagel, G.J. Cote, Nucleic Acids Res . 22, 3425 (1994) , the disclosure of which is hereby incorporated herein by reference in its entirety, or cut with 5 U of Λspl (GIBCO- BRL) at 37"C for 2 hours and run on a 10% polyacrylamide gel. Visualization of products was by silver staining. Both affected children of Family 6 were homozygous, while the parents and two unaffected siblings were found to be heterozygous, for the mutation (Figure 11D) . Preliminary semiquantitative analysis revealed markedly decreased expression of the mutant SUR message upon comparison of patient and age-matched normal control pancreatic samples, suggesting instability of the mutant message. Thirteen additional affected children, from six families of Saudi Arabian origin and one family of German origin, were found to be homozygous for this mutation, as demonstrated by loss of the Mspl restriction enzyme recognition site. In all families, homozygous loss of the Mspl site cosegregated with disease phenotype, and in Families 1-3 and 5 genotype analysis for this mutation agreed with previously reported haplotype data, P.M. Thomas, G.J. Cote, D.M. Hallman, P.M. Mathew, Am . J. Hum . Genet . , in press, supra . Direct sequencing of PCR-amplified genomic DNA from a representative affected member of each family determined that all exhibited the homozygous G to A mutation. Genomic DNA from affected and normal individuals was PCR-amplified using the SEQ ID NOS: 16 and 19 and cloned into pRSVhMT2A. Plasmids were purified using standard cesium chloride methods, restricted using the appropriate desired enzyme(s) . The fragments were purified by electrophoresis on low melt agarose and cut out of the gel. A l-to-5 microliter aliquot of the desired fragment and 1 microgram of the appropriately restricted plasmid carrying a selectable ampicillin resistance marker (such as pBluescript from Stratagene, Inc.) were melted at 65°C, mixed and diluted to 20 microliters with a buffer containing T4 DNA ligase and ATP, then incubated for 4-18 hours before transforming into E. coli and selecting on ampicillin plates. Constructs were transfected into the human glioblastoma cell line SNB 19 using Lipofectamine™ (Gibco- BRL, Gaithersburg, MD) . RT-PCR analysis was performed, with SEQ ID NOS:18 (primer 16) and 23 (primer DS8) , as described by H. Lou, G.J. Cote, R.F. Gagel, Mol . Endo . 8, 1618 (1994), the disclosure of which is incorporated herein by reference in its entirety. The plasmids and their cDNA products were sequenced with SEQ ID NO: 17 (primer 34al) . Genomic DNA fragments were PCR-amplified with SEQ ID NOS: 17 and 18 (primers 34al and 16) and digested with Weil, as in Figure 11. Family 4 demonstrated a unique mutation in the 3' splice site sequence preceding the start of the NBF-2 (Figure 12A) . This G to A mutation destroys an Weil restriction endonuclease site and homozygous loss of this site cosegregated with disease phenotype within the family. Again, genotype analysis of the members of this family supported previously reported haplotype data, P.M. Thomas, G.J. Cote, D.M. Hallman, P.M. Mathew, Am . J. Hum . Genet . , in press, supra . ; both parents are heterozygotes for the mutation and the unaffected sibling is homozygous for the wild type allele (Figure 12B) . Since a pancreatic tissue sample from an affected individual in Family 4 was unavailable and we were unable to recover the SUR message from transformed lymphocytes, a chimeric construct was created to examine the effects of this mutation on the RNA splicing pathways according to the methods of R. Takahashi, et al., Nature Genet . 7, 79 (1994); I. Satokata, et al., Proc, Natl . Acad . Sci . 87 9908 (1990); H. Lou, G.J. Cote, R.F. Gagel, Mol . Endo . 8, 1618 (1994), the disclosure of each hereby incorporated by reference in its entirety. With the construct containing the mutation, no wild type splicing pattern occurred. Instead, use of three cryptic 3' splice sites was demonstrated resulting in a 7 bp addition, a 20 bp deletion, and a 30 bp deletion in the exon (Figure 12D) . A similar intronic 3' splice acceptor mutation, described in the disorder 21-hydroxylase deficiency, also resulted in lack of the wild type splicing pattern, produced several cryptic splice products, and abolished normal protein activity. Y. Higashi, et al., Proc . Natl . Acad . Sci . , USA 85, 7486 (1988), the disclosure of which is incorporated herein by reference in its entirety. All PCR products prepared from genomic DNA of 100 normal, unrelated individuals showed normal Mspi and Weil restriction patterns, indicating that neither mutation is a common polymorphism. The data presented provides evidence that mutations in the SUR gene cause familial persistent hyperinsulinemic hypoglycemia of infancy. Various modifications of the invention in addition to those shown and described herein will be apparent to thos skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: (ii) TITLE OF INVENTION: Sequence Encoding Mammalian Sulfonylurea Receptor and Method of Detecting Persistent Hyperinsulinemic Hypoglycemia of Infancy (iii) NUMBER OF SEQUENCES: 37 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Woodcock Washburn Kurtz Mackie icz & Norris (B) STREET: One Liberty Place 46th. Floor (C) CITY: Philadelphia (D) STATE: PA (E) COUNTRY: USA (F) ZIP: 19103 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentin Release #1.0, Version #1.25 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: PCT/US95/04463 (B) FILING DATE: 12-APR-1995 (C) CLASSIFICATION: (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Beardell, Lori Y. (B) REGISTRATION NUMBER: 34,293 (C) REFERENCE/DOCKET NUMBER: BYLR-0004 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 215-568-3100 (B) TELEFAX: 215-568-3439 (2) INFORMATION FOR SEQ ID Nθ:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4599 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1 : ATGCCTTTGG CCTTCTGCGG CACCGAGAAC CACTCGGCCG CCTACCGGGT GGACCAAGGC 60 GTCCTCAACA ACGGCTGCTT CGTGGACGCG CTCAATGTGG TGCCACATGT CTTTCTGCTC 120 TCATCACCT TCCCCATCCT CTTCATCGGA TGGGGCAGCC AGAGCTCCAA GGTGCACATT 180 CACCACAGCA CCTGGCTCCA TTTCCCGGGG CACAACCTGC GCTGGATCCT GACCTTCATA 240 CTGCTCTTCG TCCTCGTGTG TGAGATCGCT GAGGGTATCC TGTCTGACGG GGTGACAGAA 300 TCCCGCCACC TCCACTTATA CATGCCAGCT GGGATGGCAT TCATGGCTGC CATCACCTCT 360 GTGGTCTACT ACCATAACAT TGAGACCTCT AACTTTCCCA AGCTGCTGAT TGCTCTGCTC 420 ATCTACTGGA CCCTGGCCTT CATCACGAAG ACCATCAAGT TCGTCAAGTT CTACGACCAC 480 GCCATTGGCT TCTCTCAGCT GCGCTTCTGC CTCACGGGGC TTCTGGTGAT CCTCTACGGG 540 ATGCTGCTGC TTGTGGAGGT CAATGTCATC CGGGTGAGGA GATACNTCTT CTTCAAGACA 600 CCAAGGGAAG TAAAGCCCCC CGAGGACCTA CAGGACCTGG GTGTGCGCTT TCTGCAGCCC 660 TTCGTTAACC TGCTATCAAA GGGGACCTAC TGGTGGATGA ATGCCTTCAT CAAGACTGCT 720 CACAAGAAGC CCATCGACCT GCGGGCCATC GNGAAGCTGC CCATTGCCAT GAGAGCCCTC 780 ACCAACTACC AGCGACTCTG CNTGGCCTTC GATGCCCAGG CGCGGAAGGA CACACAGAGC 840 CNGCAGGGTG CCCGGGCCAT CTGGAGGGCT CTCTGTCATG CCTTTGGGAG ACGGCTGGTC 900 CTCAGCAGCA CATTCCGTAT CCTGGCCGAC CTCCTGGGCT TTGCTGGGCC ACTCTGCATC 960 TTCGGGATCG TGGACCACCT CGGGAAGGAG AACCACGTCT TCCAGCCCAA GACACAGTTT 1020 CTTGGAGTTT ACTTTGTCTC ATCCCAAGAG TTCCTCGGCA ATGCCTATGT CTTGGCTGTT 1080 CTTCTGTTCC TTGCCCTCCT GCTGCAAAGG ACCTTTCTAC AAGCCTCGTA CTACGTTGCC 1140 ATTGAAACTG GGATCAACCT GAGAGGAGCA ATCCAGACCA AGATTTACAA TAAGATCATG 1200 CACNTGTCTA CTTCCAACCT GTCCATGGGG GAAATGACTG CTGGGCAGAT CTGCAACCTG 1260 GTGGCCATCG ACACCAACCA GCTCATGTGG TTTTTCTTCT TATGCCCAAA CCTCTGGNCT 1320 ATGCCGGTAC AGATCATTGT GGGCGTGATC CTCCTCTACT ACATCCTTGG GGTCAGCGCC 1380 TTGATTGGAG CGGCTGTCAT CATTCTGCTG GCTCCTGTAC AGTACTTTGT GGCCACCAAG 1440 CTGTCCCAGG CACAGCGGAC GACCCTGGAA TATTCCAATG AGAGGCTGAA GCAGACCAAT 1500 GAGATGCTCC GGGGCATNAA GTTGCTCAAG CTCTATGCGT GGGAGAACAT CTTCTGCTCC 1560 AGGGTGGAGA AGACACGCAG GAAGGAAATG ACCAGCCTCA GGGCCTTCGC TGTCTACACC 1620 TCCATCTCCA TCTTCATGAA CACAGCTATC CCCATCGCTG CTGTCCTCAT CACCTTCGTG 1680 GGCCACGTCA GCTTCTTCAA AGAGTCGGAC NTCTCGCCCT CGGTGGCCTT TGCCTCTCTC 1740 TCTCTCTTCC ACATCCTGGT CACACCGCTG TTCCTGCTGT CTAGTGTGGT TCGGTCCACT 1800 GTCAAGGCCC TGGTGAGCGT GCAAAAGCTG AGTGAGTTCC TGTCCAGTGC AGAGATCCGT 1860 GAGGAACAGT GTGCCCCCCG AGAGCCCGCA CCCCAAGGCC AAGCGGGCAA GTACCAGGCG 1920 GTGCCCCTCA AGGTCGTAAA CCGCAAGCGC CCAGCCCGAG AAGAAGTCCG GGACCTCTTG 1980 GGCCCACTGC AGAGGCTGNC TCCCAGCANG GATGGAGACG CTGACAACTT CTGTGTCCAG 2040 ATCATCGGAG GCTTCTTCAC CTGGACCCCT GATGGAATCC CCACCCTGTC CAACATCACC 2100 ATCCGTATCC CCCGAGGTCA GCTGACCATG ATCGTGGGGC AGGTGGGCTG TGGCAAGTCC 2160 TCGCTCCTTC TGGCCACCCT GGGGGAGATG CAGAAGGTCT CTGGAGCTGT CTTCTGGAAC 2220 AGCCTTCCAG ACAGCGAGGG GAGANGACCC CAGCAACCCA GAGCGGGAGA CAGCNGCNGN 2280 NTCGGATNCC AGGAGCAGAG GCCCNGTGGC TACGCATCTC AGAAACCATG GCTGCTAAAT 2340 GCCACTGTGG AGGAGAACAT CACCTTCGAG AGTCCCTTCA ATNNGCAACG GTACAAGATG 2400 GTCATCGAAG CCTGCTCCCT GCAGCCAGAC ATAGACATCC TGCCCCATGG AGACCAGACT 2460 CAGATTGGGG AACGAGGCAT CAACTTGAGT ACTGGTGGTC AGCGTCCAGA TCAGTGTNGA 2520 CCCGAGCCCT CTACCAGCAN ACCAATGNTT GTCTTTTTGG ATGACCCTTT CTCGGCTCTG 2580 GATGTCCATC TGAGTGACCA CCTAATGCAG GCTGGCATCC TCGAGCTGCT CCGGGATGAC 2640 AAGAGGACAG TGGTCTTGGT GACCCACAAG CTACAGTACC TGCCTCATGC TGACTGGATC 2700 ATTGCTATGA AGGATGGCAC CATTCAGAGG GAGGGGACAC TCAAGGACTT CCAGAGGTCT 2760 GAGTGCCAGC TCTTTGAGCA TTGGAAGACC CTCATGAACC GGCAGGACCA AGAGCTGGAG 2820 AAGGAGACAG TCATGGAGAG AAAAGCCNCN GAGCCATCTC AGGGCCTGCC CCGTGCCATG 2880 TCCTCAAGAG ATGGCCTTCT GCTGGATGAG GANGAGGAGG AAGAGGAGGC AGCCGAGAGC 2940 GAGGAAGATG ACAACTTATC CTCTGTGCTG CATCAGCGAG CCAAGATCCC ATGGCGAGCC 3000 TGCACCAAGT ATTTGTCCTC TGCTGGCATC CTGCTCCTGT CCCTGCTTGT CTTCTCCCAG 3060 CTGCTCAAGC ACATGGTCTT GGTGGCCATT GACTACTGGC TGGCCAAGTG GACGGACAGT 3120 GCCCTGGTCC TGAGCCCCGC CGCCAGGAAC TGCTCCCTCA GCCAGGAATG TGNCCTGGAC 3180 CAATCTGTCT ATGCCATGGT ATTCACCNTG CTCTGCAGCC TGGGTATCGN GCTGTGCCTT 3240 GTCACCTCTG TCACTGTGGA GTGGACGGGA CTGAAGGTGG CCAAGAGGCT GCATCGCAGC 3300 CTGCTCAACC GTATCATCCT GGCTCCCATG AGGTTCTTTG AGACCACGCC CCTGGGGAGT 3360 ATCCTGAACA GATTTTCATC TGACTGTAAC ACCATTGACC AGCATATCCC GTCCACGCTG 3420 GAGTGCCTGA GCAGATCCAC CTTACTCTGT GTCTCCGCCC TGNCTGTCAT CTCCTACGTC 3480 ACGCCTGTGT TCCTAGTGGC CCTCTTACCC CTCGCCGTCG TGTGCTACTT CATCCAGAAG 3540 TACTTCCGAG TGGCGTCCAG GGACCTGCAG CAGCTGGACG ACACAACACA GCTCCCTCTG 3600 NTCTCACACT TTGCTGAAAC TGTGGAAGGA CTCACCACCA TCCGTGCCTT CAGGTACGAG 3660 GCCCGGTTCC AGCAGAAGCT CCTAGAGTAC ACCGACTCCA ACAACATTGC CTCTCTCTTC 3720 CTCACAGCAG CCAACAGGTG GCTGGAAGTC NGCATGGAGT ACATCGGAGC ATGCGTGGTA 3780 CTCATCGCCG CTGCCACCTC CATCTCCAAC TCCCTACACA GGGAGCTCTC AGCCGGCCTA 3840 GTAGGCCTGG GCCTCACCTA TGCCTTGATG ATTGGGATCT GCGGCCGCAC AGGCAGTGGA 3900 AAATCCTCCT TCTCTCTCGC CTTTTTCCGA ATGGTGGATA TGTTTGAAGG GCGTATCATC 3960 ATCGATGGCA TTGACATCGC CAAGCTGCCG CTGCACACGC TCCGCTCACG CCTGTCTATC 4020 ATCCTACAGG ACCCTGTTCT CTTCAGTGGT ACCATCAGAT TCAACCTGGA CCCAGAGAAG 4080 AAATGCTCAG ACAGCACGCT GTGGGAGGCT CTGGAGATCG CTCAGCTGAA GCTGGTGGTG 4140 AAGGCCCTGC CAGGAGGCCT GGATGCCATC ATCACGGAAG GAGGGGAGAA TTTTAGCCAG 4200 GGCCAGAGGC AGCTGTTCTG CCTGGCCCGG GCCTTTGTGA GGAAGACCAG CATCTTCATC 4260 ATGGATGAAG CAACTGCCTC CATCGACATG GCTACGGAAA ATATCCTCCA GAAGGTGGTG 4320 ATGACAGCCT TCGCAGACCG CACCGTGGTC ACCATCGCGC ACCGCGTGCA CACCATCCTG 4380 AGTGCAGACC TAGTGATGGT CCTGAAGAGG GGCGCGATCC TGGAGTTCGA CAAGCCGGAA 4440 ANGCTTCTCA GCCAGAAGGA CAGCGTCTTT GCCTCCTTTG TCCGCGCGGA CAAATGACCA 4500 GCCAGCGCCA AAGTGCCACC CCACACCTCA CCTGCTTGCC ATGGATTTCT TACTGTAAAT 4560 CACTTGTAAA TAAAGAAACT AATTCTTTGC TAAAAAAAA 4599 (3) INFORMATION FOR SEQ ID NO:2 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: : GCGCGGAGCC GGAGCCGAGC CCGTGCGCGC GCCACC 36 (4) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: AGCCGAGCCC GTGCGCGCGC CGCC 24 (5) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4635 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE : N- terminal ( ix) FEATURE : (A) NAME/KEY: CDS (B) LOCATION: 37..4533 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4 : GCGCGGAGCC GGAGCCGAGC CCGTGCGCGC GCCACC ATG CCT TTG GCC TTC TGC 54 Met Pro Leu Ala Phe Cys 1 5 GGC ACC GAG AAC CAC TCG GCC GCC TAC CGG GTG GAC CAA GGC GTC CTC 102 Gly Thr Glu Asn His Ser Ala Ala Tyr Arg Val Asp Gin Gly Val Leu 10 15 20 AAC AAC GGC TGC TTC GTG GAC GCG CTC AAT GTG GTG CCA CAT GTC TTT 150 Asn Asn Gly Cys Phe Val Asp Ala Leu Asn Val Val Pro His Val Phe 25 30 35 CTG CTC TTC ATC ACC TTC CCC ATC CTC TTC ATC GGA TGG GGC AGC CAG 198 Leu Leu Phe Ile Thr Phe Pro Ile Leu Phe Ile Gly Trp Gly Ser Gin 40 45 50 AGC TCC AAG GTG CAC ATT CAC CAC AGC ACC TGG CTC CAT TTC CCG GGG 246 Ser Ser Lys Val His Ile His His Ser Thr Trp Leu His Phe Pro Gly 55 60 65 70 CAC AAC CTG CGC TGG ATC CTG ACC TTC ATA CTG CTC TTC GTC CTC GTG 294 His Asn Leu Arg Trp Ile Leu Thr Phe Ile Leu Leu Phe Val Leu Val 75 80 85 TGT GAG ATC GCT GAG GGT ATC CTG TCT GAC GGG GTG ACA GAA TCC CGC 342 Cys Glu Ile Ala Glu Gly Ile Leu Ser Asp Gly Val Thr Glu Ser Arg 90 95 100 CAC CTC CAC TTA TAC ATG CCA GCT GGG ATG GCA TTC ATG GCT GCC ATC 390 His Leu His Leu Tyr Met Pro Ala Gly Met Ala Phe Met Ala Ala Ile 105 110 115 ACC TCT GTG GTC TAC TAC CAT AAC ATT GAG ACC TCT AAC TTT CCC AAG 438 Thr Ser Val Val Tyr Tyr His Asn Ile Glu Thr Ser Asn Phe Pro Lys 120 125 130 CTG CTG ATT GCT CTG CTC ATC TAC TGG ACC CTG GCC TTC ATC ACG AAG 486 Leu Leu Ile Ala Leu Leu Ile Tyr Trp Thr Leu Ala Phe Ile Thr Lys 135 140 145 150 ACC ATC AAG TTC GTC AAG TTC TAC GAC CAC GCC ATT GGC TTC TCT CAG 534 Thr Ile Lys Phe Val Lys Phe Tyr Asp His Ala Ile Gly Phe Ser Gin 155 160 165 CTG CGC TTC TGC CTC ACG GGG CTT CTG GTG ATC CTC TAC GGG ATG CTG 582 Leu Arg Phe Cys Leu Thr Gly Leu Leu Val Ile Leu Tyr Gly Met Leu 170 175 180 CTG CTT GTG GAG GTC AAT GTC ATC CGG GTG AGG AGA TAC GTC TTC TTC 630 Leu Leu Val Glu Val Asn Val Ile Arg Val Arg Arg Tyr Val Phe Phe 185 190 195 AAG ACA CCA AGG GAA GTA AAG CCC CCC GAG GAC CTA CAG GAC CTG GGT 678 Lys Thr Pro Arg Glu Val Lys Pro Pro Glu Asp Leu Gin Asp Leu Gly 200 205 210 GTG CGC TTT CTG CAG CCC TTC GTT AAC CTG CTA TCA AAG GGG ACC TAC 726 Val Arg Phe Leu Gin Pro Phe Val Asn Leu Leu Ser Lys Gly Thr Tyr 215 220 225 230 TGG TGG ATG AAT GCC TTC ATC AAG ACT GCT CAC AAG AAG CCC ATC GAC 774 Trp Trp Met Asn Ala Phe Ile Lys Thr Ala His Lys Lys Pro Ile Asp 235 240 245 CTG CGG GCC ATC GGG AAG CTG CCC ATT GCC ATG AGA GCC CTC ACC AAC 822 Leu Arg Ala Ile Gly Lys Leu Pro Ile Ala Met Arg Ala Leu Thr Asn 250 255 260 TAC CAG CGA CTC TGC TTG GCC TTC GAT GCC CAG GCG CGG AAG GAC ACA 870 Tyr Gin Arg Leu Cys Leu Ala Phe Asp Ala Gin Ala Arg Lys Asp Thr 265 270 275 CAG AGC CAG CAG GGT GCC CGG GCC ATC TGG AGG GCT CTC TGT CAT GCC 918 Gin Ser Gin Gin Gly Ala Arg Ala Ile Trp Arg Ala Leu Cys His Ala 280 285 290 TTT GGG AGA CGG CTG GTC CTC AGC AGC ACA TTC CGT ATC CTG GCC GAC 966 Phe Gly Arg Arg Leu Val Leu Ser Ser Thr Phe Arg Ile Leu Ala Asp 295 " 300 305 310 CTC CTG GGC TTT GCT GGG CCA CTC TGC ATC TTC GGG ATC GTG GAC CAC 1014 Leu Leu Gly Phe Ala Gly Pro Leu Cys Ile Phe Gly Ile Val Asp His 315 320 325 CTC GGG AAG GAG AAC CAC GTC TTC CAG CCC AAG ACA CAG TTT CTT GGA 1062 Leu Gly Lys Glu Asn His Val Phe Gin Pro Lys Thr Gin Phe Leu Gly 330 335 340 GTT TAC TTT GTC TCA TCC CAA GAG TTC CTC GGC AAT GCC TAT GTC TTG 1110 Val Tyr Phe Val Ser Ser Gin Glu Phe Leu Gly Asn Ala Tyr Val Leu 345 350 355 GCT GTT CTT CTG TTC CTT GCC CTC CTG CTG CAA AGG ACC TTT CTA CAA 1158 Ala Val Leu Leu Phe Leu Ala Leu Leu Leu Gin Arg Thr Phe Leu Gin 360 365 370 GCC TCG TAC TAC GTT GCC ATT GAA ACT GGG ATC AAC CTG AGA GGA GCA 1206 Ala Ser Tyr Tyr Val Ala Ile Glu Thr Gly Ile Asn Leu Arg Gly Ala 375 380 385 390 ATC CAG ACC AAG ATT TAC AAT AAG ATC ATG CAC TTG TCT ACT TCC AAC 1254 Ile Gin Thr Lys Ile Tyr Asn Lys Ile Met His Leu Ser Thr Ser Asn 395 400 405 CTG TCC ATG GGG GAA ATG ACT GCT GGG CAG ATC TGC AAC CTG GTG GCC 1302 Leu Ser Met Gly Glu Met Thr Ala Gly Gin Ile Cys Asn Leu Val Ala 410 415 420 ATC GAC ACC AAC CAG CTC ATG TGG TTT TTC TTC TTA TGC CCA AAC CTC 1350 Ile Asp Thr Asn Gin Leu Met Trp Phe Phe Phe Leu Cys Pro Asn Leu 425 430 435 TGG GCT ATG CCG GTA CAG ATC ATT GTG GGC GTG ATC CTC CTC TAC TAC 1398 Trp Ala Met Pro Val Gin Ile Ile Val Gly Val Ile Leu Leu Tyr Tyr 440 445 450 ATC CTT GGG GTC AGC GCC TTG ATT GGA GCG GCT GTC ATC ATT CTG CTG 1446 Ile Leu Gly Val Ser Ala Leu Ile Gly Ala Ala Val Ile Ile Leu Leu 455 460 465 470 GCT CCT GTA CAG TAC TTT GTG GCC ACC AAG CTG TCC CAG GCA CAG CGG 1494 Ala Pro Val Gin Tyr Phe Val Ala Thr Lys Leu Ser Gin Ala Gin Arg 475 480 485 ACG ACC CTG GAA TAT TCC AAT GAG AGG CTG AAG CAG ACC AAT GAG ATG 1542 Thr Thr Leu Glu Tyr Ser Asn Glu Arg Leu Lys Gin Thr Asn Glu Met 490 495 500 CTC CGG GGC ATC AAG TTG CTC AAG CTC TAT GCG TGG GAG AAC ATC TTC 1590 Leu Arg Gly Ile Lys Leu Leu Lys Leu Tyr Ala Trp Glu Asn Ile Phe 505 510 515 TGC TCC AGG GTG GAG AAG ACA CGC AGG AAG GAA ATG ACC AGC CTC AGG 1638 Cys Ser Arg Val Glu Lys Thr Arg Arg Lys Glu Met Thr Ser Leu Arg 520 525 530 GCC TTC GCT GTC TAC ACC TCC ATC TCC ATC TTC ATG AAC ACA GCT ATC 1686 Ala Phe Ala Val Tyr Thr Ser Ile Ser Ile Phe Met Asn Thr Ala Ile 535 540 545 550 CCC ATC GCT GCT GTC CTC ATC ACC TTC GTG GGC CAC GTC AGC TTC TTC 1734 Pro Ile Ala Ala Val Leu Ile Thr Phe Val Gly His Val Ser Phe Phe 555 560 565 AAA GAG TCG GAC TTC TCG CCC TCG GTG GCC TTT GCC TCT CTC TCT CTC 1782 Lys Glu Ser Asp Phe Ser Pro Ser Val Ala Phe Ala Ser Leu Ser Leu 570 575 580 TTC CAC ATC CTG GTC ACA CCG CTG TTC CTG CTG TCT AGT GTG GTT CGG 1830 Phe His Ile Leu Val Thr Pro Leu Phe Leu Leu Ser Ser Val Val Arg 585 590 595 TCC ACT GTC AAG GCC CTG GTG AGC GTG CAA AAG CTG AGT GAG TTC CTG 1878 Ser Thr Val Lys Ala Leu Val Ser Val Gin Lys Leu Ser Glu Phe Leu 600 605 610 TCC AGT GCA GAG ATC CGT GAG GAA CAG TGT GCC CCC CGA GAG CCC GCA 1926 Ser Ser Ala Glu lie Arg Glu Glu Gin Cys Ala Pro Arg Glu Pro Ala 615 620 625 630 CCC CAA GGC CAA GCG GGC AAG TAC CAG GCG GTG CCC CTC AAG GTC GTA 1974 Pro Gin Gly Gin Ala Gly Lys Tyr Gin Ala Val Pro Leu Lys Val Val 635 640 645 AAC CGC AAG CGC CCA GCC CGA GAA GAA GTC CGG GAC CTC TTG GGC CCA 2022 Asn Arg Lys Arg Pro Ala Arg Glu Glu Val Arg Asp Leu Leu Gly Pro 650 655 660 CTG CAG AGG CTG ACT CCC AGC ACG GAT GGA GAC GCT GAC AAC TTC TGT 2070 Leu Gin Arg Leu Thr Pro Ser Thr Asp Gly Asp Ala Asp Asn Phe Cys 665 670 675 GTC CAG ATC ATC GGA GGC TTC TTC ACC TGG ACC CCT GAT GGA ATC CCC 2118 Val Gin Ile Ile Gly Gly Phe Phe Thr Trp Thr Pro Asp Gly Ile Pro 680 685 690 ACC CTG TCC AAC ATC ACC ATC CGT ATC CCC CGA GGT CAG CTG ACC ATG 2166 Thr Leu Ser Asn Ile Thr Ile Arg Ile Pro Arg Gly Gin Leu Thr Met 695 700 705 710 ATC GTG GGG CAG GTG GGC TGT GGC AAG TCC TCG CTC CTT CTG GCC ACC 2214 Ile Val Gly Gin Val Gly Cys Gly Lys Ser Ser Leu Leu Leu Ala Thr 715 720 725 CTG GGG GAG ATG CAG AAG GTC TCT GGA GCT GTC TTC TGG AAC AGC CTT 2262 Leu Gly Glu Met Gin Lys Val Ser Gly Ala Val Phe Trp Asn Ser Leu 730 735 740 CCA GAC AGC GAG GGG AGA AGA CCC CAG CAA CCC AGA GCG GGA GAC AGC 2310 Pro Asp Ser Glu Gly Arg Arg Pro Gin Gin Pro Arg Ala Gly Asp Ser 745 750 755 GGC CGA TTC GGA TGC CAG GAG CAG AGG CCC TGT GGC TAC GCA TCT CAG 2358 Gly Arg Phe Gly Cys Gin Glu Gin Arg Pro Cys Gly Tyr Ala Ser Gin 760 765 770 AAA CCA TGG CTG CTA AAT GCC ACT GTG GAG GAG AAC ATC ACC TTC GAG 2406 Lys Pro Trp Leu Leu Asn Ala Thr Val Glu Glu Asn Ile Thr Phe Glu 775 780 785 790 AGT CCC TTC AAT AAG CAA CGG TAC AAG ATG GTC ATC GAA GCC TGC TCC 2454 Ser Pro Phe Asn Lys Gin Arg Tyr Lys Met Val Ile Glu Ala Cys Ser 795 800 805 CTG CAG CCA GAC ATA GAC ATC CTG CCC CAT GGA GAC CAG ACT CAG ATT 2502 Leu Gin Pro Asp Ile Asp Ile Leu Pro His Gly Asp Gin Thr Gin Ile 810 815 820 GGG GAA CGA GGC ATC AAC TTG AGT ACT GGT GGT CAG CGT CCA GAT CAG 2550 Gly Glu Arg Gly Ile Asn Leu Ser Thr Gly Gly Gin Arg Pro Asp Gin 825 830 835 TGT AGA CCC GAG CCC TCT ACC AGC ACA CCA ATG ATT GTC TTT TTG GAT 2598 Cys Arg Pro Glu Pro Ser Thr Ser Thr Pro Met Ile Val Phe Leu Asp 840 845 850 GAC CCT TTC TCG GCT CTG GAT GTC CAT CTG AGT GAC CAC CTA ATG CAG 2646 Asp Pro Phe Ser Ala Leu Asp Val His Leu Ser Asp His Leu Met Gin 855 860 865 870 GCT GGC ATC CTC GAG CTG CTC CGG GAT GAC AAG AGG ACA GTG GTC TTG 2694 Ala Gly Ile Leu Glu Leu Leu Arg Asp Asp Lys Arg Thr Val Val Leu 875 880 885 GTG ACC CAC AAG CTA CAG TAC CTG CCT CAT GCT GAC TGG ATC ATT GCT 2742 Val Thr His Lys Leu Gin Tyr Leu Pro His Ala Asp Trp Ile Ile Ala 890 895 900 ATG AAG GAT GGC ACC ATT CAG AGG GAG GGG ACA CTC AAG GAC TTC CAG 2790 Met Lys Asp Gly Thr Ile Gin Arg Glu Gly Thr Leu Lys Asp Phe Gin 905 910 915 AGG TCT GAG TGC CAG CTC TTT GAG C£T TGG AAG ACC CTC ATG AAC CGG 2838 Arg Ser Glu Cys Gin Leu Phe Glu His Trp Lys Thr Leu Met Asn Arg 920 925 930 CAG GAC CAA GAC CTG GAG AAG GAG ACA GTC ATG GAG AGA AAA GCC CCA 2886 Gin Asp Gin Glu Leu Glu Lys Glu Thr Val Met Glu Arg Lys Ala Pro 935 940 945 950 GAG CCA TCT CAG GGC CTG CCC CGT GCC ATG TCC TCA AGA GAT GGC CTT 2934 Glu Pro Ser Gin Gly Leu Pro Arg Ala Met Ser Ser Arg Asp Gly Leu 955 960 965 CTG CTG GAT GAG GAT GAG GAG GAA GAG GAG GCA GCC GAG AGC GAG GAA 2982 ' Leu Leu Asp Glu Asp Glu Glu Glu Glu Glu Ala Ala Glu Ser Glu Glu 970 975 980 GAT GAC AAC TTA TCC TCT GTG CTG CAT CAG CGA GCC AAG ATC CCA TGG 3030 Asp Asp Asn Leu Ser Ser Val Leu His Gin Arg Ala Lys Ile Pro Trp 985 990 995 CGA GCC TGC ACC AAG TAT TTG TCC TCT GCT GGC ATC CTG CTC CTG TCC 3078 Arg Ala Cys Thr Lys Tyr Leu Ser Ser Ala Gly Ile Leu Leu Leu Ser 1000 1005 1010 CTG CTT GTC TTC TCC CAG CTG CTC AAG CAC ATG GTC TTG GTG GCC ATT 3126 Leu Leu Val Phe Ser Gin Leu Leu Lys His Met Val Leu Val Ala Ile 1015 1020 1025 1030 GAC TAC TGG CTG GCC AAG TGG ACG GAC AGT GCC CTG GTC CTG AGC CCC 3174 Asp Tyr Trp Leu Ala Lys Trp Thr Asp Ser Ala Leu Val Leu Ser Pro 1035 1040 1045 GCC GCC AGG AAC TGC TCC CTC AGC CAG GAA TGT GCC CTG GAC CAA TCT 3222 Ala Ala Arg Asn Cys Ser Leu Ser Gin Glu Cys Ala Leu Asp Gin Ser 1050 1055 1060 GTC TAT GCC ATG GTA TTC ACC GTG CTC TGC AGC CTG GGT ATC GCG CTG 3270 Val Tyr Ala Met Val Phe Thr Val Leu Cys Ser Leu Gly Ile Ala Leu 1065 1070 1075 TGC CTT GTC ACC TCT GTC ACT GTG GAG TGG ACG GGA CTG AAG GTG GCC 3318 Cys Leu Val Thr Ser Val Thr Val Glu Trp Thr Gly Leu Lys Val Ala 1080 1085 1090 AAG AGG CTG CAT CGC AGC CTG CTC AAC CGT ATC ATC CTG GCT CCC ATG 3366 Lys Arg Leu His Arg Ser Leu Leu Asn Arg Ile Ile Leu Ala Pro Met 1095 1100 1105 1110 AGG TTC TTT GAG ACC ACG CCC CTG GGG AGT ATC CTG AAC AGA TTT TCA 3414 Arg Phe Phe Glu Thr Thr Pro Leu Gly Ser Ile Leu Asn Arg Phe Ser 1115 1120 1125 TCT GAC TGT AAC ACC ATT GAC CAG CAT ATC CCG TCC ACG CTG GAG TGC 3462 Ser Asp Cys Asn Thr Ile Asp Gin His Ile Pro Ser Thr Leu Glu Cys 1130 1135 1140 CTG AGC AGA TCC ACC TTA CTC TGT GTC TCC GCC CTG GCT GTC ATC TCC 3510 Leu Ser Arg Ser Thr Leu Leu Cys Val Ser Ala Leu Ala Val Ile Ser 1145 1150 1155 TAC GTC ACG CCT GTG TTC CTA GTG GCC CTC TTA CCC CTC GCC GTC GTG 3558 Tyr Val Thr Pro Val Phe Leu Val Ala Leu Leu Pro Leu Ala Val Val 1160 1165 1170 TGC TAC TTC ATC CAG AAG TAC TTC CGA GTG GCG TCC AGG GAC CTG CAG 3606 Cys Tyr Phe Ile Gin Lys Tyr Phe Arg Val Ala Ser Arg Asp Leu Gin 1175 1180 1185 1190 CAG CTG GAC GAC ACA ACA CAG CTC CCT CTG CTC TCA CAC TTT GCT GAA 3654 Gin Leu Asp Asp Thr Thr Gin Leu Pro Leu Leu Ser His Phe Ala Glu 1195 1200 1205 ACT GTG GAA GGA CTC ACC ACC ATC CGT GCC TTC AGG TAC GAG GCC CGG 3702 Thr Val Glu Gly Leu Thr Thr Ile Arg Ala Phe Arg Tyr Glu Ala Arg 1210 1215 1220 TTC CAG CAG AAG CTC CTA GAG TAC ACC GAC TCC AAC AAC ATT GCC TCT .3750 Phe Gin Gin Lys Leu Leu Glu Tyr Thr Asp Ser Asn Asn Ile Ala Ser 1225 1230 1235 CTC TTC CTC ACA GCA GCC AAC AGG TGG CTG GAA GTC CGC ATG GAG TAC 3798 Leu Phe Leu Thr Ala Ala Asn Arg Trp Leu Glu Val Arg Met Glu Tyr 1240 1245 1250 ATC GGA GCA TGC GTG GTA CTC ATC GCC GCT GCC ACC TCC ATC TCC AAC 3846 Ile Gly Ala Cys Val Val Leu Ile Ala Ala Ala Thr Ser Ile Ser Asn 1255 1260 1265 1270 TCC CTA CAC AGG GAG CTC TCA GCC GGC CTA GTA GGC CTG GGC CTC ACC 3894 Ser Leu His Arg Glu Leu Ser Ala Gly Leu Val Gly Leu Gly Leu Thr 1275 1280 1285 TAT GCC TTG ATG ATT GGG ATC TGC GGC CGC ACA GGC AGT GGA AAA TCC 3942 Tyr Ala Leu Met Ile Gly Ile Cys Gly Arg Thr Gly Ser Gly Lys Ser 1290 1295 1300 TCC TTC TCT CTC GCC TTT TTC CGA ATG GTG GAT ATG TTT GAA GGG CGT 3990 Ser Phe Ser Leu Ala Phe Phe Arg Met Val Asp Met Phe Glu Gly Arg 1305 1310 1315 ATC ATC ATC GAT GGC ATT GAC ATC GCC AAG CTG CCG CTG CAC ACG CTC 4038 Ile Ile Ile Asp Gly Ile Asp Ile Ala Lys Leu Pro Leu His Thr Leu 1320 1325 1330 CGC TCA CGC CTG TCT ATC ATC CTA CAG GAC CCT GTT CTC TTC AGT GGT 4086 Arg Ser Arg Leu Ser Ile Ile Leu Gin Asp Pro Val Leu Phe Ser Gly 1335 1340 1345 1350 ACC ATC AGA TTC AAC CTG GAC CCA GAG AAG AAA TGC TCA GAC AGC ACG 4134 Thr Ile Arg Phe Asn Leu Asp Pro Glu Lys Lys Cys Ser Asp Ser Thr 1355 1360 1365 CTG TGG GAG GCT CTG GAG ATC GCT CAG CTG AAG CTG GTG GTG AAG GCC 4182 Leu Trp Glu Ala Leu Glu Ile Ala Gin Leu Lys Leu Val Val Lys Ala 1370 1375 1380 CTG CCA GGA GGC CTG GAT GCC ATC ATC ACG GAA GGA GGG GAG AAT TTT 4230 Leu Pro Gly Gly Leu Asp Ala Ile Ile Thr Glu Gly Gly Glu Asn Phe 1385 1390 1395 AGC CAG GGC CAG AGG CAG CTG TTC TGC CTG GCC CGG GCC TTT GTG AGG 4278 Ser Gin Gly Gin Arg Gin Leu Phe Cys Leu Ala Arg Ala Phe Val Arg 1400 1405 1410 AAG ACC AGC ATC TTC ATC ATG GAT GAA GCA ACT GCC TCC ATC GAC ATG 4326 Lys Thr Ser Ile Phe Ile Met Asp Glu Ala Thr Ala Ser Ile Asp Met 1415 1420 1425 1430 GCT ACG GAA AAT ATC CTC CAG AAG GTG GTG ATG ACA GCC TTC GCA GAC 4374 Ala Thr Glu Asn Ile Leu Gin Lys Val Val Met Thr Ala Phe Ala Asp 1435 1440 1445 CGC ACC GTG GTC ACC ATC GCG CAC CGC GTG CAC ACC ATC CTG AGT GCA 4422 Arg Thr Val Val Thr Ile Ala His Arg Val His Thr Ile Leu Ser Ala 1450 1455 1460 GAC CTA GTG ATG GTC CTG AAG AGG GGC GCG ATC CTG GAG TTC GAC AAG 4470 Asp Leu Val Met Val Leu Lys Arg Gly Ala Ile Leu Glu Phe Asp Lys 1465 1470 1475 CCG GAA AAG CTT CTC AGC CAG AAG GAC AGC GTC TTT GCC TCC TTT GTC 4518 Pro Glu Lys Leu Leu Ser Gin Lys Asp Ser Val Phe Ala Ser Phe Val 1480 1485 1490 CGC GCG GAC AAA TGACCAGCCA GCGCCAAAGT GCCACCCCAC ACCTCACCTG 4570 Arg Ala Asp Lys 1495 CTTGCCATGG ATTTCTTACT GTAAATCACT TGTAAATAAA GAAACTAATT CTTTGCTAAA 4630 AAAAA 4635 (6) INFORMATION FOR SEQ ID NO:5 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1498 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5 : Met Pro Leu Ala Phe Cys Gly Thr Glu Asn His Ser Ala Ala Tyr Arg 1 5 10 15 Val Asp Gin Gly Val Leu Asn Asn Gly Cys Phe Val Asp Ala Leu Asn 20 25 30 Val Val Pro His Val Phe Leu Leu Phe Ile Thr Phe Pro Ile Leu Phe 35 40 45 Ile Gly Trp Gly Ser Gin Ser Ser Lys Val His Ile His His Ser Thr 50 55 60 Trp Leu His Phe Pro Gly His Asn Leu Arg Trp Ile Leu Thr Phe Ile 65 70 75 80 Leu Leu Phe Val Leu Val Cys Glu Ile Ala Glu Gly Ile Leu Ser Asp 85 90 95 Gly Val Thr Glu Ser Arg H s Leu His Leu Tyr Met Pro Ala Gly Met 100 105 110 Ala Phe Met Ala Ala Ile Thr Ser Val Val Tyr Tyr His Asn Ile Glu 115 120 125 Thr Ser Asn Phe Pro Lys Leu Leu Ile Ala Leu Leu Ile Tyr Trp Thr 130 135 140 Leu Ala Phe Ile Thr Lys Thr Ile Lys Phe Val Lys Phe Tyr Asp His 145 150 155 160 Ala Ile Gly Phe Ser Gin Leu Arg Phe Cys Leu Thr Gly Leu Leu Val 165 170 175 Ile Leu Tyr Gly Met Leu Leu Leu Val Glu Val Asn Val Ile Arg Val 180 185 190 Arg Arg Tyr Val Phe Phe Lys Thr Pro Arg Glu Val Lys Pro Pro Glu 195 200 205 Asp Leu Gin Asp Leu Gly Val Arg Phe Leu Gin Pro Phe Val Asn Leu 210 215 220 Leu Ser Lys Gly Thr Tyr Trp Trp Met Asn Ala Phe Ile Lys Thr Ala 225 230 235 240 His Lys Lys Pro Ile Asp Leu Arg Ala Ile Gly Lys Leu Pro Ile Ala 245 250 255 Met Arg Ala Leu Thr Asn Tyr Gin Arg Leu Cys Leu Ala Phe Asp Ala 260 265 270 Gin Ala Arg Lys Asp Thr Gin Ser Gin Gin Gly Ala Arg Ala Ile Trp 275 280 285 Arg Ala Leu Cys His Ala Phe Gly Arg Arg Leu Val Leu Ser Ser Thr 290 295 300 Phe Arg Ile Leu Ala Asp Leu Leu Gly Phe Ala Gly Pro Leu Cys Ile 305 310 315 320 Phe Gly Ile Val Asp His Leu Gly Lys Glu Asn His Val Phe Gin Pro 325 330 335 Lys Thr Gin Phe Leu Gly Val Tyr Phe Val Ser Ser Gin Glu Phe Leu 340 345 350 Gly Asn Ala Tyr Val Leu Ala Val Leu Leu Phe Leu Ala Leu Leu Leu 355 360 365 Gin Arg Thr Phe Leu Gin Ala Ser Tyr Tyr Val Ala Ile Glu Thr Gly 370 375 380 Ile Asn Leu Arg Gly Ala Ile Gin Thr Lys Ile Tyr Asn Lys Ile Met 385 390 395 400 His Leu Ser Thr Ser Asn Leu Ser Met Gly Glu Met Thr Ala Gly Gin 405 410 415 Ile Cys Asn Leu Val Ala Ile Asp Thr Asn Gin Leu Met Trp Phe Phe 420 425 430 Phe Leu Cys Pro Asn Leu Trp Ala Met Pro Val Gin Ile Ile Val Gly 435 440 445 Val Ile Leu Leu Tyr Tyr Ile Leu Gly Val Ser Ala Leu Ile Gly Ala 450 455 460 Ala Val Ile Ile Leu Leu Ala Pro Val Gin Tyr Phe Val Ala Thr Lys 465 470 475 480 Leu Ser Gin Ala Gin Arg Thr Thr Leu Glu Tyr Ser Asn Glu Arg Leu 485 490 495 Lys Gin Thr Asn Glu Met Leu Arg Gly Ile Lys Leu Leu Lys Leu Tyr 500 505 510 Ala Trp Glu Asn Ile Phe Cys Ser Arg Val Glu Lys Thr Arg Arg Lys 515 520 525 Glu Met Thr Ser Leu Arg Ala Phe Ala Val Tyr Thr Ser Ile Ser Ile 530 535 540 Phe Met Asn Thr Ala Ile Pro Ile Ala Ala Val Leu Ile Thr Phe Val 545 550 555 560 Gly His Val Ser Phe Phe Lys Glu Ser Asp Phe Ser Pro Ser Val Ala 565 570 575 Phe Ala Ser Leu Ser Leu Phe His Ile Leu Val Thr Pro Leu Phe Leu 580 585 590 Leu Ser Ser Val Val Arg Ser Thr Val Lys Ala Leu Val Ser Val Gin 595 600 605 Lys Leu Ser Glu Phe Leu Ser Ser Ala Glu Ile Arg Glu Glu Gin Cys 610 615 620 Ala Pro Arg Glu Pro Ala Pro Gin Gly Gin Ala Gly Lys Tyr Gin Ala 625 630 635 640 Val Pro Leu Lys Val Val Asn Arg Lys Arg Pro Ala Arg Glu Glu Val 645 650 655 Arg Asp Leu Leu Gly Pro Leu Gin Arg Leu Thr Pro Ser Thr Asp Gly 660 665 670 Asp Ala Asp Asn Phe Cys Val Gin Ile Ile Gly Gly Phe Phe Thr Trp 675 680 685 Thr Pro Asp Gly Ile Pro Thr Leu Ser Asn Ile Thr Ile Arg Ile Pro 690 695 700 Arg Gly Gin Leu Thr Met Ile Val Gly Gin Val Gly Cys Gly Lys Ser 705 710 715 720 Ser Leu Leu Leu Ala Thr Leu Gly Glu Met Gin Lys Val Ser Gly Ala 725 730 735 Val Phe Trp Asn Ser Leu Pro Asp Ser Glu Gly Arg Arg Pro Gin Gin 740 745 750 Pro Arg Ala Gly Asp Ser Gly Arg Phe Gly Cys Gin Glu Gin Arg Pro 755 760 765 Cys Gly Tyr Ala Ser Gin Lys Pro Trp Leu Leu Asn Ala Thr Val Glu 770 775 780 Glu Asn Ile Thr Phe Glu Ser Pro Phe Asn Lys Gin Arg Tyr Lys Met 785 790 795 800 Val Ile Glu Ala Cys Ser Leu Gin Pro Asp Ile Asp Ile Leu Pro His 805 810 815 Gly Asp Gin Thr Gin Ile Gly Glu Arg Gly Ile Asn Leu Ser Thr Gly 820 825 830 Gly Gin Arg Pro Asp Gin Cys Arg Pro Glu Pro Ser Thr Ser Thr Pro 835 840 845 Met Ile Val Phe Leu Asp Asp Pro Phe Ser Ala Leu Asp Val His Leu 850 855 860 Ser Asp His Leu Met Gin Ala Gly Ile Leu Glu Leu Leu Arg Asp Asp 865 870 875 880 Lys Arg Thr Val Val Leu Val Thr His Lys Leu Gin Tyr Leu Pro His 885 890 895 Ala Asp Trp Ile Ile Ala Met Lys Asp Gly Thr Ile Gin Arg Glu Gly 900 905 910 Thr Leu Lys Asp Phe Gin Arg Ser Glu Cys Gin Leu Phe Glu His Trp 915 920 925 Lys Thr Leu Met Asn Arg Gin Asp Gin Glu Leu Glu Lys Glu Thr Val 930 935 940 Met Glu Arg Lys Ala Pro Glu Pro Ser Gin Gly Leu Pro Arg Ala Met 945 950 955 960 Ser Ser Arg Asp Gly Leu Leu Leu Asp Glu Asp Glu Glu Glu Glu Glu 965 970 975 Ala Ala Glu Ser Glu Glu Asp Asp Asn Leu Ser Ser Val Leu His Gin 980 985 990 Arg Ala Lys Ile Pro Trp Arg Ala Cys Thr Lys Tyr Leu Ser Ser Ala 995 1000 1005 Gly Ile Leu Leu Leu Ser Leu Leu Val Phe Ser Gin Leu Leu Lys His 1010 1015 1020 Met Val Leu Val Ala Ile Asp Tyr Trp Leu Ala Lys Trp Thr Asp Ser 1025 1030 1035 1040 Ala Leu Val Leu Ser Pro Ala Ala Arg Asn Cys Ser Leu Ser Gin Glu 1045 1050 1055 Cys Ala Leu Asp Gin Ser Val Tyr Ala Met Val Phe Thr Val Leu Cys 1060 1065 1070 Ser Leu Gly Ile Ala Leu Cys Leu Val Thr Ser Val Thr Val Glu Trp 1075 1080 1085 Thr Gly Leu Lys Val Ala Lys Arg Leu His Arg Ser Leu Leu Asn Arg 1090 1095 1100 Ile Ile Leu Ala Pro Met Arg Phe Phe Glu Thr Thr Pro Leu Gly Ser 1105 1110 1115 1120 Ile Leu Asn Arg Phe Ser Ser Asp Cys Asn Thr Ile Asp Gin His Ile 1125 1130 1135 Pro Ser Thr Leu Glu Cys Leu Ser Arg Ser Thr Leu Leu Cys Val Ser 1140 1145 1150 Ala Leu Ala Val Ile Ser Tyr Val Thr Pro Val Phe Leu Val Ala Leu 1155 1160 1165 Leu Pro Leu Ala Val Val Cys Tyr Phe Ile Gin Lys Tyr Phe Arg Val 1170 1175 1180 Ala Ser Arg Asp Leu Gin Gin Leu Asp Asp Thr Thr Gin Leu Pro Leu 1185 1190 1195 1200 Leu Ser His Phe Ala Glu Thr Val Glu Gly Leu Thr Thr Ile Arg Ala 1205 1210 1215 Phe Arg Tyr Glu Ala Arg Phe Gin Gin Lys Leu Leu Glu Tyr Thr Asp 1220 1225 1230 Ser Asn Asn Ile Ala Ser Leu Phe Leu Thr Ala Ala Asn Arg Trp Leu 1235 1240 1245 Glu Val Arg Met Glu Tyr Ile Gly Ala Cys Val Val Leu Ile Ala Ala 1250 1255 1260 Ala Thr Ser Ile Ser Asn Ser Leu His Arg Glu Leu Ser Ala Gly Leu 1265 1270 1275 1280 Val Gly Leu Gly Leu Thr Tyr Ala Leu Met Ile Gly Ile Cys Gly Arg 1285 1290 1295 Thr Gly Ser Gly Lys Ser Ser Phe Ser Leu Ala Phe Phe Arg Met Val 1300 1305 1310 Asp Met Phe Glu Gly Arg Ile Ile Ile Asp Gly Ile Asp Ile Ala Lys 1315 1320 1325 Leu Pro Leu His Thr Leu Arg Ser Arg Leu Ser Ile Ile Leu Gin Asp 1330 1335 1340 Pro Val Leu Phe Ser Gly Thr Ile Arg Phe Asn Leu Asp Pro Glu Lys 1345 1350 1355 1360 'Lys Cys Ser Asp Ser Thr Leu Trp Glu Ala Leu Glu Ile Ala Gin Leu 1365 1370 1375 Lys Leu Val Val Lys Ala Leu Pro Gly Gly Leu Asp Ala Ile Ile Thr 1380 1385 1390 Glu Gly Gly Glu Asn Phe Ser Gin Gly Gin Arg Gin Leu Phe Cys Leu 1395 1400 1405 Ala Arg Ala Phe Val Arg Lys Thr Ser Ile Phe Ile Met Asp Glu Ala 1410 1415 1420 Thr Ala Ser Ile Asp Met Ala Thr Glu Asn Ile Leu Gin Lys Val Val 1425 1430 1435 1440 Met Thr Ala Phe Ala Asp Arg Thr Val Val Thr Ile Ala His Arg Val 1445 1450 1455 His Thr Ile Leu Ser Ala Asp Leu Val Met Val Leu Lys Arg Gly Ala 1460 1465 1470 Ile Leu Glu Phe Asp Lys Pro Glu Lys Leu Leu Ser Gin Lys Asp Ser 1475 1480 1485 Val Phe Ala Ser Phe Val Arg Ala Asp Lys 1490 1495 (7) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4625 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 25..4521 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: AGCCGAGCCC GTGCGCGCGC CGCC ATG CCC TTG GCC TTC TGC GGT ACC GAG 51 Met Pro Leu Ala Phe Cys Gly Thr Glu 1 5 AAC CAC TCG GCC GCC TAC CGG GTG GAC CAG GGC GTC CTC AAC AAC GGC 99 Asn His Ser Ala Ala Tyr Arg Val Asp Gin Gly Val Leu Asn Asn Gly 10 15 20 25 TGC TTC GTG GAC GCG CTC AAC GTG GTG CCG CAC GTT TTC CTG CTC TTC 147 Cys Phe Val Asp Ala Leu Asn Val Val Pro His Val Phe Leu Leu Phe 30 35 40 ATC ACC TTC CCC ATC CTC TTC ATC GGA TGG GGC AGC CAG AGC TCC AAG 195 Ile Thr Phe Pro Ile Leu Phe Ile Gly Trp Gly Ser Gin Ser Ser Lys 45 50 55 GTG CAC ATC CAC CAC AGC ACC TGG CTG CAC TTT CCA GGG CAC AAC CTG 243 Val His Ile His His Ser Thr Trp Leu His Phe Pro Gly His Asn Leu 60 65 70 CGC TGG ATC CTT ACC TTC ATT TTG CTC TTC GTC CTT GTG TGT GAG ATC 291 Arg Trp Ile Leu Thr Phe Ile Leu Leu Phe Val Leu Val Cys Glu Ile 75 80 85 GCT GAG GGC ATC CTG TCT GAT GGG GTG ACA GAA TCC CGC CAC CTC CAC 339 Ala Glu Gly Ile Leu Ser Asp Gly Val Thr Glu Ser Arg His Leu His 90 95 100 105 CTG TAC ATG CCA GCC GGG ATG GCG TTC ATG GCT GCC ATC ACC TCT GTA 387 Leu Tyr Met Pro Ala Gly Met Ala Phe Met Ala Ala Ile Thr Ser Val 110 115 120 GTC TAC TAT CAT AAC ATC GAG ACC TCC AAC TTC CCC AAG CTT TTG ATC 435 Val Tyr Tyr His Asn Ile Glu Thr Ser Asn Phe Pro Lys Leu Leu Ile 125 130 135 GCT CTG CTC ATC TAT TGG ACC CTG GCC TTC ATC ACG AAG ACC ATC AAG 483 Ala Leu Leu Ile Tyr Trp Thr Leu Ala Phe Ile Thr Lys Thr Ile Lys 140 145 150 TTT GTC AAG TTC TAT GAC CAC GCC ATC GGC TTC TCC CAG CTG CGC TTC 531 Phe Val Lys Phe Tyr Asp His Ala Ile Gly Phe Ser Gin Leu Arg Phe 155 160 165 TGC CTC ACG GGG CTT CTG GTG ATC CTG TAT GGG ATG TTG CTG CTT GTG 579 Cys Leu Thr Gly Leu Leu Val Ile Leu Tyr Gly Met Leu Leu Leu Val 170 175 180 185 GAG GTC AAC GTC ATC AGA GTG AGG AGG TAC ATC TTC TTC AAG ACG CCA 627 Glu Val Asn Val Ile Arg Val Arg Arg Tyr Ile Phe Phe Lys Thr Pro 190 195 200 CGG GAG GTG AAG CCC CCT GAG GAC CTG CAG GAC CTG GGT GTG CGC TTT 675 Arg Glu Val Lys Pro Pro Glu Asp Leu Gin Asp Leu Gly Val Arg Phe 205 210 215 CTG CAG CCC TTC GTT AAC CTG CTG TCA AAG GGG ACC TAT TGG TGG ATG 723 Leu Gin Pro Phe Val Asn Leu Leu Ser Lys Gly Thr Tyr Trp Trp Met 220 225 230 AAT GCC TTC ATC AAG ACG GCC CAC AAG AAG CCC ATC GAC CTG CGG GCC 771 Asn Ala Phe Ile Lys Thr Ala His Lys Lys Pro Ile Asp Leu Arg Ala 235 240 245 ATC GCG AAG CTG CCC ATC GCC ATG AGA GCC CTC ACC AAC TAT CAG CGC 819 Ile Ala Lys Leu Pro Ile Ala Met Arg Ala Leu Thr Asn Tyr Gin Arg 250 255 260 265 CTC TGC GTG GCC TTC GAT GCT CAG GCG CGG AAG GAC ACA CAG AGC CCA 867 Leu Cys Val Ala Phe Asp Ala Gin Ala Arg Lys Asp Thr Gin Ser Pro 270 275 280 CAG GGT GCC CGG GCC ATC TGG AGG GCT CTA TGC CAT GCC TTT GGG AGA 915 Gin Gly Ala Arg Ala Ile Trp Arg Ala Leu Cys His Ala Phe Gly Arg 285 290 295 CGC CTG ATC CTC AGC AGC ACA TTC CGC ATC CTG GCT GAC CTG TTG GGC 963 Arg Leu Ile Leu Ser Ser Thr Phe Arg Ile Leu Ala Asp Leu Leu Gly 300 305 310 TTC GCT GGA CCA CTC TGC ATC TTT GGG ATC GTG GAC CAC CTG GGG AAG 1011 Phe Ala Gly Pro Leu Cys Ile Phe Gly Ile Val Asp His Leu Gly Lys 315 320 325 GAG AAC CAC GTC TTC CAG CCC AAG ACA CAG TTT CTC GGG GTT TAC TTC 1059 ' Glu Asn His Val Phe Gin Pro Lys Thr Gin Phe Leu Gly Val Tyr Phe 330 335 340 345 GTC TCT TCT CAA GAG TTC CTT GGC AAT GCC TAC GTC TTG GCC GTG CTT 1107 Val Ser Ser Gin Glu Phe Leu Gly Asn Ala Tyr Val Leu Ala Val Leu 350 355 360 CTG TTC CTT GCC CTG CTA CTG CAA AGG ACA TTC CTG CAA GCC TCA TAC 1155 Leu Phe Leu Ala Leu Leu Leu Gin Arg Thr Phe Leu Gin Ala Ser Tyr 365 370 375 TAC GTC GCC ATT GAA ACT GGA ATT AAC CTG AGA GGA GCA ATC CAG ACC 1203 Tyr Val Ala Ile Glu Thr Gly Ile Asn Leu Arg Gly Ala Ile Gin Thr 380 385 390 AAG ATT TAC AAT AAA ATC ATG CAC ATG TCC ACC TCC AAC CTG TCA ATG 1251 Lys Ile Tyr Asn Lys Ile Met His Met Ser Thr Ser Asn Leu Ser Met 395 400 405 GGG GAA ATG ACT GCT GGG CAG ATC TGC AAC CTG GTG GCC ATC GAC ACA 1299 Gly Glu Met Thr Ala Gly Gin Ile Cys Asn Leu Val Ala Ile Asp Thr 410 415 420 425 AAC CAG CTC ATG TGG TTC TTC TTT CTG TGC CCA AAC CTC TGG ACG ATG 1347 Asn Gin Leu Met Trp Phe Phe Phe Leu Cys Pro Asn Leu Trp Thr Met 430 435 440 CCA GTA CAG ATC ATT GTG GGC GTG ATC CTT CTC TAC TAC ATC CTT GGG 1395 Pro Val Gin Ile Ile Val Gly Val Ile Leu Leu Tyr Tyr Ile Leu Gly 445 450 455 GTC AGT GCC TTG ATT GGA GCA GCT GTC ATC ATT CTG CTG GCT CCT GTA 1443 Val Ser Ala Leu Ile Gly Ala Ala Val Ile Ile Leu Leu Ala Pro Val 460 465 470 CAG TAC TTT GTG GCC ACC AAG CTC TCC CAG GCA CAG CGG ACG ACC TTG 1491 Gin Tyr Phe Val Ala Thr Lys Leu Ser Gin Ala Gin Arg Thr Thr Leu 475 480 485 GAG CAC TCC AAC GAG AGG CTG AAG CAG ACC AAC GAG ATG CTC CGG GGC 1539 Glu His Ser Asn Glu Arg Leu Lys Gin Thr Asn Glu Met Leu Arg Gly 490 495 500 505 ATG AAG CTG CTC AAA CTG TAT GCG TGG GAG AGC ATC TTC TGC TCC AGG 1587 Met Lys Leu Leu Lys Leu Tyr Ala Trp Glu Ser Ile Phe Cys Ser Arg 510 515 520 GTG GAG GTG ACT CGC AGG AAG GAG ATG ACC AGC CTG AGG GCG TTT GCT 1635 Val Glu Val Thr Arg Arg Lys Glu Met Thr Ser Leu Arg Ala Phe Ala 525 530 535 GTC TAC ACT TCC ATC TCC ATC TTC ATG AAC ACA GCC ATC CCC ATT GCT 1683 Val Tyr Thr Ser Ile Ser Ile Phe Met Asn Thr Ala Ile Pro Ile Ala 540 545 550 GCC GTC CTC ATC ACC TTC GTG GGC CAC GTC AGC TTC TTC AAA GAG TCG 1731 Ala Val Leu Ile Thr Phe Val Gly His Val Ser Phe Phe Lys Glu Ser 555 560 565 GAC TTG TCA CCC TCG GTG GCC TTT GCC TCC CTC TCT CTC TTC CAC ATC 1779 Asp Leu Ser Pro Ser Val Ala Phe Ala Ser Leu Ser Leu Phe His Ile 570 575 580 585 CTG GTC ACT CCA CTG TTC CTG CTG TCT AGC GTG GTT CGG TCC ACT GTC 1827 Leu Val Thr Pro Leu Phe Leu Leu Ser Ser Val Val Arg Ser Thr Val 590 595 600 AAA GCC CTG GTG AGC GTG CAA AAA CTG AGC GAG TTC CTG TCT AGT GCA 1875 Lys Ala Leu Val Ser Val Gin Lys Leu Ser Glu Phe Leu Ser Ser Ala 605 610 615 GAG ATC CGT GAG GAG CAG TGT GCC CCC CGA GAG CCT GCA CCC CAA GGC 1923 Glu Ile Arg Glu Glu Gin Cys Ala Pro Arg Glu Pro Ala Pro Gin Gly 620 625 630 CAA GCC GGC AAG TAC CAG GCA GTG CCC CTC AAG GTT GTG AAC CGC AAA 1971 Gin Ala Gly Lys Tyr Gin Ala Val Pro Leu Lys Val Val Asn Arg Lys 635 640 645 CGC CCA GCC CGG GAA GAG GTC CGG GAC CTC CTG GGC CCA CTG CAG AGG 2019 Arg Pro Ala Arg Glu Glu Val Arg Asp Leu Leu Gly Pro Leu Gin Arg 650 655 660 665 CTG GCC CCT AGC ATG GAC GGG GAT GCT GAC AAC TTC TGT GTC CAG ATC 2067 Leu Ala Pro Ser Met Asp Gly Asp Ala Asp Asn Phe Cys Val Gin Ile 670 675 680 ATC GGA GGC TTC TTC ACC TGG ACC CCT GAT GGA ATC CCC ACT CTG TCC 2115 Ile Gly Gly Phe Phe Thr Trp Thr Pro Asp Gly Ile Pro Thr Leu Ser 685 690 695 AAC ATC ACC ATC CGT ATT CCC CGA GGT CAG CTA ACC ATG ATT GTG GGG 2163 Asn Ile Thr Ile Arg Ile Pro Arg Gly Gin Leu Thr Met Ile Val Gly 700 705 710 CAG GTG GGC TGC GGC AAG TCC TCG CTC CTC CTC GCC ACC CTG GGG GAG 2211 Gin Val Gly Cys Gly Lys Ser Ser Leu Leu Leu Ala Thr Leu Gly Glu 715 720 725 ATG CAG AAG GTG TCG GGG GCC GTC TTC TGG AAC AGC AAC CTT CCG GAC 2259 Met Gin Lys Val Ser Gly Ala Val Phe Trp Asn Ser Asn Leu Pro Asp 730 735 740 745 AGC GAG GGG AGA GGA CCC CAG CAG CCC AGA GCG GGA GAC AGC AGC TGG 2307 Ser Glu Gly Arg Gly Pro Gin Gin Pro Arg Ala Gly Asp Ser Ser Trp 750 755 760 CTC GGA TAT CAG GAG CAG AGG CCC CGT GGC TAC GCA TCT CAG AAA CCA 2355 Leu Gly Tyr Gin Glu Gin Arg Pro Arg Gly Tyr Ala Ser Gin Lys Pro 765 770 775 TGG CTG CTA AAC GCC ACC GTG GAA GAG AAC ATC ACC TTC GAG AGT CCC 2403 Trp Leu Leu Asn Ala Thr Val Glu Glu Asn Ile Thr Phe Glu Ser Pro 780 785 790 TTC AAT CCG CAG CGG TAC AAG ATG GTC ATC GAA GCC TGC TCC CTG CAG 2451 Phe Asn Pro Gin Arg Tyr Lys Met Val Ile Glu Ala Cys Ser Leu Gin 795 800 805 CCG GAC ATA GAC ATC CTG CCC CAC GGA GAC CAG ACT CAG ATT GGG GAA 2499 Pro Asp Ile Asp Ile Leu Pro His Gly Asp Gin Thr Gin Ile Gly Glu 810 815 820 825 CGG GGC ATC AAC CTG TCT GGT GGT CAG CGT CCA GAT CAG TGT GGT CCA 2547 Arg Gly Ile Asn Leu Ser Gly Gly Gin Arg Pro Asp Gin Cys Gly Pro 830 835 840 GAG CCC TCT ACC AGC AGA CCA ATG TTC GTC TTC TTG GAT GAC CCC TTC 2595 Glu Pro Ser Thr Ser Arg Pro Met Phe Val Phe Leu Asp Asp Pro Phe 845 850 855 TCA GCT TTG GAT GTC CAT CTG AGT GAC CAC CTG ATG CAG GCC GGC ATC 2643 Ser Ala Leu Asp Val His Leu Ser Asp His Leu Met Gin Ala Gly Ile 860 865 870 CTT GAG CTG CTC CGG GAT GAC AAG AGG ACA GTG GTC TTG GTG ACC CAC 2691 'Leu Glu Leu Leu Arg Asp Asp Lys Arg Thr Val Val Leu Val Thr His 875 880 885 AAG CTA CAG TAT CTG CCT CAT GCA GAC TGG ATC ATT GCC ATG AAG GAT 2739 Lys Leu Gin Tyr Leu Pro His Ala Asp Trp Ile Ile Ala Met Lys Asp 890 895 900 905 GGG ACC ATT CAG AGG GAA GGG ACG CTC AAG GAC TTC CAG AGG TCC GAG 2787 Gly Thr Ile Gin Arg Glu Gly Thr Leu Lys Asp Phe Gin Arg Ser Glu 910 915 920 TGC CAG CTC TTT GAG CAC TGG AAG ACC CTC ATG AAC CGG CAG GAC CAA 2835 Cys Gin Leu Phe Glu His Trp Lys Thr Leu Met Asn Arg Gin Asp Gin 925 930 935 GAG CTG GAG AAG GAG ACA GTC ATG GAG AGG AAA GCC TCA GAG CCA TCT 2883 Glu Leu Glu Lys Glu Thr Val Met Glu Arg Lys Ala Ser Glu Pro Ser 940 945 950 CAG GGC CTG CCC CGT GCC ATG TCC TCC AGA GAC GGC CTT CTG CTG GAT 2931 Gin Gly Leu Pro Arg Ala Met Ser Ser Arg Asp Gly Leu Leu Leu Asp 955 960 965 GAG GAA GAG GAG GAA GAG GAG GCA GCC GAA AGC GAG GAA GAT GAC AAC 2979 Glu Glu Glu Glu Glu Glu Glu Ala Ala Glu Ser Glu Glu Asp Asp Asn 970 975 980 985 TTA TCT TCA GTG CTG CAT CAG CGA GCT AAG ATC CCC TGG CGA GCC TGC 3027 Leu Ser Ser Val Leu His Gin Arg Ala Lys Ile Pro Trp Arg Ala Cys 990 995 1000 ACT AAG TAT CTG TCC TCT GCT GGC ATT CTG CTC CTG TCC CTG CTT GTC 3075 Thr Lys Tyr Leu Ser Ser Ala Gly Ile Leu Leu Leu Ser Leu Leu Val 1005 1010 1015 TTC TCC CAG CTG CTC AAG CAC ATG GTC TTG GTG GCC ATT GAT TAT TGG 3123 Phe Ser Gin Leu Leu Lys His Met Val Leu Val Ala Ile Asp Tyr Trp 1020 1025 1030 CTG GCC AAG TGG ACG GAC AGT GCC CTG GTC CTG AGC CCC GCT GCC AGG 3171 Leu Ala Lys Trp Thr Asp Ser Ala Leu Val Leu Ser Pro Ala Ala Arg 1035 1040 1045 AAC TGT TCG CTC AGC CAG GAA TGT GAC CTG GAC CAG TCT GTC TAT GCC 3219 Asn Cys Ser Leu Ser Gin Glu Cys Asp Leu Asp Gin Ser Val Tyr Ala 1050 1055 1060 1065 ATG GTA TTC ACC TTG CTC TGC AGC CTG GGT ATC GTG CTG TGC CTG GTC 3267 Met Val Phe Thr Leu Leu Cys Ser Leu Gly Ile Val Leu Cys Leu Val 1070 1075 1080 ACC TCT GTC ACT GTG GAG TGG ACG GGA CTG AAG GTG GCC AAG AGG CTA 3315 Thr Ser Val Thr Val Glu Trp Thr Gly Leu Lys Val Ala Lys Arg Leu 1085 1090 1095 CAC CGC AGC CTG CTC AAC CGC ATC ATC CTG GCC CCC ATG AGG TTC TTT 3363 His Arg Ser Leu Leu Asn Arg Ile Ile Leu Ala Pro Met Arg Phe Phe 1100 1105 1110 GAG ACC ACA CCC CTC GGG AGT ATC CTG AAC AGA TTT TCA TCC GAC TGT 3411 Glu Thr Thr Pro Leu Gly Ser Ile Leu Asn Arg Phe Ser Ser Asp Cys 1115 1120 1125 AAC ACC ATT GAC CAG CAC ATC CCA TCC ACG CTG GAG TGT CTG AGC CGG 3459 Asn Thr Ile Asp Gin His Ile Pro Ser Thr Leu Glu Cys Leu Ser Arg 1130 1135 1140 1145 TCC ACC CTG CTG TGT GTC TCC GCC CTG ACT GTC ATC TCC TAT GTC ACA 3507 Ser Thr Leu Leu Cys Val Ser Ala Leu Thr Val Ile Ser Tyr Val Thr 1150 1155 1160 CCC GTG TTC CTC GTG GCC CTC TTA CCC CTA GCT GTT GTG TGC TAC TTC 3555 Pro Val Phe Leu Val Ala Leu Leu Pro Leu Ala Val Val Cys Tyr Phe 1165 1170 1175 ATT CAG AAG TAC TTC CGA GTG GCA TCC AGG GAC CTG CAG CAG CTG GAC 3603 Ile Gin Lys Tyr Phe Arg Val Ala Ser Arg Asp Leu Gin Gin Leu Asp 1180 1185 1190 GAC ACG ACG CAG CTC CCG CTC GTC TCA CAC TTT GCT GAA ACT GTG GAG 3651 Asp Thr Thr Gin Leu Pro Leu Val Ser His Phe Ala Glu Thr Val Glu 1195 1200 1205 GGA CTC ACC ACC ATC CGT GCC TTC AGG TAC GAG GCC CGG TTC CAG CAG 3699 Gly Leu Thr Thr Ile Arg Ala Phe Arg Tyr Glu Ala Arg Phe Gin Gin 1210 1215 1220 1225 AAG CTT CTA GAA TAT ACC GAC TCC AAC AAC ATC GCC TCC CTC TTC CTC 3747 Lys Leu Leu Glu Tyr Thr Asp Ser Asn Asn Ile Ala Ser Leu Phe Leu 1230 1235 1240 ACG GCA GCC AAC AGA TGG CTG GAA GTC TGC ATG GAG TAC ATC GGA GCG 3795 Thr Ala Ala Asn Arg Trp Leu Glu Val Cys Met Glu Tyr Ile Gly Ala 1245 1250 1255 TGC GTG GTA CTC ATT GCG GCT GCC ACC TCC ATC TCC AAC TCC CTG CAC 3843 Cys Val Val Leu Ile Ala Ala Ala Thr Ser Ile Ser Asn Ser Leu His 1260 1265 1270 AGG GAA CTT TCT GCT GGC CTG GTG GGC CTG GGC CTC ACC TAT GCC TTG 3891 Arg Glu Leu Ser Ala Gly Leu Val Gly Leu Gly Leu Thr Tyr Ala Leu 1275 1280 1285 ATG ATC GGG ATC TGC GGC CGC ACA GCG AGC GGG AAG TCC TCC TTC TCC 3939 Met Ile Gly Ile Cys Gly Arg Thr Ala Ser Gly Lys Ser Ser Phe Ser 1290 1295 1300 1305 CTG GCC TTT TTC CGA ATG GTG GAC ATG TTT GAA GGA CGC ATC ATC ATT 3987 Leu Ala Phe Phe Arg Met Val Asp Met Phe Glu Gly Arg Ile Ile Ile 1310 1315 1320 GAT GGC ATC GAC ATC GCC AAG CTG CCA CTT CAC ACG CTG CGC TCA CGC 4035 Asp Gly Ile Asp Ile Ala Lys Leu Pro Leu His Thr Leu Arg Ser Arg 1325 1330 1335 CTG TCC ATC ATC CTA CAG GAC CCC GTC CTC TTC AGC GGC ACG ATC AGA 4083 Leu Ser Ile Ile Leu Gin Asp Pro Val Leu Phe Ser Gly Thr Ile Arg 1340 1345 1350 TTC AAC CTG GAC CCC GAG AAG AAA TGC TCA GAC AGC ACA CTG TGG GAG 4131 Phe Asn Leu Asp Pro Glu Lys Lys Cys Ser Asp Ser Thr Leu Trp Glu 1355 1360 1365 GCC CTG GAG ATC GCC CAG CTG AAG CTG GTA GTG AAG GCA CTG CCA GGA 4179 Ala Leu Glu Ile Ala Gin Leu Lys Leu Val Val Lys Ala Leu Pro Gly 1370 1375 1380 1385 GGC CTA GAT GCC ATC ATC ACA GAA GGA GGG GAG AAT TTT AGC CAG GGC 4227 Gly Leu Asp Ala Ile Ile Thr Glu Gly Gly Glu Asn Phe Ser Gin Gly 1390 1395 1400 CAG AGG CAG CTG TTC TGC CTG GCC CGG GCC TTC GTG AGG AAG ACC AGC 4275 Gin Arg Gin Leu Phe Cys Leu Ala Arg Ala Phe Val Arg Lys Thr Ser 1405 1410 1415 ATC TTC ATC ATG GAT GAA GCA ACC GCC TCC ATC GAC ATG GCT ACG GAG 4323 ' lie Phe Ile Met Asp Glu Ala Thr Ala Ser Ile Asp Met Ala Thr Glu 1420 1425 1430 AAC ATC CTC CAG AAG GTG GTG ATG ACA GCC TTC GCA GAC CGC ACG GTG 4371 Asn Ile Leu Gin Lys Val Val Met Thr Ala Phe Ala Asp Arg Thr Val 1435 1440 1445 GTC ACC ATC GCG CAT CGT GTG CAC ACC ATC CTG AGT GCA GAC CTG GTG 4419 Val Thr Ile Ala His Arg Val His Thr Ile Leu Ser Ala Asp Leu Val 1450 1455 1460 1465 ATG GTC CTC AAG AGG GGT GCT ATC CTG GAG TTT GAC AAG CCA GAG ACG 4467 Met Val Leu Lys Arg Gly Ala Ile Leu Glu Phe Asp Lys Pro Glu Thr 1470 1475 1480 CTC CTC AGC CAG AAG GAC AGC GTG TTC GCC TCC TTT GTC CGT GCG GAC 4515 Leu Leu Ser Gin Lys Asp Ser Val Phe Ala Ser Phe Val Arg Ala Asp 1485 1490 1495 AAG TGACTTACCG GAGCCAAAGT GCCACCCCGC GCCTCGCTTG CTTGCCTAGG 4568 Lys ATTTCTAACT GCAAATCACT TGTAAATAAA TTAATTCTTT GCTAAAAAAA AAAAAAA 4625 (8) INFORMATION FOR SEQ ID NO:7 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1498 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7: Met Pro Leu Ala Phe Cys Gly Thr Glu Asn His Ser Ala Ala Tyr Arg 1 5 10 15 Val Asp Gin Gly Val Leu Asn Asn Gly Cys Phe Val Asp Ala Leu Asn 20 25 30 Val Val Pro His Val Phe Leu Leu Phe Ile Thr Phe Pro Ile Leu Phe 35 40 45 Ile Gly Trp Gly Ser Gin Ser Ser Lys Val His Ile His His Ser Thr 50 55 60 Trp Leu His Phe Pro Gly His Asn Leu Arg Trp Ile Leu Thr Phe Ile 65 70 75 80 Leu Leu Phe Val Leu Val Cys Glu Ile Ala Glu Gly Ile Leu Ser Asp 85 90 95 Gly Val Thr Glu Ser Arg His Leu His Leu Tyr Met Pro Ala Gly Met 100 105 110 Ala Phe Met Ala Ala Ile Thr Ser Val Val Tyr Tyr His Asn Ile Glu 115 120 125 Thr Ser Asn Phe Pro Lys Leu Leu Ile Ala Leu Leu Ile Tyr Trp Thr 130 135 140 Leu Ala Phe Ile Thr Lys Thr Ile Lys Phe Val Lys Phe Tyr Asp His 145 150 155 160 Ala Ile Gly Phe Ser Gin Leu Arg Phe Cys Leu Thr Gly Leu Leu Val 165 170 175 Ile Leu Tyr Gly Met Leu Leu Leu Val Glu Val Asn Val Ile Arg Val 180 185 190 Arg Arg Tyr Ile Phe Phe Lys Thr Pro Arg Glu Val Lys Pro Pro Glu 195 200 205 Asp Leu Gin Asp Leu Gly Val Arg Phe Leu Gin Pro Phe Val Asn Leu 210 215 220 Leu Ser Lys Gly Thr Tyr Trp Trp Met Asn Ala Phe Ile Lys Thr Ala 225 230 235 240 His Lys Lys Pro Ile Asp Leu Arg Ala Ile Ala Lys Leu Pro Ile Ala 245 250 255 Met Arg Ala Leu Thr Asn Tyr Gin Arg Leu Cys Val Ala Phe Asp Ala 260 265 270 Gin Ala Arg Lys Asp Thr Gin Ser Pro Gin Gly Ala Arg Ala Ile Trp 275 280 285 Arg Ala Leu Cys His Ala Phe Gly Arg Arg Leu Ile Leu Ser Ser Thr 290 295 300 Phe Arg Ile Leu Ala Asp Leu Leu Gly Phe Ala Gly Pro Leu Cys Ile 305 310 315 320 Phe Gly Ile Val Asp His Leu Gly Lys Glu Asn His Val Phe Gin Pro 325 330 335 Lys Thr Gin Phe Leu Gly Val Tyr Phe Val Ser Ser Gin Glu Phe Leu 340 345 350 Gly Asn Ala Tyr Val Leu Ala Val Leu Leu Phe Leu Ala Leu Leu Leu 355 360 365 Gin Arg Thr Phe Leu Gin Ala Ser Tyr Tyr Val Ala Ile Glu Thr Gly 370 375 380 Ile Asn Leu Arg Gly Ala Ile Gin Thr Lys Ile Tyr Asn Lys Ile Met 385 390 395 400 Hi ' s Met Ser Thr Ser Asn Leu Ser Met Gly Glu Met Thr Ala Gly Gin 405 410 415 Ile Cys Asn Leu Val Ala Ile Asp Thr Asn Gin Leu Met Trp Phe Phe 420 425 430 Phe Leu Cys Pro Asn Leu Trp Thr Met Pro Val Gin Ile Ile Val Gly 435 440 445 Val Ile Leu Leu Tyr Tyr Ile Leu Gly Val Ser Ala Leu Ile Gly Ala 450 455 460 Ala Val Ile Ile Leu Leu Ala Pro Val Gin Tyr Phe Val Ala Thr Lys 465 470 475 480 Leu Ser Gin Ala Gin Arg Thr Thr Leu Glu His Ser Asn Glu Arg Leu 485 490 495 Lys Gin Thr Asn Glu Met Leu Arg Gly Met Lys Leu Leu Lys Leu Tyr 500 505 510 Ala Trp Glu Ser lie Phe Cys Ser Arg Val Glu Val Thr Arg Arg Lys 515 520 525 Glu Met Thr Ser Leu Arg Ala Phe Ala Val Tyr Thr Ser Ile Ser Ile 530 535 540 Phe Met Asn Thr Ala Ile Pro Ile Ala Ala Val Leu Ile Thr Phe Val 545 550 555 560 Gly His Val Ser Phe Phe Lys Glu Ser Asp Leu Ser Pro Ser Val Ala 565 570 575 Phe Ala Ser Leu Ser Leu Phe His Ile Leu Val Thr Pro Leu Phe Leu 580 585 590 Leu Ser Ser Val Val Arg Ser Thr Val Lys Ala Leu Val Ser Val Gin 595 600 605 Lys Leu Ser Glu Phe Leu Ser Ser Ala Glu Ile Arg Glu Glu Gin Cys 610 615 620 Ala Pro Arg Glu Pro Ala Pro Gin Gly Gin Ala Gly Lys Tyr Gin Ala 625 630 635 640 Val Pro Leu Lys Val Val Asn Arg Lys Arg Pro Ala Arg Glu Glu Val 645 650 655 Arg Asp Leu Leu Gly Pro Leu Gin Arg Leu Ala Pro Ser Met Asp Gly 660 665 670 Asp Ala Asp Asn Phe Cys Val Gin Ile Ile Gly Gly Phe Phe Thr Trp 675 680 685 Thr Pro Asp Gly Ile Pro Thr Leu Ser Asn Ile Thr Ile Arg Ile Pro 690 695 700 Arg Gly Gin Leu Thr Met Ile Val Gly Gin Val Gly Cys Gly Lys Ser 705 710 715 720 Ser Leu Leu Leu Ala Thr Leu Gly Glu Met Gin Lys Val Ser Gly Ala 725 730 735 Val Phe Trp Asn Ser Asn Leu Pro Asp Ser Glu Gly Arg Gly Pro Gin 740 745 750 Gin Pro Arg Ala Gly Asp Ser Ser Trp Leu Gly Tyr Gin Glu Gin Arg 755 760 765 Pro Arg Gly Tyr Ala Ser Gin Lys Pro Trp Leu Leu Asn Ala Thr Val 770 775 780 Glu Glu Asn Ile Thr Phe Glu Ser Pro Phe Asn Pro Gin Arg Tyr Lys 785 790 795 800 Met Val Ile Glu Ala Cys Ser Leu Gin Pro Asp Ile Asp Ile Leu Pro 805 810 815 His Gly Asp Gin Thr Gin Ile Gly Glu Arg Gly Ile Asn Leu Ser Gly 820 825 830 Gly Gin Arg Pro Asp Gin Cys Gly Pro Glu Pro Ser Thr Ser Arg Pro 835 840 845 Met Phe Val Phe Leu Asp Asp Pro Phe Ser Ala Leu Asp Val His Leu 850 855 860 Ser Asp His Leu Met Gin Ala Gly Ile Leu Glu Leu Leu Arg Asp Asp 865 870 875 880 Lys Arg Thr Val Val Leu Val Thr His Lys Leu Gin Tyr Leu Pro His 885 890 895 Ala Asp Trp Ile Ile Ala Met Lys Asp Gly Thr Ile Gin Arg Glu Gly 900 905 910 Thr Leu Lys Asp Phe Gin Arg Ser Glu Cys Gin Leu Phe Glu His Trp 915 920 925 Lys Thr Leu Met Asn Arg Gin Asp Gin Glu Leu Glu Lys Glu Thr Val 930 935 940 Met Glu Arg Lys Ala Ser Glu Pro Ser Gin Gly Leu Pro Arg Ala Met 945 950 955 960 Ser Ser Arg Asp Gly Leu Leu Leu Asp Glu Glu Glu Glu Glu Glu Glu 965 970 975 Ala Ala Glu Ser Glu Glu Asp Asp Asn Leu Ser Ser Val Leu His Gin 980 985 990 Arg Ala Lys Ile Pro Trp Arg Ala Cys Thr Lys Tyr Leu Ser Ser Ala 995 1000 1005 Gly Ile Leu Leu Leu Ser Leu Leu Val Phe Ser Gin Leu Leu Lys His 1010 1015 1020 Met Val Leu Val Ala Ile Asp Tyr Trp Leu Ala Lys Trp Thr Asp Ser 1025 1030 1035 1040 Ala Leu Val Leu Ser Pro Ala Ala Arg Asn Cys Ser Leu Ser Gin Glu 1045 1050 1055 Cys Asp Leu Asp Gin Ser Val Tyr Ala Met Val Phe Thr Leu Leu Cys 1060 1065 1070 Ser Leu Gly Ile Val Leu Cys Leu Val Thr Ser Val Thr Val Glu Trp 1075 1080 1085 Thr Gly Leu Lys Val Ala Lys Arg Leu His Arg Ser Leu Leu Asn Arg 1090 1095 1100 Ile Ile Leu Ala Pro Met Arg Phe Phe Glu Thr Thr Pro Leu Gly Ser 1105 1110 1115 1120 Ile Leu Asn Arg Phe Ser Ser Asp Cys Asn Thr Ile Asp Gin His Ile 1125 1130 1135 Pro Ser Thr Leu Glu Cys Leu Ser Arg Ser Thr Leu Leu Cys Val Ser 1140 1145 1150 Ala Leu Thr Val Ile Ser Tyr Val Thr Pro Val Phe Leu Val Ala Leu 1155 1160 1165 Leu Pro Leu Ala Val Val Cys Tyr Phe Ile Gin Lys Tyr Phe Arg Val 1170 1175 1180 Ala Ser Arg Asp Leu Gin Gin Leu Asp Asp Thr Thr Gin Leu Pro Leu 1185 1190 1195 1200 Val Ser His Phe Ala Glu Thr Val Glu Gly Leu Thr Thr Ile Arg Ala 1205 1210 1215 Phe Arg Tyr Glu Ala Arg Phe Gin Gin Lys Leu Leu Glu Tyr Thr Asp 1220 1225 1230 Ser Asn Asn Ile Ala Ser Leu Phe Leu Thr Ala Ala Asn Arg Trp Leu 1235 1240 1245 Glu Val Cys Met Glu Tyr Ile Gly Ala Cys Val Val Leu Ile Ala Ala 1250 1255 1260 Ala Thr Ser Ile Ser Asn Ser Leu His Arg Glu Leu Ser Ala Gly Leu 1265 1270 1275 1280 Val Gly Leu Gly Leu Thr Tyr Ala Leu Met Ile Gly Ile Cys Gly Arg 1285 1290 1295 Thr Ala Ser Gly Lys Ser Ser Phe Ser Leu Ala Phe Phe Arg Met Val 1300 1305 1310 Asp Met Phe Glu Gly Arg Ile Ile Ile Asp Gly Ile Asp Ile Ala Lys 1315 1320 1325 Leu Pro Leu His Thr Leu Arg Ser Arg Leu Ser Ile Ile Leu Gin Asp 1330 1335 1340 Pro Val Leu Phe Ser Gly Thr Ile Arg Phe Asn Leu Asp Pro Glu Lys 1345 1350 1355 1360 Lys Cys Ser Asp Ser Thr Leu Trp Glu Ala Leu Glu Ile Ala Gin Leu 1365 1370 1375 Lys Leu Val Val Lys Ala Leu Pro Gly Gly Leu Asp Ala Ile Ile Thr 1380 1385 1390 Glu Gly Gly Glu Asn Phe Ser Gin Gly Gin Arg Gin Leu Phe Cys Leu 1395 1400 1405 Ala Arg Ala Phe Val Arg Lys Thr Ser Ile Phe Ile Met Asp Glu Ala 1410 1415 1420 Thr Ala Ser Ile Asp Met Ala Thr Glu Asn Ile Leu Gin Lys Val Val 1425 1430 1435 1440 Met Thr Ala Phe Ala Asp Arg Thr Val Val Thr Ile Ala His Arg Val 1445 1450 1455 His Thr Ile Leu Ser Ala Asp Leu Val Met Val Leu Lys Arg Gly Ala 1460 1465 1470 Ile Leu Glu Phe Asp Lys Pro Glu Thr Leu Leu Ser Gin Lys Asp Ser 1475 1480 1485 Val Phe Ala Ser Phe Val Arg Ala Asp Lys 1490 1495 (9) INFORMATION FOR SEQ ID NO: 8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: ' amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8 : Met Pro Leu Ala Phe Cys Gly Thr 1 5 (10) INFORMATION FOR SEQ ID NO:9 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 11 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9: Asn His Ser Ala Ala Tyr Arg Val Asp Gin Gly 1 5 10 (11) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: GAGAGAAGCT TNTGNGGNGA NAANCA 26 (12) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA ( i) SEQUENCE DESCRIPTION: SEQ ID NO:11: GAGAGAGAAT TCCNTGNTCN ACNCNNTA 28 (13) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 47 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: TTTTGCGGGA CGGAGAATCA CTCGGCCGCC TACCGCGTCG ACCAAGG 47 (14) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: 'GCCNCCAUG 9 (15) INFORMATION FOR SEQ ID NO:14 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14 : GXXGXGK (16) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS (A) LENGTH. 4 ammo acids (D) TOPOLOGY linear (ii) MOLECULE TYPE: protem (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: XXXD (17) INFORMATION FOR SEQ ID NO:16: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: nucleic acids (ill) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (Xl) SEQUENCE DESCRIPTION SEQ ID NO:16- CACGCTCAGG TTCTGGAT 18 (18) INFORMATION FOR SEQ ID NO:17: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (n) MOLECULE TYPE: nucleic acids (ill) HYPOTHETICAL: NO (iv) ANTI-SENSE- YES (xi) SEQUENCE DESCRIPTION. SEQ ID NO:17: TCAACTGGAT GGTGAGGA 18 (17) INFORMATION FOR SEQ ID NO:18. (l) SEQUENCE CHARACTERISTICS. (A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS single (D) TOPOLOGY- linear (n) MOLECULE TYPE nucleic acid ( ll) HYPOTHETICAL: NO (iv) ANTI-SENSE. NO (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: TGACATCGCC AAACTGC 17 (18) INFORMATION FOR SEQ ID NO:19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: nucleic acid (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: YES (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19: TCCTGGCAGT GCCTTCA 17 (19) INFORMATION FOR SEQ ID NO:20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: nucleic acid (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: YES (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: TCCTCTCAGG GTCCAGGTTA 20 (20) INFORMATION FOR SEQ ID NO:21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: nucleic acid (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: ACAAGGAGCC TGGGGAT 17 (21) INFORMATION FOR SEQ ID NO:22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: Single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: nucleic acid (ill) HYPOTHETICAL: NO (iv) ANTI-SENSE: YES (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22: TGCATGGGTC CCAGTGA 17 (22) INFORMATION FOR SEQ ID NO: 3: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: nucleic acid (ill) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: TTGACCATTC ACCACATTGG TGTGC 25 (23) INFORMATION FOR SEQ ID NO:24: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: nucleic acid (ill) HYPOTHETICAL: NO (iv) ANTI-SENSE: YES (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24- TCCTGGCAGT GCCTTCA 17 (24) INFORMATION FOR SEQ ID NO:25- (l) SEQUENCE CHARACTERISTICS . (A) LENGTH- 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY, linear (n) MOLECULE TYPE: protein (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25: ACCATCGACC AGCACATC 18 (25) INFORMATION FOR SEQ ID NO:26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1308 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: nucleic acid (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26: GGACCTGCAG CAGCTGGATG ACACCACCCA GCTTCCACTT CTCTCACACT TTGCCGAAAC 60 CGTAGAAGGA CTCACCACCA TCCGGGCCTT CAGGTATGAG GCCCGGTTCC AGCAGAAGCT 120 TCTCGAATAC ACAGACTCCA ACAACATTGC TTCCCTCTTC CTCACAGCTG CCAACAGATG 180 GCTGGAAGTC CGAATGGAGT ACATCGGTGC ATGTGTGGTG CTCATCGCAG CGGTGACCTC 240 CATCTCCAAC TCCCTGCACA GGGAGCTCTC TGCTGGCCTG GTGGGCCTGG GCCTTACCTA 300 CGCCCTAATG GTCTCCAACT ACCTCAACTG GATGGTGAGG AACCTGGCAG ACATGGAGCT 360 CCAGCTGGGG GCTGTGAAGC GCATCCATGG GCTCCTGAAA ACCGAGGCAG AGAGCTACGA 420 GGGACTCCTG GCACCATCGC TGATCCCAAA GAACTGGCCA GACCAAGGGA AGATCCAGAT 480 CCAGAACCTG AGCGTGCGCT ACGACAGCTC CCTGAAGCCG GTGCTGAAGC ACGTCAATGC 540 CCTCATCTCC CCTGGACAGA AGATCGGGAT CTGCGGCCGC ACCGGCAGTG GGAAGTCCTC 600 CTTCTCTCTT GCCTTCTTCC GCATGGTGGA CACGTTCGAA GGGCACATCA TCATTGATGG 660 CATTGACATC GCCAAACTGC CGCTGCACAC CCTGCGCTCA CGCCTCTCCA TCATCCTGCA 720 GGACCCCGTC CTCTTCAGCG GCACCATCCG ATTTAACCTG GACCCTGAGA GGAAGTGCTC 780 AGATAGCACA CTGTGGGAGG CCCTGGAAAT CGCCCAGCTG AAGCTGGTGG TGAAGGCACT 840 GCCAGGAGGC CTCGATGCCA TCATCACAGA AGGCGGGGAG AATTTCAGCC AGGGACAGAG 900 GCAGCTGTTC TGCCTGGCCC GGGCCTTCGT GAGGAAGACC AGCATCTTCA TCATGGACGA 960 GGCCACGGCT TCCATTGACA TGGCCACGGA AAACATCCTC CAAAAGGTGG TGATGACAGC 1020 CTTCGCAGAC CGCACTGTGG TCACCATCGC GCATCGAGTG CACACCATCC TGAGTGCAGA 1080 CCTGGTGATC GTCCTGAAGC GGGGTGCCAT CCTTGAGTTC GATAAGCCAG AGAAGCTGCT 1140 CAGCCGGAAG GACAGCGTCT TCGCCTCCTT CGTCCGTGCA GACAAGTGAC CTGCCAGAGC 1200 CCAAGTGCCA TCCCACATTC GGACCCTGCC CATACCCCTG CCTGGGTTTT CTAACTGTAA 1260 ATCACTTGTA AATAAATAGA TTTGATTATT TCCTAAAAAA AAAAAAAA 1308 (26) INFORMATION FOR SEQ ID NO:27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1308 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 2..1186 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27: G GAC CTG CAG CAG CTG GAT GAC ACC ACC CAG CTT CCA CTT CTC TCA 46 Asp Leu Gin Gin Leu Asp Asp Thr Thr Gin Leu Pro Leu Leu Ser 1 5 10 15 CAC TTT GCC GAA ACC GTA GAA GGA CTC ACC ACC ATC CGG GCC TTC AGG 94 His Phe Ala Glu Thr Val Glu Gly Leu Thr Thr Ile Arg Ala Phe Arg 20 25 30 TAT GAG GCC CGG TTC CAG CAG AAG CTT CTC GAA TAC ACA GAC TCC AAC 142 Tyr Glu Ala Arg Phe Gin Gin Lys Leu Leu Glu Tyr Thr Asp Ser Asn 35 40 45 AAC ATT GCT TCC CTC TTC CTC ACA GCT GCC AAC AGA TGG CTG GAA GTC 190 Asn Ile Ala Ser Leu Phe Leu Thr Ala Ala Asn Arg Trp Leu Glu Val 50 55 60 CGA ATG GAG TAC ATC GGT GCA TGT GTG GTG CTC ATC GCA GCG GTG ACC 238 Arg Met Glu Tyr Ile Gly Ala Cys Val Val Leu Ile Ala Ala Val Thr 65 70 75 TCC ATC TCC AAC TCC CTG CAC AGG GAG CTC TCT GCT GGC CTG GTG GGC 286 Ser Ile Ser Asn Ser Leu His Arg Glu Leu Ser Ala Gly Leu Val Gly 80 85 90 95 CTG GGC CTT ACC TAC GCC CTA ATG GTC TCC AAC TAC CTC AAC TGG ATG 334 Leu Gly Leu Thr Tyr Ala Leu Met Val Ser Asn Tyr Leu Asn Trp Met 100 105 110 GTG AGG AAC CTG GCA GAC ATG GAG CTC CAG CTG GGG GCT GTG AAG CGC 382 Val Arg Asn Leu Ala Asp Met Glu Leu Gin Leu Gly Ala Val Lys Arg 115 120 125 ATC CAT GGG CTC CTG AAA ACC GAG GCA GAG AGC TAC GAG GGA CTC CTG 430 Ile His Gly Leu Leu Lys Thr Glu Ala Glu Ser Tyr Glu Gly Leu Leu 130 135 140 GCA CCA TCG CTG ATC CCA AAG AAC TGG CCA GAC CAA GGG AAG ATC CAG 478 Ala Pro Ser Leu Ile Pro Lys Asn Trp Pro Asp Gin Gly Lys Ile Gin 145 150 155 ATC CAG AAC CTG AGC GTG CGC TAC GAC AGC TCC CTG AAG CCG GTG CTG 526 Ile Gin Asn Leu Ser Val Arg Tyr Asp Ser Ser Leu Lys Pro Val Leu 160 165 170 175 AAG CAC GTC AAT GCC CTC ATC TCC CCT GGA CAG AAG ATC GGG ATC TGC 574 Lys His Val Asn Ala Leu Ile Ser Pro Gly Gin Lys Ile Gly Ile Cys 180 185 190 GGC CGC ACC GGC AGT GGG AAG TCC TCC TTC TCT CTT GCC TTC TTC CGC 622 Gly Arg Thr Gly Ser Gly Lys Ser Ser Phe Ser Leu Ala Phe Phe Arg 195 200 205 ATG GTG GAC ACG TTC GAA GGG CAC ATC ATC ATT GAT GGC ATT GAC ATC 670 Met Val Asp Thr Phe Glu Gly His Ile Ile Ile Asp Gly Ile Asp Ile 210 215 220 GCC AAA CTG CCG CTG CAC ACC CTG CGC TCA CGC CTC TCC ATC ATC CTG 718 Ala Lys Leu Pro Leu His Thr Leu Arg Ser Arg Leu Ser Ile Ile Leu 225 230 235 CAG GAC CCC GTC CTC TTC AGC GGC ACC ATC CGA TTT AAC CTG GAC CCT 766 Gin Asp Pro Val Leu Phe Ser Gly Thr Ile Arg Phe Asn Leu Asp Pro 240 245 250 255 GAG AGG AAG TGC TCA GAT AGC ACA CTG TGG GAG GCC CTG GAA ATC GCC 814 Glu Arg Lys Cys Ser Asp Ser Thr Leu Trp Glu Ala Leu Glu Ile Ala 260 265 270 CAG CTG AAG CTG GTG GTG AAG GCA CTG CCA GGA GGC CTC GAT GCC ATC 862 Gin Leu Lys Leu Val Val Lys Ala Leu Pro Gly Gly Leu Asp Ala Ile 275 280 285 ATC ACA GAA GGC GGG GAG AAT TTC AGC CAG GGA CAG AGG CAG CTG TTC 910 Ile Thr Glu Gly Gly Glu Asn Phe Ser Gin Gly Gin Arg Gin Leu Phe 290 295 300 TGC CTG GCC CGG GCC TTC GTG AGG AAG ACC AGC ATC TTC ATC ATG GAC 958 Cys Leu Ala Arg Ala Phe Val Arg Lys Thr Ser Ile Phe Ile Met Asp 305 310 315 GAG GCC ACG GCT TCC ATT GAC ATG GCC ACG GAA AAC ATC CTC CAA AAG 1006 Glu Ala Thr Ala Ser Ile Asp Met Ala Thr Glu Asn Ile Leu Gin Lys 320 325 330 335 GTG GTG ATG ACA GCC TTC GCA GAC CGC ACT GTG GTC ACC ATC GCG CAT 1054 Val Val Met Thr Ala Phe Ala Asp Arg Thr Val Val Thr Ile Ala His 340 345 350 CGA GTG CAC ACC ATC CTG AGT GCA GAC CTG GTG ATC GTC CTG AAG CGG 1102 Arg Val His Thr Ile Leu Ser Ala Asp Leu Val Ile Val Leu Lys Arg 355 360 365 GGT GCC ATC CTT GAG TTC GAT AAG CCA GAG AAG CTG CTC AGC CGG AAG 1150 Gly Ala Ile Leu Glu Phe Asp Lys Pro Glu Lys Leu Leu Ser Arg Lys 370 375 380 GAC AGC GTC TTC GCC TCC TTC GTC CGT GCA GAC AAG TGACCTGCCA 1196 Asp Ser Val Phe Ala Ser Phe Val Arg Ala Asp Lys 385 390 395 GAGCCCAAGT GCCATCCCAC ATTCGGACCC TGCCCATACC CCTGCCTGGG TTTTCTAACT 1256 GTAAATCACT TGTAAATAAA TAGATTTGAT TATTTCCTAA AAAAAAAAAA AA 1308 (27) INFORMATION FOR SEQ ID NO:28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 395 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28: Asp Leu Gin Gin Leu Asp Asp Thr Thr Gin Leu Pro Leu Leu Ser His 1 5 10 15 Phe Ala Glu Thr Val Glu Gly Leu Thr Thr Ile Arg Ala Phe Arg Tyr 20 25 30 Glu Ala Arg Phe Gin Gin Lys Leu Leu Glu Tyr Thr Asp Ser Asn Asn 35 40 45 Ile Ala Ser Leu Phe Leu Thr Ala Ala Asn Arg Trp Leu Glu Val Arg 50 55 60 Met Glu Tyr Ile Gly Ala Cys Val Val Leu Ile Ala Ala Val Thr Ser 65 70 75 80 Ile Ser Asn Ser Leu His Arg Glu Leu Ser Ala Gly Leu Val Gly Leu 85 90 95 Gly Leu Thr Tyr Ala Leu Met Val Ser Asn Tyr Leu Asn Trp Met Val 100 105 . 110 Arg Asn Leu Ala Asp Met Glu Leu Gin Leu Gly Ala Val Lys Arg Ile 115 120 125 His Gly Leu Leu Lys Thr Glu Ala Glu Ser Tyr Glu Gly Leu Leu Ala 130 135 140 Pro Ser Leu Ile Pro Lys Asn Trp Pro Asp Gin Gly Lys Ile Gin Ile 145 150 155 160 Gin Asn Leu Ser Val Arg Tyr Asp Ser Ser Leu Lys Pro Val Leu Lys 165 170 175 His Val Asn Ala Leu Ile Ser Pro Gly Gin Lys Ile Gly Ile Cys Gly 180 185 190 Arg Thr Gly Ser Gly Lys Ser Ser Phe Ser Leu Ala Phe Phe Arg Met 195 200 205 Val Asp Thr Phe Glu Gly His Ile Ile Ile Asp Gly Ile Asp Ile Ala 210 215 220 Lys Leu Pro Leu His Thr Leu Arg Ser Arg Leu Ser Ile Ile Leu Gin 225 230 235 240 Asp Pro Val Leu Phe Ser Gly Thr Ile Arg Phe Asn Leu Asp Pro Glu 245 250 255 Arg Lys Cys Ser Asp Ser Thr Leu Trp Glu Ala Leu Glu Ile Ala Gin 260 265 270 Leu Lvs Leu Val Val Lys Ala Leu Pro Gly Gly Leu Asp Ala Ile Ile 275 280 285 Thr Glu Gly Gly Glu Asn Phe Ser Gin Gly Gin Arg Gin Leu Phe Cys 290 295 300 Leu Ala Arg Ala Phe Val Arg Lys Thr Ser Ile Phe Ile Met Asp Glu 305 310 315 320 Ala Thr Ala Ser Ile Asp Met Ala Thr Glu Asn Ile Leu Gin Lys Val 325 330 335 Val Met Thr Ala Phe Ala Asp Arg Thr Val Val Thr Ile Ala His Arg 340 345 350 Val His Thr Ile Leu Ser Ala Asp Leu Val Ile Val Leu Lys Arg Gly 355 360 365 Ala Ile Leu Glu Phe Asp Lys Pro Glu Lys Leu Leu Ser Arg Lys Asp 370 375 380 Ser Val Phe Ala Ser Phe Val Arg Ala Asp Lys 385 390 395 (28) INFORMATION FOR SEQ ID NO:29: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 195 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: nucleic acid (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9: CCATGCCTGG TGGCTGAGCC CAGCCCAGCC CCCAGCACCA TCGCTGATCC CAAAGAACTG 60 GCCAGACCAA GGGAAGATCC AGATCCAGAA CCTGAGCGTG CGCTACGACA GCTCCCTGAA 120 GCCGGTGCTG AAGCACGTCA ATGCCCTCAT CTCCCCTGGA CAGAAGGTCA GTGCACGGGC 180 CCAACCCAAT GCTGC 195 (29) INFORMATION FOR SEQ ID NO:30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2454 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: nucleic acid (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30: CTGCTCTCTG CAGCCAGACA TCGACATCCT GCCCCATGGA GACCAGACCC AGATTGGGGA 60 ACGGGGCATC AACCTGTCTG GTGGTCAACG CCAGCGAATC AGTGTGGCCC GAGCCCTCTA 120 CCAGCACGCC AACGTTGTCT TCTTGGATGA CCCCTTCTCA GCTCTGGATA TCCATCTGAG 180 TGACCACTTA ATGCAGGCCG GCATCCTTGA GCTGCTCCGG GACGACAAGA GGACAGTGGT 240 CTTAGTGACC CACAAGCTAC AGTACCTGCC CCATGCAGAC TGGATCATTG CCATGAAGGA 300 TGGCACCATC CAGAGGGAGG GTACCCTCAA GGACTTCCAG AGGTCTGAAT GCCAGCTCTT 360 TGAGCACTGG AAGACCCTCA TGAACCGACA GGACCAAGAG CTGGAGAAGG AGACTGTCAC 420 AGAGAGAAAA GCCACAGAGC CACCCCAGGG CCTATCTCGT GCCATGTCCT CGAGGGATGG 480 CCTTCTGCAG GATGAGGAAG AGGAGGAAGA GGAGGCAGCT GAGAGCGAGG AGGATGACAA 540 CCTGTCGTCC ATGCTGCACC AGCGTGCTGA GATCCCATGG CGAGCCTGCG CCAAGTACCT 600 GTCCTCCGCC GGCATCCTGC TCCTGTCGTT GCTGGTCTTC TCACAGCTGC TCAAGCACAT 660 GGTCCTGGTG GCCATCGACT ACTGGCTGGC CAAGTGGACC GACAGCGCCC TGACCCTGAC 720 CCCTGCAGCC AGGAACTGCT CCCTCAGCCA GGAGTGCACC CTCGACCAGA CTGTCTATGC 780 CATGGTGTTC ACGGTGCTCT GCAGCCTGGG CATTGTGCTG TGCCTCGTCA CGTCTGTCAC 840 TGTGGAGTGG ACAGGGCTGA AGGTGGCCAA GAGACTGCAC CGCAGCCTGC TAAACCGGAT 900 CATCCTAGCC CCCATGAGGT TTTTTGAGAC CACTCCCCTT GGGAGCATCC TGAACAGATT 960 TTCATCTGAC TGTAACACCA TCGACCAGCA CATCCCATCC ACGCTGGAGT GCCTGAGCCG 1020 CTCCACCCTG CTCTGTGTCT CAGCCCTGGC CGTCATCTCC TATGTCACAC CTGTGTTCCT 1080 CGTGGCCCTC CTTCCCCTGG CCATCGTGTG CTACTTCATC CAGAAGTACT TCCGGGTGGC 1140 GTCCAGGGAC CTGCAGCAGC TGGATGACAC CACCCAGCTT CCACTTCTCT CACACTTTGC 1200 CGAAACCGTA GAAGGACTCA CCACCATCCG GGCCTTCAGG TATGAGGCCC GGTTCCAGCA 1260 GAAGCTTCTC GAATACACAG ACTCCAACAA CATTGCTTCC CTCTTCCTCA CAGCTGCCAA 1320 CAGATGGCTG GAAGTCCGAA TGGAGTACAT CGGTGCATGT GTGGTGCTCA TCGCAGCGGT 1380 GACCTCCATC TCCAACTCCC TGCACAGGGA GCTCTCTGCT GGCCTGGTGG GCCTGGGCCT 1440 TACCTACGCC CTAATGGTCT CCAACTACCT CAACTGGATG GTGAGGAACC TGGCAGACAT 1500 GGAGCTCCAG CTGGGGGCTG TGAAGCGCAT CCATGGGCTC CTGAAAACCG AGGCAGAGAG 1560 CTACGAGGGA CTCCTGGCAC CATCGCTGAT CCCAAAGAAC TGGCCAGACC AAGGGAAGAT 1620 CCAGATCCAG AACCTGAGCG TGCGCTACGA CAGCTCCCTG AAGCCGGTGC TGAAGCACGT 1680 CAATGCCCTC ATCTCCCCTG GACAGAAGAT CGGGATCTGC GGCCGCACCG GCAGTGGGAA 1740 GTCCTCCTTC TCTCTTGCCT TCTTCCGCAT GGTGGACACG TTCGAAGGGC ACATCATCAT 1800 TGATGGCATT GACATCGCCA AACTGCCGCT GCACACCCTG CGCTCACGCC TCTCCATCAT 1860 CCTGCAGGAC CCCGTCCTCT TCAGCGGCAC CATCCGATTT AACCTGGACC CTGAGAGGAA 1920 GTGCTCAGAT AGCACACTGT GGGAGGCCCT GGAAATCGCC CAGCTGAAGC TGGTGGTGAA 1980 GGCACTGCCA GGAGGCCTCG ATGCCATCAT CACAGAAGGC GGGGAGAATT TCAGCCAGGG 2040 ACAGAGGCAG CTGTTCTGCC TGGCCCGGGC CTTCGTGAGG AAGACCAGCA TCTTCATCAT 2100 GGACGAGGCC ACGGCTTCCA TTGACATGGC CACGGAAAAC ATCCTCCAAA AGGTGGTGAT 2160 GACAGCCTTC GCAGACCGCA CTGTGGTCAC CATCGCGCAT CGAGTGCACA CCATCCTGAG 2220 TGCAGACCTG GTGATCGTCC TGAAGCGGGG TGCCATCCTT GAGTTCGATA AGCCAGAGAA 2280 GCTGCTCAGC CGGAAGGACA GCGTCTTCGC CTCCTTCGTC CGTGCAGACA AGTGACCTGC 2340 CAGAGCCCAA GTGCCATCCC ACATTCGGAC CCTGCCCATA CCCCTGCCTG GGTTTTCTAA 2400 CTGTAAATCA CTTGTAAATA AATAGATTTG ATTATTTCCT AAAAAAAAAA AAAA 2454 (30) INFORMATION FOR SEQ ID NO:31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2294 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: nucleic acid (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO ( i) SEQUENCE DESCRIPTION: SEQ ID NO:31: GATGACCCCT TCTCAGCTTT GGATGTCCAT CTGAGTGACC ACCTGATGCA GGCCGGCATC 60 CTTGAGCTGC TCCGGGATGA CAAGAGGACA GTGGTCTTGG TGACCCACAA GCTACAGTAT 120 CTGCCTCATG CAGACTGGAT CATTGCCATG AAGGATGGGA CCATTCAGAG GGAAGGGACG 180 CTCAAGGACT TCCAGAGGTC CGAGTGCCAG CTCTTTGAGC ACTGGAAGAC CCTCATGAAC 240 CGGCAGGACC AAGAGCTGGA GAAGGAGACA GTCATGGAGA GGAAAGCCTC AGAGCCATCT 300 CAGGGCCTGC CCCGTGCCAT GTCCTCCAGA GACGGCCTTC TGCTGGATGA GGAAGAGGAG 360 GAAGAGGAGG CAGCCGAAAG CGAGGAAGAT GACAACTTAT CTTCAGTGCT GCATCAGCGA 420 GCTAAGATCC CCTGGCGAGC CTGCACTAAG TATCTGTCCT CTGCTGGCAT TCTGCTCCTG 480 TCCCTGCTTG TCTTCTCCCA GCTGCTCAAG CACATGGTCT TGGTGGCCAT TGATTATTGG 540 CTGGCCAAGT GGACGGACAG TGCCCTGGTC CTGAGCCCCG CTGCCAGGAA CTGTTCGCTC 600 AGCCAGGAAT GTGACCTGGA CCAGTCTGTC TATGCCATGG TATTCACCTT GCTCTGCAGC 660 CTGGGTATCG TGCTGTGCCT GGTCACCTCT GTCACTGTGG AGTGGACGGG ACTGAAGGTG 720 GCCAAGAGGC TACACCGCAG CCTGCTCAAC CGCATCATCC TGGCCCCCAT GAGGTTCTTT 780 GAGACCACAC CCCTCGGGAG TATCCTGAAC AGATTTTCAT CCGACTGTAA CACCATTGAC 840 CAGCACATCC CATCCACGCT GGAGTGTCTG AGCCGGTCCA CCCTGCTGTG TGTCTCCGCC 900 CTGACTGTCA TCTCCTATGT CACACCCGTG TTCCTCGTGG CCCTCTTACC CCTAGCTGTT 960 GTGTGCTACT TCATTCAGAA GTACTTCCGA GTGGCATCCA GGGACCTGCA GCAGCTGGAC 1020 GACACGACGC AGCTCCCGCT CGTCTCACAC TTTGCTGAAA CTGTGGAGGG ACTCACCACC 1080 ATCCGTGCCT TCAGGTACGA GGCCCGGTTC CAGCAGAAGC TTCTAGAATA TACCGACTCC 1140 AACAACATCG CCTCCCTCTT CCTCACGGCA GCCAACAGAT GGCTGGAAGT CTGCATGGAG 1200 TACATCGGAG CGTGCGTGGT ACTCATTGCG GCTGCCACCT CCATCTCCAA CTCCCTGCAC 1260 AGGGAACTTT CTGCTGGCCT GGTGGGCCTG GGCCTCACCT ATGCCTTGAT GGTCTCCAAC 1320 TACCTCAACT GGATGGTGAG GAACCTGGCG GACATGGAGA TCCAGCTGGG GGCTGTGAAG 1380 AGGATCCACG CACTCCTGAA AACCGAGGCG GAGAGCTATG AGGGGCTCCT GGCGCCGTCG 1440 ■ TTGATCCCCA AGAACTGGCC AGACCAAGGG AAGATCCAAA TTCAGAACCT GAGCGTGCGC 1500 TATGACAGCT CCCTGAAGCC AGTGCTGAAG CATGTCAACA CCCTCATCTC CCCGGGGCAG 1560 AAGATCGGGA TCTGCGGCCG CACAGGCAGC GGGAAGTCCT CCTTCTCCCT GGCCTTTTTC 1620 CGAATGGTGG ACATGTTTGA AGGACGCATC ATCATTGATG GCATCGACAT CGCCAAGCTG 1680 CCACTTCACA CGCTGCGCTC ACGCCTGTCC ATCATCCTAC AGGACCCCGT CCTCTTCAGC 1740 GGCACGATCA GATTCAACCT GGACCCCGAG AAGAAATGCT CAGACAGCAC ACTGTGGGAG 1800 GCCCTGGAGA TCGCCCAGCT GAAGCTGGTA GTGAAGGCAC TGCCAGGAGG CCTAGATGCC 1860 ATCATCACAG AAGGAGGGGA GAATTTTAGC CAGGGCCAGA GGCAGCTGTT CTGCCTGGCC 1920 CGGGCCTTCG TGAGGAAGAC CAGCATCTTC ATCATGGATG AAGCAACCGC CTCCATCGAC 1980 ATGGCTACGG AGAACATCCT CCAGAAGGTG GTGATGACAG CCTTCGCAGA CCGCACGGTG 2040 GTCACCATCG CGCATCGTGT GCACACCATC CTGAGTGCAG ACCTGGTGAT GGTCCTCAAG 2100 AGGGGTGCTA TCCTGGAGTT TGACAAGCCA GAGACGCTCC TCAGCCAGAA GGACAGCGTG 2160 TTCGCCTCCT TTGTCCGTGC GGACAAGTGA CTTACCGGAG CCAAAGTGCC ACCCCGCGCC 2220 TCGCTTGCTT GCCTAGGATT TCTAACTGCA AATCACTTGT AAATAAATTA ATTCTTTGCT 2280 AAAAAAAAAA AAAA 2294 (31) INFORMATION FOR SEQ ID N0:32: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5110 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: nucleic acid (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32: CCCTTGTGAC AGGTCAGTCT TACGAGAATA TGGTAACTGA GATCATGTCA ATGGGCTATG 60 AACGAGAACA AGTAATTGCA GCCCTGAGAG CCAGCTTCAA CAACCCTGAT AGAGCTGTGG 120 AATATCTTCT AATGGGAATC CCTGGAGACT GAGGAGTTCC AGTACTCACA GCCTGTGGAG 180 GAGGATCAAC CACGGCCTGA CTTTCGCGGC CGCCGCGGGA GGCGCGCGGA GCCGGAGCCG 240 AGCCCGTGCG CGCGCCACCA TGCCTTTGGC CTTCTGCGGC ACCGAGAACC ACTCGGCCGC 300 CTACCGGGTG GACCAAGGCG TCCTCAACAA CGGCTGCTTC GTGGACGCGC TCAATGTGGT 360 GCCACATGTC TTTCTGCTCT TCATCACCTT CCCCATCCTC TTCATCGGAT GGGGCAGCCA 420 GAGCTCCAAG GTGCACATTC ACCACAGCAC CTGGCTCCAT TTCCCGGGGC ACAACCTGCG 480 CTGGATCCTG ACCTTCATAC TGCTCTTCGT CCTCGTGTGT GAGATCGCTG AGGGTATCCT 540 GTCTGACGGG GTGACAGAAT CCCGCCACCT CCACTTATAC ATGCCAGCTG GGATGGCATT 600 CATGGCTGCC ATCACCTCTG TGGTCTACTA CCATAACATT GAGACCTCTA ACTTTCCCAA 660 GCTGCTGATT GCTCTGCTCA TCTACTGGAC CCTGGCCTTC ATCACGAAGA CCATCAAGTT 720 CGTCAAGTTC TACGACCACG CCATTGGCTT CTCTCAGCTG CGCTTCTGCC TCACGGGGCT 780 TCTGGTGATC CTCTACGGGA TGCTGCTGCT TGTGGAGGTC AATGTCATCC GGGTGAGGAG 840 ATACGTCTTC TTCAAGACAC CAAGGGAAGT AAAGCCCCCC GAGGACCTAC AGGACCTGGG 900 TGTGCGCTTT CTGCAGCCCT TCGTTAACCT GCTATCAAAG GGGACCTACT GGTGGATGAA 960 TGCCTTCATC AAGACTGCTC ACAAGAAGCC CATCGACCTG CGGGCCATCG GGAAGCTGCC 1020 CATTGCCATG AGAGCCCTCA CCAACTACCA GCGACTCTGC TTGGCCTTCG ATGCCCAGGC 1080 GCGGAAGGAC ACACAGAGCC AGCAGGGTGC CCGGGCCATC TGGAGGGCTC TCTGTCATGC 1140 CTTTGGGAGA CGGCTGGTCC TCAGCAGCAC ATTCCGTATC CTGGCCGACC TCCTGGGCTT 1200 TGCTGGGCCA CTCTGCATCT TCGGGATCGT GGACCACCTC GGGAAGGAGA ACCACGTCTT 1260 CCAGCCCAAG ACACAGTTTC TTGGAGTTTA CTTTGTCTCA TCCCAAGAGT TCCTCGGCAA 1320 TGCCTATGTC TTGGCTGTTC TTCTGTTCCT TGCCCTCCTG CTGCAAAGGA CCTTTCTACA 1380 AGCCTCGTAC TACGTTGCCA TTGAAACTGG GATCAACCTG AGAGGAGCAA TCCAGACCAA 1440 GATTTACAAT AAGATCATGC ACTTGTCTAC TTCCAACCTG TCCATGGGGG AAATGACTGC 1500 TGGGCAGATC TGCAACCTGG TGGCCATCGA CACCAACCAG CTCATGTGGT TTTTCTTCTT 1560 ATGCCCAAAC CTCTGGGCTA TGCCGGTACA GATCATTGTG GGCGTGATCC TCCTCTACTA 1620 CATCCTTGGG GTCAGCGCCT TGATTGGAGC GGCTGTCATC ATTCTGCTGG CTCCTGTACA 1680 GTACTTTGTG GCCACCAAGC TGTCCCAGGC ACAGCGGACG ACCCTGGAAT ATTCCAATGA 1740 GAGGCTGAAG CAGACCAATG AGATGCTCCG GGGCATCAAG TTGCTCAAGC TCTATGCGTG 1800 GGAGAACATC TTCTGCTCCA GGGTGGAGAA GACACGCAGG AAGGAAATGA CCAGCCTCAG 1860 GGCCTTCGCT GTCTACACCT CCATCTCCAT CTTCATGAAC ACAGCTATCC CCATCGCTGC 1920 TGTCCTCATC ACCTT GTGG GCCACGTCAG CTTCTTCAAA GAGTCGGACT TCTCGCCCTC 1980 GGTGGCCTTT GCCTCTCTCT CTCTCTTCCA CATCCTGGTC ACACCGCTGT TCCTGCTGTC 2040 TAGTGTGGTT CGGTCCACTG TCAAGGCCCT GGTGAGCGTG CAAAAGCTGA GTGAGTTCCT 2100 GTCCAGTGCA GAGATCCGTG AGGAACAGTG TGCCCCCCGA GAGCCCGCAC CCCAAGGCCA 2160 AGCGGGCAAG TACCAGGCGG TGCCCCTCAA GGTCGTAAAC CGCAAGCGCC CAGCCCGAGA 2220 AGAAGTCCGG GACCTCTTGG GCCCACTGCA GAGGCTGACT CCCAGCACGG ATGGAGACGC 2280 TGACAACTTC TGTGTCCAGA TCATCGGAGG CTTCTTCACC TGGACCCCTG ATGGAATCCC 2340 CACCCTGTCC AACATCACCA TCCGTATCCC CCGAGGTCAG CTGACCATGA TCGTGGGGCA 2400 GGTGGGCTGT GGCAAGTCCT CGCTCCTTCT GGCCACCCTG GGGGAGATGC AGAAGGTCTC 2460 TGGAGCTGTC TTCTGGAACA GCCTTCCAGA CAGCGAGGGG AGAAGACCCC AGCAACCCAG 2520 AGCGGGAGAC AGCGGCCGAT TCGGATGCCA GGAGCAGAGG CCCTGTGGCT ACGCATCTCA 2580 GAAACCATGG CTGCTAAATG CCACTGTGGA GGAGAACATC ACCTTCGAGA GTCCCTTCAA 2640 TAAGCAACGG TACAAGATGG TCATCGAAGC CTGCTCCCTG CAGCCAGACA TAGACATCCT 2700 GCCCCATGGA GACCAGACTC AGATTGGGGA ACGAGGCATC AACTTGAGTA CTGGTGGTCA 2760 GCGTCCAGAT CAGTGTAGAC CCGAGCCCTC TACCAGCACA CCAATGATTG TCTTTTTGGA 2820 TGACCCTTTC TCGGCTCTGG ATGTCCATCT GAGTGACCAC CTAATGCAGG CTGGCATCCT 2880 CGAGCTGCTC CGGGATGACA AGAGGACAGT GGTCTTGGTG ACCCACAAGC TACAGTACCT 2940 GCCTCATGCT GACTGGATCA TTGCTATGAA GGATGGCACC ATTCAGAGGG AGGGGACACT 3000 CAAGGACTTC CAGAGGTCTG AGTGCCAGCT CTTTGAGCAT TGGAAGACCC TCATGAACCG 3060 GCAGGACCAA GAGCTGGAGA AGGAGACAGT CATGGAGAGA AAAGCCCCAG AGCCATCTCA 3120 GGGCCTGCCC CGTGCCATGT CCTCAAGAGA TGGCCTTCTG CTGGATGAGG ATGAGGAGGA 3180 AGAGGAGGCA GCCGAGAGCG AGGAAGATGA CAACTTATCC TCTGTGCTGC ATCAGCGAGC 3240 CAAGATCCCA TGGCGAGCCT GCACCAAGTA TTTGTCCTCT GCTGGCATCC TGCTCCTGTC 3300 CCTGCTTGTC TTCTCCCAGC TGCTCAAGCA CATGGTCTTG GTGGCCATTG ACTACTGGCT 3360 GGCCAAGTGG ACGGACAGTG CCCTGGTCCT GAGCCCCGCC GCCAGGAACT GCTCCCTCAG 3420 CCAGGAATGT GCCCTGGACC AATCTGTCTA TGCCATGGTA TTCACCGTGC TCTGCAGCCT 3480 GGGTATCGCG CTGTGCCTTG TCACCTCTGT CACTGTGGAG TGGACGGGAC TGAAGGTGGC 3540 CAAGAGGCTG CATCGCAGCC TGCTCAACCG TATCATCCTG GCTCCCATGA GGTTCTTTGA 3600 GACCACGCCC CTGGGGAGTA TCCTGAACAG ATTTTCATCT GACTGTAACA CCATTGACCA 3660 GCATATCCCG TCCACGCTGG AGTGCCTGAG CAGATCCACC TTACTCTGTG TCTCCGCCCT 3720 GGCTGTCATC TCCTACGTCA CGCCTGTGTT CCTAGTGGCC CTCTTACCCC TCGCCGTCGT 3780 GTGCTACTTC ATCCAGAAGT ACTTCCGAGT GGCGTCCAGG GACCTGCAGC AGCTGGACGA 3840 CACAACACAG CTCCCTCTGC TCTCACACTT TGCTGAAACT GTGGAAGGAC TCACCACCAT 3900 CCGTGCCTTC AGGTACGAGG CCCGGTTCCA GCAGAAGCTC CTAGAGTACA CCGACTCCAA 3960 CAACATTGCC TCTCTCTTCC TCACAGCAGC CAACAGGTGG CTGGAAGTCC GCATGGAGTA 4020 CATCGGAGCA TGCGTGGTAC TCATCGCCGC TGCCACCTCC ATCTCCAACT CCCTACACAG 4080 GGAGCTCTCA GCCGGCCTAG TAGGCCTGGG CCTCACCTAT GCCTTGATGG TCTCCAACTA 4140 CCTCAACTGG ATGGTGAGGA ACCTGGCAGA CATGGAGATC CAACTGGGAG CTGTGAAGGG 4200 TATCCACACA CTCCTGAAAA CTGAGGCAGA GAGCTATGAG GGGCTCCTGG CACCATCGCT 4260 GATCCCCAAG AACTGGCCAG ACCAAGGGAA GATCCAAATT CAAAACCTGA GTGTACGCTA 4320 TGACAGCTCC CTGAAGCCCG TGCTGAAGCA CGTCAACGCC CTCATCTCCC CAGGACAGAA 4380 GATTGGGATC TGCGGCCGCA CAGGCAGTGG AAAATCCTCC TTCTCTCTCG CCTTTTTCCG 4440 AATGGTGGAT ATGTTTGAAG GGCGTATCAT CATCGATGGC ATTGACATCG CCAAGCTGCC 4500 GCTGCACACG CTCGGCTCAC GCCTGTCTAT CATCCTACAG GACCCTGTTC TCTTCAGTGG 4560 TACCATCAGA TTCAACCTGG ACCCAGAGAA GAAATGCTCA GACAGCACGC TGTGGGAGGC 4620 TCTGGAGATC GCTCAGCTGA AGCTGGTGGT GAAGGCCCTG CCAGGAGGCC TGGATGCCAT 4680 CATCACGGAA GGAGGGGAGA ATTTTAGCCA GGGCCAGAGG CAGCTGTTCT GCCTGGCCCG 4740 GGCCTTTGTG AGGAAGACCA GCATCTTCAT CATGGATGAA GCAACTGCCT CCATCGACAT 4800 GGCTACGGAA AATATCCTCC AGAAGGTGGT GATGACAGCC TTCGCAGACC GCACCGTGGT 4860 CACCATCGCG CACCGCGTGC ACACCATCCT GAGTGCAGAC CTAGTGATGG TCCTGAAGAG 4920 GGGCGCGATC CTGGAGTTCG ACAAGCCGGA AAAGCTTCTC AGCCAGAAGG ACAGCGTCTT 4980 TGCCTCCTTT GTCCGCGCGG ACAAATGACC AGCCAGCGCC AAAGTGCCAC CCCACACCTC 5040 ACCTGCTTGC CATGGATTTC TTACTGTAAA TCACTTGTAA ATAAAGAAAC TAATTCTTTG 5100 CTAAAAAAAA 5110 (32) INFORMATION FOR SEQ ID NO:33: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5110 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: Single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ill) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 260..5004 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33: CCCTTGTGAC AGGTCAGTCT TACGAGAATA TGGTAACTGA GATCATGTCA ATGGGCTATG 60 AACGAGAACA AGTAATTGCA GCCCTGAGAG CCAGCTTCAA CAACCCTGAT AGAGCTGTGG 120 AATATCTTCT AATGCGAATC CCTGGAGACT GAGGAGTTCC AGTACTCACA GCCTGTGGAG 180 GAGGATCAAC CACGGCCTGA CTTTCGCGGC CGCCGCGGGA GGCGCGCGGA GCCGGAGCCG 240 AGCCCGTGCG CGCGCCACC ATG CCT TTG GCC TTC TGC GGC ACC GAG AAC CAC 292 Met Pro Leu Ala Phe Cys Gly Thr Glu Asn His 1 5 10 TCG GCC GCC TAC CGG GTG GAC CAA GGC GTC CTC AAC AAC GGC TGC TTC 340 Ser Ala Ala Tyr Arg Val Asp Gin Gly Val Leu Asn Asn Gly Cys Phe 15 20 25 GTG GAC GCG CTC AAT GTG GTG CCA CAT GTC TTT CTG CTC TTC ATC ACC 388 Val Asp Ala Leu Asn Val Val Pro His Val Phe Leu Leu Phe Ile Thr 30 35 40 TTC CCC ATC CTC TTC ATC GGA TGG GGC AGC CAG AGC TCC AAG GTG CAC 436 Phe Pro Ile Leu Phe Ile Gly Trp Gly Ser Gin Ser Ser Lys Val His 45 50 55 ATT CAC CAC AGC ACC TGG CTC CAT TTC CCG GGG CAC AAC CTG CGC TGG 484 Ile His His Ser Thr Trp Leu His Phe Pro Gly His Asn Leu Arg Trp 60 65 70 75 ATC CTG ACC TTC ATA CTG CTC TTC GTC CTC GTG TGT GAG ATC GCT GAG 532 Ile Leu Thr Phe Ile Leu Leu Phe Val Leu Val Cys Glu Ile Ala Glu 80 85 90 GGT ATC CTG TCT GAC GGG GTG ACA GAA TCC CGC CAC CTC CAC TTA TAC 580 Gly Ile Leu Ser Asp Gly Val Thr Glu Ser Arg His Leu His Leu Tyr 95 100 105 ATG CCA GCT GGG ATG GCA TTC ATG GCT GCC ATC ACC TCT GTG GTC TAC 628 Met Pro Ala Gly Met Ala Phe Met Ala Ala Ile Thr Ser Val Val Tyr 110 115 120 TAC CAT AAC ATT GAG ACC TCT AAC TTT CCC AAG CTG CTG ATT GCT CTG 676 Tyr His Asn Ile Glu Thr Ser Asn Phe Pro Lys Leu Leu Ile Ala Leu 125 130 135 CTC ATC TAC TGG ACC CTG GCC TTC ATC ACG AAG ACC ATC AAG TTC GTC 724 Leu Ile Tyr Trp Thr Leu Ala Phe Ile Thr Lys Thr Ile Lys Phe Val 140 145 150 155 AAG TTC TAC GAC CAC GCC ATT GGC TTC TCT CAG CTG CGC TTC TGC CTC 772 Lys Phe Tyr Asp His Ala Ile Gly Phe Ser Gin Leu Arg Phe Cys Leu 160 165 170 ACG GGG CTT CTG GTG ATC CTC TAC GGG ATG CTG CTG CTT GTG GAG GTC 820 Thr Gly Leu Leu Val Ile Leu Tyr Gly Met Leu Leu Leu Val Glu Val 175 180 185 AAT GTC ATC CGG GTG AGG AGA TAC GTC TTC TTC AAG ACA CCA AGG GAA 868 Asn Val Ile Arg Val Arg Arg Tyr Val Phe Phe Lys Thr Pro Arg Glu 190 195 200 GTA AAG CCC CCC GAG GAC CTA CAG GAC CTG GGT GTG CGC TTT CTG CAG 916 Val Lys Pro Pro Glu Asp Leu Gin Asp Leu Gly Val Arg Phe Leu Gin 205 210 215 CCC TTC GTT AAC CTG CTA TCA AAG GGG ACC TAC TGG TGG ATG AAT GCC 964 Pro Phe Val Asn Leu Leu Ser Lys Gly Thr Tyr Trp Trp Met Asn Ala 220 225 230 235 TTC ATC AAG ACT GCT CAC AAG AAG CCC ATC GAC CTG CGG GCC ATC GGG 1012 Phe Ile Lys Thr Ala His Lys Lys Pro Ile Asp Leu Arg Ala Ile Gly 240 245 250 AAG CTG CCC ATT GCC ATG AGA GCC CTC ACC AAC TAC CAG CGA CTC TGC 1060 Lys Leu Pro Ile Ala Met Arg Ala Leu Thr Asn Tyr Gin Arg Leu Cys 255 260 265 TTG GCC TTC GAT GCC CAG GCG CGG AAG GAC ACA CAG AGC CAG CAG GGT 1108 Leύ Ala Phe Asp Ala Gin Ala Arg Lys Asp Thr Gin Ser Gin Gin Gly 270 275 280 GCC CGG GCC ATC TGG AGG GCT CTC TGT CAT GCC TTT GGG AGA CGG CTG 1156 Ala Arg Ala Ile Trp Arg Ala Leu Cys His Ala Phe Gly Arg Arg Leu 285 290 295 GTC CTC AGC AGC ACA TTC CGT ATC CTG GCC GAC CTC CTG GGC TTT GCT 1204 Val Leu Ser Ser Thr Phe Arg Ile Leu Ala Asp Leu Leu Gly Phe Ala 300 305 310 315 GGG CCA CTC TGC ATC TTC GGG ATC GTG GAC CAC CTC GGG AAG GAG AAC 1252 Gly Pro Leu Cys Ile Phe Gly Ile Val Asp His Leu Gly Lys Glu Asn 320 325 330 CAC GTC TTC CAG CCC AAG ACA CAG TTT CTT GGA GTT TAC TTT GTC TCA 1300 His Val Phe Gin Pro Lys Thr Gin Phe Leu Gly Val Tyr Phe Val Ser 335 340 345 TCC CAA GAG TTC CTC GGC AAT GCC TAT GTC TTG GCT GTT CTT CTG TTC 1348 Ser Gin Glu Phe Leu Gly Asn Ala Tyr Val Leu Ala Val Leu Leu Phe 350 355 360 CTT GCC CTC CTG CTG CAA AGG ACC TTT CTA CAA GCC TCG TAC TAC GTT 1396 Leu Ala Leu Leu Leu Gin Arg Thr Phe Leu Gin Ala Ser Tyr Tyr Val 365 370 375 GCC ATT GAA ACT GGG ATC AAC CTG AGA GGA GCA ATC CAG ACC AAG ATT 1444 Ala Ile Glu Thr Gly Ile Asn Leu Arg Gly Ala Ile Gin Thr Lys Ile 380 385 390 395 TAC AAT AAG ATC ATG CAC TTG TCT ACT TCC AAC CTG TCC ATG GGG GAA 1492 Tyr Asn Lys Ile Met His Leu Ser Thr Ser Asn Leu Ser Met Gly Glu 400 405 410 ATG ACT GCT GGG CAG ATC TGC AAC CTG GTG GCC ATC GAC ACC AAC CAG 1540 Met Thr Ala Gly Gin Ile Cys Asn Leu Val Ala Ile Asp Thr Asn Gin 415 420 425 CTC ATG TGG TTT TTC TTC TTA TGC CCA AAC CTC TGG GCT ATG CCG GTA 1588 Leu Met Trp Phe Phe Phe Leu Cys Pro Asn Leu Trp Ala Met Pro Val 430 435 440 CAG ATC ATT GTG GGC GTG ATC CTC CTC TAC TAC ATC CTT GGG GTC AGC 1636 Gin Ile Ile Val Gly Val Ile Leu Leu Tyr Tyr Ile Leu Gly Val Ser 445 450 455 GCC TTG ATT GGA GCG GCT GTC ATC ATT CTG CTG GCT CCT GTA CAG TAC 1684 Ala Leu Ile Gly Ala Ala Val Ile Ile Leu Leu Ala Pro Val Gin Tyr 460 465 470 475 TTT GTG GCC ACC AAG CTG TCC CAG GCA CAG CGG ACG ACC CTG GAA TAT 1732 Phe Val Ala Thr Lys Leu Ser Gin Ala Gin Arg Thr Thr Leu Glu Tyr 480 485 490 TCC AAT GAG AGG CTG AAG CAG ACC AAT GAG ATG CTC CGG GGC ATC AAG 1780 Ser Asn Glu Arg Leu Lys Gin Thr Asn Glu Met Leu Arg Gly Ile Lys 495 500 505 TTG CTC AAG CTC TAT GCG TGG GAG AAC ATC TTC TGC TCC AGG GTG GAG 1828 Leu Leu Lys Leu Tyr Ala Trp Glu Asn Ile Phe Cys Ser Arg Val Glu 510 515 520 AAG ACA CGC AGG AAG GAA ATG ACC AGC CTC AGG GCC TTC GCT GTC TAC 1876 Lys Thr Arg Arg Lys Glu Met Thr Ser Leu Arg Ala Phe Ala Val Tyr 525 530 535 ACC TCC ATC TCC ATC TTC ATG AAC ACA GCT ATC CCC ATC GCT GCT GTC 1924 ' Thr Ser Ile Ser Ile Phe Met Asn Thr Ala Ile Pro Ile Ala Ala Val 540 545 550 555 CTC ATC ACC TTC GTG GGC CAC GTC AGC TTC TTC AAA GAG TCG GAC TTC 1972 Leu Ile Thr Phe Val Gly His Val Ser Phe Phe Lys Glu Ser Asp Phe 560 565 570 TCG CCC TCG GTG GCC TTT GCC TCT CTC TCT CTC TTC CAC ATC CTG GTC 2020 Ser Pro Ser Val Ala Phe Ala Ser Leu Ser Leu Phe His Ile Leu Val 575 580 585 ACA CCG CTG TTC CTG CTG TCT AGT GTG GTT CGG TCC ACT GTC AAG GCC 2068 Thr Pro Leu Phe Leu Leu Ser Ser Val Val Arg Ser Thr Val Lys Ala 590 595 600 CTG GTG AGC GTG CAA AAG CTG AGT GAG TTC CTG TCC AGT GCA GAG ATC 2116 Leu Val Ser Val Gin Lys Leu Ser Glu Phe Leu Ser Ser Ala Glu Ile 605 610 615 CGT GAG GAA CAG TGT GCC CCC CGA GAG CCC GCA CCC CAA GGC CAA GCG 2164 Arg Glu Glu Gin Cys Ala Pro Arg Glu Pro Ala Pro Gin Gly Gin Ala 620 625 630 635 GGC AAG TAC CAG GCG GTG CCC CTC AAG GTC GTA AAC CGC AAG CGC CCA 2212 Gly Lys Tyr Gin Ala Val Pro Leu Lys Val Val Asn Arg Lys Arg Pro 640 645 650 GCC CGA GAA GAA GTC CGG GAC CTC TTG GGC CCA CTG CAG AGG CTG ACT 2260 Ala Arg Glu Glu Val Arg Asp Leu Leu Gly Pro Leu Gin Arg Leu Thr 655 660 665 CCC AGC ACG GAT GGA GAC GCT GAC AAC TTC TGT GTC CAG ATC ATC GGA 2308 Pro Ser Thr Asp Gly Asp Ala Asp Asn Phe Cys Val Gin Ile Ile Gly 670 675 680 GGC TTC TTC ACC TGG ACC CCT GAT GGA ATC CCC ACC CTG TCC AAC ATC 2356 Gly Phe Phe Thr Trp Thr Pro Asp Gly Ile Pro Thr Leu Ser Asn Ile 685 690 695 ACC ATC CGT ATC CCC CGA GGT CAG CTG ACC ATG ATC GTG GGG CAG GTG 2404 Thr Ile Arg Ile Pro Arg Gly Gin Leu Thr Met Ile Val Gly Gin Val 700 705 710 715 GGC TGT GGC AAG TCC TCG CTC CTT CTG GCC ACC CTG GGG GAG ATG CAG 2452 Gly Cys Gly Lys Ser Ser Leu Leu Leu Ala Thr Leu Gly Glu Met Gin 720 725 730 AAG GTC TCT GGA GCT GTC TTC TGG AAC AGC CTT CCA GAC AGC GAG GGG 2500 Lys Val Ser Gly Ala Val Phe Trp Asn Ser Leu Pro Asp Ser Glu Gly 735 740 745 AGA AGA CCC CAG CAA CCC AGA GCG GGA GAC AGC GGC CGA TTC GGA TGC 2548 Arg Arg Pro Gin Gin Pro Arg Ala Gly Asp Ser Gly Arg Phe Gly Cys 750 755 760 CAG GAG CAG AGG CCC TGT GGC TAC GCA TCT CAG AAA CCA TGG CTG CTA 2596 Gin Glu Gin Arg Pro Cys Gly Tyr Ala Ser Gin Lys Pro Trp Leu Leu 765 770 775 AAT GCC ACT GTG GAG GAG AAC ATC ACC TTC GAG AGT CCC TTC AAT AAG 2644 Asn Ala Thr Val Glu Glu Asn Ile Thr Phe Glu Ser Pro Phe Asn Lys 780 785 790 795 CAA CGG TAC AAG ATG GTC ATC GAA GCC TGC TCC CTG CAG CCA GAC ATA 2692 Gin Arg Tyr Lys Met Val Ile Glu Ala Cys Ser Leu Gin Pro Asp Ile 800 805 810 GAC ATC CTG CCC CAT GGA GAC CAG ACT CAG ATT GGG GAA CGA GGC ATC 2740 Asp Ile Leu Pro His Gly Asp Gin Thr Gin Ile Gly Glu Arg Gly Ile 815 820 825 AAC TTG AGT ACT GGT GGT CAG CGT CCA GAT CAG TGT AGA CCC GAG CCC 2788 Asn Leu Ser Thi Gly Gly Gin Arg Pro Asp Gin Cys Arg Pro Glu Pro 830 835 840 TCT ACC AGC ACA CCA ATG ATT GTC TTT TTG GAT GAC CCT TTC TCG GCT 2836 Ser Thr Ser Thr Pro Met Ile Val Phe Leu Asp Asp Pro Phe Ser Ala 845 850 855 CTG GAT GTC CAT CTG AGT GAC CAC CTA ATG CAG GCT GGC ATC CTC GAG 2884 Leu Asp Val His Leu Ser Asp His Leu Met Gin Ala Gly Ile Leu Glu 860 865 870 875 97 CTG CTC CGG GAT GAC AAG AGG ACA GTG GTC TTG GTG ACC CAC AAG CTA 2932 Leu Leu Arg Asp Asp Lys Arg Thr Val Val Leu Val Thr His Lys Leu 880 885 890 CAG TAC CTG CCT CAT GCT GAC TGG ATC ATT GCT ATG AAG GAT GGC ACC 2980 Gin Tyr Leu Pro His Ala Asp Trp Ile Ile Ala Met Lys Asp Gly Thr 895 900 905 ATT CAG AGG GAG GGG ACA CTC AAG GAC TTC CAG AGG TCT GAG TGC CAG 3028 Ile Gin Arg Glu Gly Thr Leu Lys Asp Phe Gin Arg Ser Glu Cys Gin 910 915 920 CTC TTT GAG CAT TGG AAG ACC CTC ATG AAC CGG CAG GAC CAA GAG CTG 3076 Leu Phe Glu His Trp Lys Thr Leu Met Asn Arg Gin Asp Gin Glu Leu 925 930 935 GAG AAG GAG ACA GTC ATG GAG AGA AAA GCC CCA GAG CCA TCT CAG GGC 3124 Glu Lys Glu Thr Val Met Glu Arg Lys Ala Pro Glu Pro Ser Gin Gly 940 945 950 955 CTG CCC CGT GCC ATG TCC TCA AGA GAT GGC CTT CTG CTG GAT GAG GAT 3172 Leu Pro Arg Ala Met Ser Ser Arg Asp Gly Leu Leu Leu Asp Glu Asp 960 965 970 GAG GAG GAA GAG GAG GCA GCC GAG AGC GAG GAA GAT GAC AAC TTA TCC 3220 Glu Glu Glu Glu Glu Ala Ala Glu Ser Glu Glu Asp Asp Asn Leu Ser 975 980 985 TCT GTG CTG CAT CAG CGA GCC AAG ATC CCA TGG CGA GCC TGC ACC AAG 3268 Ser Val Leu His Gin Arg Ala Lys Ile Pro Trp Arg Ala Cys Thr Lys 990 995 1000 TAT TTG TCC TCT GCT GGC ATC CTG CTC CTG TCC CTG CTT GTC TTC TCC 3316 Tyr Leu Ser Ser Ala Gly Ile Leu Leu Leu Ser Leu Leu Val Phe Ser 1005 1010 1015 CAG CTG CTC AAG CAC ATG GTC TTG GTG GCC ATT GAC TAC TGG CTG GCC 3364 Gin Leu Leu Lys His Met Val Leu Val Ala Ile Asp Tyr Trp Leu Ala 1020 1025 1030 1035 AAG TGG ACG GAC AGT GCC CTG GTC CTG AGC CCC GCC GCC AGG AAC TGC 3412 Lys Trp Thr Asp Ser Ala Leu Val Leu Ser Pro Ala Ala Arg Asn Cys 1040 1045 1050 TCC CTC AGC CAG GAA TGT GCC CTG GAC CAA TCT GTC TAT GCC ATG GTA 3460 Ser Leu Ser Gin Glu Cys Ala Leu Asp Gin Ser Val Tyr Ala Met Val 1055 1060 1065 TTC ACC GTG CTC TGC AGC CTG GGT ATC GCG CTG TGC CTT GTC ACC TCT 3508 Phe Thr Val Leu Cys Ser Leu Gly Ile Ala Leu Cys Leu Val Thr Ser 1070 1075 1080 GTC ACT GTG GAG TGG ACG GGA CTG AAG GTG GCC AAG AGG CTG CAT CGC 3556 Val Thr Val Glu Trp Thr Gly Leu Lys Val Ala Lys Arg Leu His Arg 1085 1090 1095 AGC CTG CTC AAC CGT ATC ATC CTG GCT CCC ATG AGG TTC TTT GAG ACC 3604 Ser Leu Leu Asn Arg Ile Ile Leu Ala Pro Met Arg Phe Phe Glu Thr 1100 1105 1110 1115 ACG CCC CTG GGG AGT ATC CTG AAC AGA TTT TCA TCT GAC TGT AAC ACC 3652 Thr Pro Leu Gly Ser lie Leu Asn Arg Phe Ser Ser Asp Cys Asn Thr 1120 1125 1130 ATT GAC CAG CAT ATC CCG TCC ACG CTG GAG TGC CTG AGC AGA TCC ACC 3700 Ile Asp Gin His Ile Pro Ser Thr Lea Glu Cys Leu Ser Arg Ser Thr 1135 1140 1145 TTA CTC TGT GTC TCC GCC CTG GCT GTC ATC TCC TAC GTC ACG CCT GTG 3748 Leu Leu Cys Val Ser Ala Leu Ala Val Ile Ser Tyr Val Thr Pro Val 1150 1155 1160 TTC CTA GTG GCC CTC TTA CCC CTC GCC GTC GTG TGC TAC TTC ATC CAG 3796 Phe Leu Val Ala Leu Leu Pro Leu Ala Val Val Cys Tyr Phe Ile Gin 1165 1170 1175 AAG TAC TTC CGA GTG GCG TCC AGG GAC CTG CAG CAG CTG GAC GAC ACA 3844 Lys Tyr Phe Arg Val Ala Ser Arg Asp Leu Gin Gin Leu Asp Asp Thr 1180 1185 1190 1195 ACA CAG CTC CCT CTG CTC TCA CAC TTT GCT GAA ACT GTG GAA GGA CTC 3892 Thr Gin Leu Pro Leu Leu Ser His Phe Ala Glu Thr Val Glu Gly Leu 1200 1205 1210 ACC ACC ATC CGT GCC TTC AGG TAC GAG GCC CGG TTC CAG CAG AAG CTC 3940 Thr Thr Ile Arg Ala Phe Arg Tyr Glu Ala Arg Phe Gin Gin Lys Leu 1215 1220 1225 CTA GAG TAC ACC GAC TCC AAC AAC ATT GCC TCT CTC TTC CTC ACA GCA 3988 Leu Glu Tyr Thr Asp Ser Asn Asn Ile Ala Ser Leu Phe Leu Thr Ala 1230 1235 1240 GCC AAC AGG TGG CTG GAA GTC CGC ATG GAG TAC ATC GGA GCA TGC GTG 4036 Ala Asn Arg Trp Leu Glu Val Arg Met Glu Tyr Ile Gly Ala Cys Val 1245 1250 1255 GTA CTC ATC GCC GCT GCC ACC TCC ATC TCC AAC TCC CTA CAC AGG GAG 4084 Val Leu Ile Ala Ala Ala Thr Ser Ile Ser Asn Ser Leu His Arg Glu 1260 1265 1270 1275 CTC TCA GCC GGC CTA GTA GGC CTG GGC CTC ACC TAT GCC TTG ATG GTC 4132 Leu Ser Ala Gly Leu Val Gly Leu Gly Leu Thr Tyr Ala Leu Met Val 1280 1285 1290 TCC AAC TAC CTC AAC TGG ATG GTG AGG AAC CTG GCA GAC ATG GAG ATC 4180 Ser Asn Tyr Leu Asn Trp Met Val Arg Asn Leu Ala Asp Met Glu Ile 1295 1300 1305 CAA CTG GGA GCT GTG AAG GGT ATC CAC ACA CTC CTG AAA ACT GAG GCA 4228 Gin Leu Gly Ala Val Lys Gly Ile His Thr Leu Leu Lys Thr Glu Ala 1310 1315 1320 GAG AGC TAT GAG GGG CTC CTG GCA CCA TCG CTG ATC CCC AAG AAC TGG 4276 Glu Ser Tyr Glu Gly Leu Leu Ala Pro Ser Leu Ile Pro Lys Asn Trp 1325 1330 1335 CCA GAC CAA GGG AAG ATC CAA ATT CAA AAC CTG AGT GTA CGC TAT GAC 4324 Pro Asp Gin Gly Lys Ile Gin Ile Gin Asn Leu Ser Val Arg Tyr Asp 1340 1345 1350 1355 AGC TCC CTG AAG CCC GTG CTG AAG CAC GTC AAC GCC CTC ATC TCC CCA 4372 Ser Ser Leu Lys Pro Val Leu Lys His Val Asn Ala Leu Ile Ser Pro ±360 1365 1370 GGA CAG AAG ATT GGG ATC TGC GGC CGC ACA GGC AGT GGA AAA TCC TCC 4420 Gly Gin Lys Ile Gly Ile Cys Gly Arg Thr Gly Ser Gly Lys Ser Ser 1375 1380 1385 TTC TCT CTC GCC TTT TTC CGA ATG GTG GAT ATG TTT GAA GGG CGT ATC 4468 Phe Ser Leu Ala Phe Phe Arg Met Val Asp Met Phe Glu Gly Arg Ile 1390 1395 1400 ATC ATC GAT GGC ATT GAC ATC GCC AAG CTG CCG CTG CAC ACG CTC GGC 4516 Ile Ile Asp Gly Ile Asp Ile Ala Lys Leu Pro Leu His Thr Leu Gly 1405 1410 1415 TCA CGC CTG TCT ATC ATC CTA CAG GAC CCT GTT CTC TTC AGT GGT ACC 4564 Ser Arg Leu Ser Ile Ile Leu Gin Asp Pro Val Leu Phe Ser Gly Thr 1420 1425 1430 1435 ATC AGA TTC AAC CTG GAC CCA GAG AAG AAA TGC TCA GAC AGC ACG CTG 612 Ile Arg Phe Asn Leu Asp Pro Glu Lys Lys Cys Ser Asp Ser Thr Leu 1440 1445 1450 TGG GAG GCT CTG GAG ATC GCT CAG CTG AAG CTG GTG GTG AAG GCC CTG 4660 Trp Glu Ala Leu Glu Ile Ala Gin Leu Lys Leu Val Val Lys Ala Leu 1455 1460 1465 CCA GGA GGC CTG GAT GCC ATC ATC ACG GAA GGA GGG GAG AAT TTT AGC 4708 Pro Gly Gly Leu Asp Ala Ile Ile Thr Glu Gly Gly Glu Asn Phe Ser 1470 1475 1480 CAG GGC CAG AGG CAG CTG TTC TGC CTG GCC CGG GCC TTT GTG AGG AAG 4756 Gin Gly Gin Arg Gin Leu Phe Cys Leu Ala Arg Ala Phe Val Arg Lys 1485 1490 1495 ACC AGC ATC TTC ATC ATG GAT GAA GCA ACT GCC TCC ATC GAC ATG GCT 4804 Thr Ser Ile Phe Ile Met Asp Glu Ala Thr Ala Ser Ile Asp Met Ala 1500 1505 1510 1515 ACG GAA AAT ATC CTC CAG AAG GTG GTG ATG ACA GCC TTC GCA GAC CGC 4852 Thr Glu Asn Ile Leu Gin Lys Val Val Met Thr Ala Phe Ala Asp Arg 1520 1525 1530 ACC GTG GTC ACC ATC GCG CAC CGC GTG CAC ACC ATC CTG AGT GCA GAC 4900 Thr Val Val Thr Ile Ala His Arg Val His Thr Ile Leu Ser Ala Asp 1535 1540 1545 CTA GTG ATG GTC CTG AAG AGG GGC GCG ATC CTG GAG TTC GAC AAG CCG 4948 Leu Val Met Val Leu Lys Arg Gly Ala Ile Leu Glu Phe Asp Lys Pro 1550 1555 1560 GAA AAG CTT CTC AGC CAG AAG GAC AGC GTC TTT GCC TCC TTT GTC CGC 4996 Glu Lys Leu Leu Ser Gin Lys Asp Ser Val Phe Ala Ser Phe Val Arg 1565 1570 1575 GCG GAC AA ATGACCAGCC AGCGCCAAAG TGCCACCCCA CACCTCACCT GCTTGCCATG 5054 Ala Asp 1580 GATTTCTTAC TGTAAATCAC TTGTAAATAA AGAAACTAAT TCTTTGCTAA AAAAAA 5110 (33) INFORMATION FOR SEQ ID N0:34: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1581 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34: Met Pro Leu Ala Phe Cys Gly Thr Glu Asn His Ser Ala Ala Tyr Arg 1 5 10 15 Val Asp Gin Gly Val Leu Asn Asn Gly Cys Phe Val Asp Ala Leu Asn 20 25 30 Val Val Pro His Val Phe Leu Leu Phe Ile Thr Phe Pro Ile Leu Phe 35 40 45 Ile Gly Trp Gly Ser Gin Ser Ser Lys Val His Ile His His Ser Thr 50 55 60 Trp Leu His Phe Pro Gly His Asn Leu Arg Trp Ile Leu Thr Phe Ile 65 70 75 80 Leu Leu Phe Val Leu Val Cys Glu Ile Ala Glu Gly Ile Leu Ser Asp 85 90 95 Gly Val Thr Glu Ser Arg His Leu His Leu Tyr Met Pro Ala Gly Met 100 105 110 Ala Phe Met Ala Ala Ile Thr Ser Val Val Tyr Tyr His Asn Ile Glu 115 120 125 Thr Ser Asn Phe Pro Lys Leu Leu Ile Ala Leu Leu Ile Tyr Trp Thr 130 135 140 Leu Ala Phe Ile Thr Lys Thr Ile Lys Phe Val Lys Phe Tyr Asp His 145 150 155 160 Ala Ile Gly Phe Ser Gin Leu Arg Phe Cys Leu Thr Gly Leu Leu Val 165 170 175 Ile Leu Tyr Gly Met Leu Leu Leu Val Glu Val Asn Val Ile Arg Val 180 185 190 Arg Arg Tyr Val Phe Phe Lys Thr Pro Arg Glu Val Lys Pro Pro Glu 195 200 205 Asp Leu Gin Asp Leu Gly Val Arg Phe Leu Gin Pro Phe Val Asn Leu 210 215 220 Leu Ser Lys Gly Thr Tyr Trp Trp Met Asn Ala Phe Ile Lys Thr Ala 225 230 235 240 His Lys Lys Pro Ile Asp Leu Arg Ala Ile Gly Lys Leu Pro Ile Ala 245 250 255 Met Arg Ala Leu Thr Asn Tyr Gin Arg Leu Cys Leu Ala Phe Asp Ala 260 265 270 Gin Ala Arg Lys Asp Thr Gin Ser Gin Gin Gly Ala Arg Ala Ile Trp 275 280 285 Arg Ala Leu Cys His Ala Phe Gly Arg Arg Leu Val Leu Ser Ser Thr 290 295 300 Phe Arg Ile Leu Ala Asp Leu Leu Gly Phe Ala Gly Pro Leu Cys Ile 305 310 315 320 Phe Gly Ile Val Asp His Leu Gly Lys Glu Asn His Val Phe Gin Pro 325 330 335 Lys Thr Gin Phe Leu Gly Val Tyr Phe Val Ser Ser Gin Glu Phe Leu 340 345 350 Gly Asn Ala Tyr Val Leu Ala Val Leu Leu Phe Leu Ala Leu Leu Leu 355 360 365 Gin Arg Thr Phe Leu Gin Ala Ser Tyr Tyr Val Ala Ile Glu Thr Gly 370 375 380 Ile Asn Leu Arg Gly Ala Ile Gin Thr Lys Ile Tyr Asn Lys Ile Met 385 390 395 400 His Leu Ser Thr Ser Asn Leu Ser Met Gly Glu Met Thr Ala Gly Gin 405 410 415 lie Cys Asn Leu Val Ala Ile Asp Thr Asn Gin Leu Met Trp Phe Phe 420 425 430 Phe Leu Cys Pro Asn Leu Trp Ala Met Pro Val Gin Ile Ile Val Gly 435 440 445 Val Ile Leu Leu Tyr Tyr Ile Leu Gly Val Ser Ala Leu Ile Gly Ala 450 455 460 Ala Val Ile Ile Leu Leu Ala Pro Val Gin Tyr Phe Val Ala Thr Lys 465 470 475 480 Leu Ser Gin Ala Gin Arg Thr Thr Leu Glu Tyr Ser Asn Glu Arg Leu 485 490 495 Lys Gin Thr Asn Glu Met Leu Arg Gly Ile Lys Leu Leu Lys Leu Tyr 500 505 510 Ala Trp Glu Asn Ile Phe Cys Ser Arg Val Glu Lys Thr Arg Arg Lys 515 520 525 Glu Met Thr Ser Leu Arg Ala Phe Ala Val Tyr Thr Ser Ile Ser Ile 530 535 540 Phe Met Asn Thr Ala Ile Pro Ile Ala Ala Val Leu Ile Thr Phe Val 545 550 555 560 Gly His Val Ser Phe Phe Lys Glu Ser Asp Phe Ser Pro Ser Val Ala 565 570 575 Phe Ala Ser Leu Ser Leu Phe His Ile Leu Val Thr Pro Leu Phe Leu 580 585 590 Leu Ser Ser Val Val Arg Ser Thr Val Lys Ala Leu Val Ser Val Gin 595 600 605 Lys Leu Ser Glu Phe Leu Ser Ser Ala Glu Ile Arg Glu Glu Gin Cys 610 615 620 Ala Pro Arg Glu Pro Ala Pro Gin Gly Gin Ala Gly Lys Tyr Gin Ala 625 630 635 640 Val Pro Leu Lys Val Val Asn Arg Lys Arg Pro Ala Arg Glu Glu Val 645 650 655 Arg Asp Leu Leu Gly Pro Leu Gin Arg Leu Thr Pro Ser Thr Asp Gly 660 665 670 Asp Ala Asp Asn Phe Cys Val Gin Ile Ile Gly Gly Phe Phe Thr Trp 675 680 685 Thr Pro Asp Gly Ile Pro Thr Leu Ser Asn Ile Thr Ile Arg Ile Pro 690 695 700 Arg Gly Gin Leu Thr Met Ile Val Gly Gin Val Gly Cys Gly Lys Ser 705 710 715 720 Ser Leu Leu Leu Ala Thr Leu Gly Glu Met Gin Lys Val Ser Gly Ala 725 730 735 Val Phe Trp Asn Ser Leu Pro Asp Ser Glu Gly Arg Arg Pro Gin Gin 740 745 750 Pro Arg Ala Gly Asp Ser Gly Arg Phe Gly Cys Gin Glu Gin Arg Pro 755 760 765 Cys Gly Tyr Ala Ser Gin Lys Pro Trp Leu Leu Asn Ala Thr Val Glu 770 775 780 Glu Asn Ile Thr Phe Glu Ser Pro Phe Asn Lys Gin Arg Tyr Lys Met 785 790 795 800 Val Ile Glu Ala Cys Ser Leu Gin Pro Asp- Ile Asp Ile Leu Pro His 805 810 815 Gly Asp Gin Thr Gin Ile Gly Glu Arg Gly Ile Asn Leu Ser Thr Gly 820 825 830 Gly Gin Arg Pro Asp Gin Cys Arg Pro Glu Pro Ser Thr Ser Thr Pro 835 840 845 Met Ile Val Phe Leu Asp Asp Pro Phe Ser Ala Leu Asp Val His Leu 850 855 860 Ser Asp His Leu Met Gin Ala Gly Ile Leu Glu Leu Leu Arg Asp Asp 865 870 875 880 Lys Arg Thr Val Val Leu Val Thr His Lys Leu Gin Tyr Leu Pro His 885 890 895 Ala Asp Trp Ile Ile Ala Met Lys Asp Gly Thr Ile Gin Arg Glu Gly 900 905 910 Thr Leu Lys Asp Phe Gin Arg Ser Glu Cys Gin Leu Phe Glu His Trp 915 920 925 Lys Thr Leu Met Asn Arg Gin Asp Gin Glu Leu Glu Lys Glu Thr Val 930 935 940 Met Glu Arg Lys Ala Pro Glu Pro Ser Gin Gly Leu Pro Arg Ala Met 945 950 955 960 Ser Ser Arg Asp Gly Leu Leu Leu Asp Glu Asp Glu Glu Glu Glu Glu 965 970 975 Ala Ala Glu Ser Glu Glu Asp Asp Asn Leu Ser Ser Val Leu His Gin 980 985 990 Arg Ala Lys Ile Pro Trp Arg Ala Cys Thr Lys Tyr Leu Ser Ser Ala 995 1000 1005 Gly Ile Leu Leu Leu Ser Leu Leu Val Phe Ser Gin Leu Leu Lys His 1010 1015 1020 Met Val Leu Val Ala Ile Asp Tyr Trp Leu Ala Lys Trp Thr Asp Ser 1025 1030 1035 1040 Ala Leu Val Leu Ser Pro Ala Ala Arg Asn Cys Ser Leu Ser Gin Glu 1045 1050 1055 Cys Ala Leu Asp Gin Ser Val Tyr Ala Met Val Phe Thr Val Leu Cys 1060 1065 1070 Ser Leu Gly Ile Ala Leu Cys Leu Val Thr Ser Val Thr Val Glu Trp 1075 1080 1085 Thr Gly Leu Lys Val Ala Lys Arg Leu His Arg Ser Leu Leu Asn Arg 1090 1095 1100 Ile Ile Leu Ala Pro Met Arg Phe Phe Glu Thr Thr Pro Leu Gly Ser 1105 1110 1115 1120 Ile Leu Asn Arg Phe Ser Ser Asp Cys Asn Thr Ile Asp Gin His Ile 1125 1130 1135 Pro Ser Thr Leu Glu Cys Leu Ser Arg Ser Thr Leu Leu Cys Val Ser 1140 1145 1150 Ala Leu Ala Val Ile Ser Tyr Val Thr Pro Val Phe Leu Val Ala Leu 1155 1160 1165 Leu Pro Leu Ala Val Val Cys Tyr Phe Ile Gin Lys Tyr Phe Arg Val 1170 1175 1180 Ala Ser Arg Asp Leu Gin Gin Leu Asp Asp Thr Thr Gin Leu Pro Leu 1185 1190 1195 1200 Leu Ser His Phe Ala Glu Thr Val Glu Gly Leu Thr Thr Ile Arg Ala 1205 1210 1215 Phe Arg Tyr Glu Ala Arg Phe Gin Gin Lys Leu Leu Glu Tyr Thr Asp 1220 1225 1230 Ser Asn Asn Ile Ala Ser Leu Phe Leu Thr Ala Ala Asn Arg Trp Leu 1235 1240 1245 Glu Val Arg Met Glu Tyr Ile Gly Ala Cys Val Val Leu Ile Ala Ala 1250 1255 1260 Ala Thr Ser Ile Ser Asn Ser Leu His Arg Glu Leu Ser Ala Gly Leu 1265 1270 1275 1280 Val Gly Leu Gly Leu Thr Tyr Ala Leu Met Val Ser Asn Tyr Leu Asn 1285 1290 1295 Trp Met Val Arg Asn Leu Ala Asp Met Glu Ile Gin Leu Gly Ala Val 1300 1305 1310 Lys Gly Ile His Thr Leu Leu Lys Thr Glu Ala Glu Ser Tyr Glu Gly 1315 1320 1325 Leu Leu Ala Pro Ser Leu Ile Pro Lys Asn Trp Pro Asp Gin Gly Lys 1330 1335 1340 Ile Gin Ile Gin Asn Leu Ser Val Arg Tyr Asp Ser Ser Leu Lys Pro 1345 1350 1355 1360 Val Leu Lys His Val Asn Ala Leu Ile Ser Pro Gly Gin Lys Ile Gly 1365 1370 1375 Ile Cys Gly Arg Thr Gly Ser Gly Lys Ser Ser Phe Ser Leu Ala Phe 1380 1385 1390 Phe Arg Met Val Asp Met Phe Glu Gly Arg Ile Ile Ile Asp Gly Ile 1395 1400 1405 Asp Ile Ala Lys Leu Pro Leu His Thr Leu Gly Ser Arg Leu Ser Ile 1410 1415 1420 Ile Leu Gin Asp Pro Val Leu Phe Ser Gly Thr Ile Arg Phe Asn Leu 1425 1430 1435 1440 Asp Pro Glu Lys Lys Cys Ser Asp Ser Thr Leu Trp Glu Ala Leu Glu 1445 1450 1455 Ile Ala Gin Leu Lys Leu Val Val Lys Ala Leu Pro Gly Gly Leu Asp 1460 1465 1470 Ala Ile Ile Thr Glu Gly Gly Glu Asn Phe Ser Gin Gly Gin Arg Gin 1475 1480 1485 Leu Phe Cys Leu Ala Arg Ala Phe Val Arg Lys Thr Ser Ile Phe Ile 1490 1495 1500 Met Asp Glu Ala Thr Ala Ser Ile Asp Met Ala Thr Glu Asn Ile Leu 1505 1510 1515 1520 -Gin Lys Val Val Met Thr Ala Phe Ala Asp Arg Thr Val Val Thr Ile 1525 1530 1535 Ala His Arg Val His Thr Ile Leu Ser Ala Asp Leu Val Met Val Leu 1540 1545 1550 Lys Arg Gly Ala Ile Leu Glu Phe Asp Lys Pro Glu Lys Leu Leu Ser 1555 1560 1565 Gin Lys Asp Ser Val Phe Ala Ser Phe Val Arg Ala Asp 1570 1575 1580 (34) INFORMATION FOR SEQ ID NO:35: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4877 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: nucleic acid (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35: AGCCGAGCCC GTGCGCGCGC CGCCATGCCC TTGGCCTTCT GCGGTACCGA GAACCACTCG 60 GCCGCCTACC GGGTGGACCA GGGCGTCCTC AACAACGGCT GCTTCGTGGA CGCGCTCAAC 120 GTGGTGCCGC ACGTTTTCCT GCTCTTCATC ACCTTCCCCA TCCTCTTCAT CGGATGGGGC 180 AGCCAGAGCT CCAAGGTGCA CATCCACCAC AGCACCTGGC TGCACTTTCC AGGGCACAAC 240 CTGCGCTGGA TCCTTACCTT CATTTTGCTC TTCGTCCTTG TGTGTGAGAT CGCTGAGGGC 300 ATCCTGTCTG ATGGGGTGAC AGAATCCCGC CACCTCCACC TGTACATGCC AGCCGGGATG 360 GCGTTCATGG CTGCCATCAC CTCTGTAGTC TACTATCATA ACATCGAGAC CTCCAACTTC 420 CCCAAGCTTT TGATCGCTCT GCTCATCTAT TGGACCCTGG CCTTCATCAC GAAGACCATC 480 AAGTTTGTCA AGTTCTATGA CCACGCCATC GGCTTCTCCC AGCTGCGCTT CTGCCTCACG 540 GGGCTTCTGG TGATCCTGTA TGGGATGTTG CTGCTTGTGG AGGTCAACGT CATCAGAGTG 600 AGGAGGTACA TCTTCTTCAA GACGCCACGG GAGGTGAAGC CCCCTGAGGA CCTGCAGGAC 660 CTGGGTGTGC GCTTTCTGCA GCCCTTCGTT AACCTGCTGT CAAAGGGGAC CTATTGGTGG 720 ATGAATGCCT TCATCAAGAC GGCCCACAAG AAGCCCATCG ACCTGCGGGC CATCGCGAAG 780 CTGCCCATCG CCATGAGAGC CCTCACCAAC TATCAGCGCC TCTGCGTGGC CTTCGATGCT 840 CAGGCGCGGA AGGACACACA GAGCCCACAG GGTGCCCGGG CCATCTGGAG GGCTCTATGC 900 CATGCCTTTG GGAGACGCCT GATCCTCAGC AGCACATTCC GCATCCTGGC TGACCTGTTG 960 GGCTTCGCTG GACCACTCTG CATCTTTGGG ATCGTGGACC ACCTGGGGAA GGAGAACCAC 1020 GTCTTCCAGC CCAAGACACA GTTTCTCGGG GTTTACTTCG TCTCTTCTCA AGAGTTCCTT 1080 GGCAATGCCT ACGTCTTGGC CGTGCTTCTG TTCCTTGCCC TGCTACTGCA AAGGACATTC 1140 CTGCAAGCCT CATACTACGT CGCCATTGAA ACTGGAATTA ACCTGAGAGG AGCAATCCAG 1200 ACCAAGATTT ACAATAAAAT CATGCACATG TCCACCTCCA ACCTGTCAAT GGGGGAAATG 1260 ACTGCTGGGC AGATCTGCAA CCTGGTGGCC ATCGACACAA ACCAGCTCAT GTGGTTCTTC 1320 TTTCTGTGCC CAAACCTCTG GACGATGCCA GTACAGATCA TTGTGGGCGT GATCCTTCTC 1380 TACTACATCC TTGGGGTCAG TGCCTTGATT GGAGCAGCTG TCATCATTCT GCTGGCTCCT 1440 GTACAGTACT TTGTGGCCAC CAAGCTCTCC CAGGCACAGC GGACGACCTT GGAGCACTCC 1500 AACGAGAGGC TGAAGCAGAC CAACGAGATG CTCCGGGGCA TGAAGCTGCT CAAACTGTAT 1560 GCGTGGGAGA GCATCTTCTG CTCCAGGGTG GAGGTGACTC GCAGGAAGGA GATGACCAGC 1620 CTGAGGGCGT TTGCTGTCTA CACTTCCATC TCCATCTTCA TGAACACAGC CATCCCCATT 1680 GCTGCCGTCC TCATCACCTT CGTGGGCCAC GTCAGCTTCT TCAAAGAGTC GGACTTGTCA 1740 CCCTCGGTGG CCTTTGCCTC CCTCTCTCTC TTCCACATCC TGGTCACTCC ACTGTTCCTG 1800 CTGTCTAGCG TGGTTCGGTC CACTGTCAAA GCCCTGGTGA GCGTGCAAAA ACTGAGCGAG 1860 TTCCTGTCTA GTGCAGAGAT CCGTGAGGAG CAGTGTGCCC CCCGAGAGCC TGCACCCCAA 1920 GGCCAAGCCG GCAAGTACCA GGCAGTGCCC CTCAAGGTTG TGAACCGCAA ACGCCCAGCC 1980 CGGGAAGAGG TCCGGGACCT CCTGGGCCCA CTGCAGAGGC TGGCCCCTAG CATGGACGGG 2040 GATGCTGACA ACTTCTGTGT CCAGATCATC GGAGGCTTCT TCACCTGGAC CCCTGATGGA 2100 ATCCCCACTC TGTCCAACAT CACCATCCGT ATTCCCCGAG GTCAGCTAAC CATGATTGTG 2160 GGGCAGGTGG GCTGCGGCAA GTCCTCGCTC CTCCTCGCCA CCCTGGGGGA GATGCAGAAG 2220 GTGTCGGGGG CCGTCTTCTG GAACAGCAAC CTTCCGGACA GCGAGGGGAG AGGACCCCAG 2280 CAGCCCAGAG CGGGAGACAG CAGCTGGCTC GGATATCAGG AGCAGAGGCC CCGTGGCTAC 2340 GCATCTCAGA AACCATGGCT GCTAAACGCC ACCGTGGAAG AGAACATCAC CTTCGAGAGT 2400 CCCTTCAATC CGCAGCGGTA CAAGATGGTC ATCGAAGCCT GCTCCCTGCA GCCGGACATA 2460 GACATCCTGC CCCACGGAGA CCAGACTCAG ATTGGGGAAC GGGGCATCAA CCTGTCTGGT 2520 GGTCAGCGTC CAGATCAGTG TGGTCCAGAG CCCTCTACCA GCAGACCAAT GTTCGTCTTC 2580 TTGGATGACC CCTTCTCAGC TTTGGATGTC CATCTGAGTG ACCACCTGAT GCAGGCCGGC 2640 ATCCTTGAGC TGCTCCGGGA TGACAAGAGG ACAGTGGTCT TGGTGACCCA CAAGCTACAG 2700 TATCTGCCTC ATGCAGACTG GATCATTGCC ATGAAGGATG GGACCATTCA GAGGGAAGGG 2760 ACGCTCAAGG ACTTCCAGAG GTCCGAGTGC CAGCTCTTTG AGCACTGGAA GACCCTCATG 2820 AACCGGCAGG ACCAAGAGCT GGAGAAGGAG ACAGTCATGG AGAGGAAAGC CTCAGAGCCA 2880 TCTCAGGGCC TGCCCCGTGC CATGTCCTCC AGAGACGGCC TTCTGCTGGA TGAGGAAGAG 2940 GAGGAAGAGG AGGCAGCCGA AAGCGAGGAA GATGACAACT TATCTTCAGT GCTGCATCAG 3000 CGAGCTAAGA TCCCCTGGCG AGCCTGCACT AAGTATCTGT CCTCTGCTGG CATTCTGCTC 3060 CTGTCCCTGC TTGTCTTCTC CCAGCTGCTC AAGCACATGG TCTTGGTGGC CATTGATTAT 3120 TGGCTGGCCA AGTGGACGGA CAGTGCCCTG GTCCTGAGCC CCGCTGCCAG GAACTGTTCG 3180 CTCAGCCAGG AATGTGACCT GGACCAGTCT GTCTATGCCA TGGTATTCAC CTTGCTCTGC 3240 AGCCTGGGTA TCGTGCTGTG CCTGGTCACC TCTGTCACTG TGGAGTGGAC GGGACTGAAG 3300 GTGGCCAAGA GGCTACACCG CAGCCTGCTC AACCGCATCA TCCTGGCCCC CATGAGGTTC 3360 TTTGAGACCA CACCCCTCGG GAGTATCCTG AACAGATTTT CATCCGACTG TAACACCATT 3420 GACCAGCACA TCCCATCCAC GCTGGAGTGT CTGAGCCGGT CCACCCTGCT GTGTGTCTCC 3480 GCCCTGACTG TCATCTCCTA TGTCACACCC GTGTTCCTCG TGGCCCTCTT ACCCCTAGCT 3540 GTTGTGTGCT ACTTCATTCA GAAGTACTTC CGAGTGGCAT CCAGGGACCT GCAGCAGCTG 3600 GACGACACGA CGCAGCTCCC GCTCGTCTCA CACTTTGCTG AAACTGTGGA GGGACTCACC 3660 ACCATCCGTG CCTTCAGGTA CGAGGCCCGG TTCCAGCAGA AGCTTCTAGA ATATACCGAC 3720 TCCAACAACA TCGCCTCCCT CTTCCTCACG GCAGCCAACA GATGGCTGGA AGTCTGCATG 3780 GAGTACATCG GAGCGTGCGT GGTACTCATT GCGGCTGCCA CCTCCATCTC CAACTCCCTG 3840 CACAGGGAAC TTTCTGCTGG CCTGGTGGGC CTGGGCCTCA CCTATGCCTT GATGGTCTCC 3900 AACTACCTCA ACTGGATGGT GAGGAACCTG GCGGACATGG AGATCCAGCT GGGGGCTGTG 3960 AAGAGGATCC ACGCACTCCT GAAAACCGAG GCGGAGAGCT ATGAGGGGCT CCTGGCGCCG 4020 TCGTTGATCC CCAAGAACTG GCCAGACCAA GGGAAGATCC AAATTCAGAA CCTGAGCGTG 4080 CGCTATGACA GCTCCCTGAA GCCAGTGCTG AAGCATGTCA ACACCCTCAT CTCCCCGGGG 4140 CAGAAGATCG GGATCTGCGG CCGCACAGGC AGCGGGAAGT CCTCCTTCTC CCTGGCCTTT 4200 TTCCGAATGG TGGACATGTT TGAAGGACGC ATCATCATTG ATGGCATCGA CATCGCCAAG 4260 CTGCCACTTC ACACGCTGCG CTCACGCCTG TCCATCATCC TACAGGACCC CGTCCTCTTC 4320 AGCGGCACGA TCAGATTCAA CCTGGACCCC GAGAAGAAAT GCTCAGACAG CACACTGTGG 4380 GAGGCCCTGG AGATCGCCCA GCTGAAGCTG GTAGTGAAGG CACTGCCAGG AGGCCTAGAT 4440 GCCATCATCA CAGAAGGAGG GGAGAATTTT AGCCAGGGCC AGAGGCAGCT GTTCTGCCTG 4500 GCCCGGGCCT TCGTGAGGAA GACCAGCATC TTCATCATGG ATGAAGCAAC CGCCTCCATC 4560 GACATGGCTA CGGAGAACAT CCTCCAGAAG GTGGTGATGA CAGCCTTCGC AGACCGCACG 4620 GTGGTCACCA TCGCGCATCG TGTGCACACC ATCCTGAGTG CAGACCTGGT GATGGTCCTC 4680 AAGAGGGGTG CTATCCTGGA GTTTGACAAG CCAGAGACGC TCCTCAGCCA GAAGGACAGC 4740 GTGTTCGCCT CCTTTGTCCG TGCGGACAAG TGACTTACCG GAGCCAAAGT GCCACCCCGC 4800 GCCTCGCTTG CTTGCCTAGG ATTTCTAACT GCAAATCACT TGTAAATAAA TTAATTCTTT 4860 GCTAAAAAAA AAAAAAA 4877 (35) INFORMATION FOR SEQ ID NO:36: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4877 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 25..4770 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36: AGCCGAGCCC GTGCGCGCGC CGCC ATG CCC TTG GCC TTC TGC GGT ACC GAG 51 Met Pro Leu Ala Phe Cys Gly Thr Glu 1 5 AAC CAC TCG GCC GCC TAC CGG GTG GAC CAG GGC GTC CTC AAC AAC GGC 99 Asn His Ser Ala Ala Tyr Arg Val Asp Gin Gly Val Leu Asn Asn Gly 10 15 20 25 TGC TTC GTG GAC GCG CTC AAC GTG GTG CCG CAC GTT TTC CTG CTC TTC 147 Cys Phe Val Asp Ala Leu Asn Val Val Pro His Val Phe Leu Leu Phe 30 35 40 ATC ACC TTC CCC ATC CTC TTC ATC GGA TGG GGC AGC CAG AGC TCC AAG 195 Ile Thr Phe Pro Ile Leu Phe Ile Gly Trp Gly Ser Gin Ser Ser Lys 45 50 55 GTG CAC ATC CAC CAC AGC ACC TGG CTG CAC TTT CCA GGG CAC AAC CTG 243 Val His Ile His His Ser Thr Trp Leu His Phe Pro Gly His Asn Leu 60 65 70 CGC TGG ATC CTT ACC TTC ATT TTG CTC TTC GTC CTT GTG TGT GAG ATC 291 Arg Trp Ile Leu Thr Phe Ile Leu Leu Phe Val Leu Val Cys Glu Ile 75 80 85 GCT GAG GGC ATC CTG TCT GAT GGG GTG ACA GAA TCC CGC CAC CTC CAC 339 Ala Glu Gly Ile Leu Ser Asp Gly Val Thr Glu Ser Arg His Leu His 90 95 100 105 CTG TAC ATG CCA GCC GGG ATG GCG TTC ATG GCT GCC ATC ACC TCT GTA 387 Leu Tyr Met Pro Ala Gly Met Ala Phe Met Ala Ala Ile Thr Ser Val 110 115 120 GTC TAC TAT CAT AAC ATC GAG ACC TCC AAC TTC CCC AAG CTT TTG ATC 435 Val Tyr Tyr His Asn Ile Glu Thr Ser Asn Phe Pro Lys Leu Leu Ile 125 130 135 GCT CTG CTC ATC TAT TGG ACC CTG GCC TTC ATC ACG AAG ACC ATC AAG 483 Ala Leu Leu Ile Tyr Trp Thr Leu Ala Phe Ile Thr Lys Thr Ile Lys 140 145 150 TTT GTC AAG TTC TAT GAC CAC GCC ATC GGC TTC TCC CAG CTG CGC TTC 531 Phe Val Lys Phe Tyr Asp His Ala Ile Gly Phe Ser Gin Leu Arg Phe 155 160 165 TGC CTC ACG GGG CTT CTG GTG ATC CTG TAT GGG ATG TTG CTG CTT GTG 579 Cys Leu Thr Gly Leu Leu Val Ile Leu Tyr Gly Met Leu Leu Leu Val 170 175 180 185 GAG GTC AAC GTC ATC AGA GTG AGG AGG TAC ATC TTC TTC AAG ACG CCA 627 Glu Val Asn Val Ile Arg Val Arg Arg Tyr Ile Phe Phe Lys Thr Pro 190 195 200 CGG GAG GTG AAG CCC CCT GAG GAC CTG CAG GAC CTG GGT GTG CGC TTT 675 Arg Glu Val Lys Pro Pro Glu Asp Leu Gin Asp Leu Gly Val Arg Phe 205 210 215 CTG CAG CCC TTC GTT AAC CTG CTG TCA AAG GGG ACC TAT TGG TGG ATG 723 Leu Gin Pro Phe Val Asn Leu Leu Ser Lys Gly Thr Tyr Trp Trp Met 220 225 230 AAT GCC TTC ATC AAG ACG GCC CAC AAG AAG CCC ATC GAC CTG CGG GCC 771 Asn Ala Phe Ile Lys Thr Ala His Lys Lys Pro Ile Asp Leu Arg Ala 235 240 245 ATC GCG AAG CTG CCC ATC GCC ATG AGA GCC CTC ACC AAC TAT CAG CGC 819 Ile Ala Lys Leu Pro Ile Ala Met Arg Ala Leu Thr Asn Tyr Gin Arg 250 255 260 265 CTC TGC GTG GCC TTC GAT GCT CAG GCG CGG AAG GAC ACA CAG AGC CCA 867 Leu Cys Val Ala Phe Asp Ala Gin Ala Arg Lys Asp Thr Gin Ser Pro 270 275 280 CAG GGT GCC CGG GCC ATC TGG AGG GCT CTA TGC CAT GCC TTT GGG AGA 915 Gin Gly Ala Arg Ala Ile Trp Arg Ala Leu Cys His Ala Phe Gly Arg 285 290 295 CGC CTG ATC CTC AGC AGC ACA TTC CGC ATC CTG GCT GAC CTG TTG GGC 963 Arg Leu Ile Leu Ser Ser Thr Phe Arg Ile Leu Ala Asp Leu Leu Gly 300 305 310 TTC GCT GGA CCA CTC TGC ATC TTT GGG ATC GTG GAC CAC CTG GGG AAG 1011 Phe Ala Gly Pro Leu Cys Ile Phe Gly Ile Val Asp His Leu Gly Lys 315 320 325 GAG AAC CAC GTC TTC CAG CCC AAG ACA CAG TTT CTC GGG GTT TAC TTC 1059 Glu Asn His Val Phe Gin Pro Lys Thr Gin Phe Leu Gly Val Tyr Phe 330 335 340 345 GTC TCT TCT CAA GAG TTC CTT GGC AAT GCC TAC GTC TTG GCC GTG CTT 1107 Val Ser Ser Gin Glu Phe Leu Gly Asn Ala Tyr Val Leu Ala Val Leu 350 355 360 CTG TTC CTT GCC CTG CTA CTG CAA AGG ACA TTC CTG CAA GCC TCA TAC 1155 Leu Phe Leu Ala Leu Leu Leu Gin Arg Thr Phe Leu Gin Ala Ser Tyr 365 370 375 TAC GTC GCC ATT GAA ACT GGA ATT AAC CTG AGA GGA GCA ATC CAG ACC 1203 Tyr Val Ala Ile Glu Thr Gly Ile Asn Leu Arg Gly Ala Ile Gin Thr 380 385 390 AAG ATT TAC AAT AAA ATC ATG CAC ATG TCC ACC TCC AAC CTG TCA ATG 1251 Lys Ile Tyr Asn Lys Ile Met His Met Ser Thr Ser Asn Leu Ser Met 395 400 405 GGG GAA ATG ACT GCT GGG CAG ATC TGC AAC CTG GTG GCC ATC GAC ACA 1299 Gly Glu Met Thr Ala Gly Gin Ile Cys Asn Leu Val Ala Ile Asp Thr 410 415 420 425 AAC CAG CTC ATG TGG TTC TTC TTT CTG TGC CCA AAC CTC TGG ACG ATG 1347 Asn Gin Leu Met Trp Phe Phe Phe Leu Cys Pro Asn Leu Trp Thr Met 430 435 440 CCA GTA CAG ATC ATT GTG GGC GTG ATC CTT CTC TAC TAC ATC CTT GGG 1395 Pro Val Gin Ile Ile Val Gly Val Ile Leu Leu Tyr Tyr Ile Leu Gly 445 450 455 GTC AGT GCC TTG ATT GGA GCA GCT GTC ATC ATT CTG CTG GCT CCT GTA 1443 Val Ser Ala Leu Ile Gly Ala Ala Val Ile Ile Leu Leu Ala Pro Val 460 465 470 CAG TAC TTT GTG GCC ACC AAG CTC TCC CAG GCA CAG CGG ACG ACC TTG 1491 Gin Tyr Phe Val Ala Thr Lys Leu Ser Gin Ala Gin Arg Thr Thr Leu 475 480 485 GAG CAC TCC AAC GAG AGG CTG AAG CAG ACC AAC GAG ATG CTC CGG GGC 1539 Glu His Ser Asn Glu Arg Leu Lys Gin Thr Asn Glu Met Leu Arg Gly 490 495 500 505 ATG AAG CTG CTC AAA CTG TAT GCG TGG GAG AGC ATC TTC TGC TCC AGG 1587 Met Lys Leu Leu Lys Leu Tyr Ala Trp Glu Ser Ile Phe Cys Ser Arg 510 515 520 GTG GAG GTG ACT CGC AGG AAG GAG ATG ACC AGC CTG AGG GCG TTT GCT 1635 Val Glu Val Thr Arg Arg Lys Glu Met Thr Ser Leu Arg Ala Phe Ala 525 530 535 GTC TAC ACT TCC ATC TCC ATC TTC ATG AAC ACA GCC ATC CCC ATT GCT 1683 Val Tyr Thr Ser Ile Ser Ile Phe Met Asn Thr Ala Ile Pro Ile Ala 540 545 550 GCC GTC CTC ATC ACC TTC GTG GGC CAC GTC AGC TTC TTC AAA GAG TCG 1731 Ala Val Leu Ile Thr Phe Val Gly His Val Ser Phe Phe Lys Glu Ser 555 560 565 GAC TTG TCA CCC TCG GTG GCC TTT GCC TCC CTC TCT CTC TTC CAC ATC 1779 Asp Leu Ser Pro Ser Val Ala Phe Ala Ser Leu Ser Leu Phe His Ile 570 575 580 585 CTG GTC ACT CCA CTG TTC CTG CTG TCT AGC GTG GTT CGG TCC ACT GTC 1827 Leu Val Thr Pro Leu Phe Leu Leu Ser Ser Val Val Arg Ser Thr Val 590 595 600 AAA GCC CTG GTG AGC GTG CAA AAA CTG AGC GAG TTC CTG TCT AGT GCA 1875 Lys Ala Leu Val Ser Val Gin Lys Leu Ser Glu Phe Leu Ser Ser Ala 605 610 615 GAG ATC CGT GAG GAG CAG TGT GCC CCC CGA GAG CCT GCA CCC CAA GGC 1923 Glu Ile Arg Glu Glu Gin Cys Ala Pro Arg Glu Pro Ala Pro Gin Gly 620 625 630 CAA GCC GGC AAG TAC CAG GCA GTG CCC CTC AAG GTT GTG AAC CGC AAA 1971 Gin Ala Gly Lys Tyr Gin Ala Val Pro Leu Lys Val Val Asn Arg Lys 635 640 645 CGC CCA GCC CGG GAA GAG GTC CGG GAC CTC CTG GGC CCA CTG CAG AGG 2019 Arg Pro Ala Arg Glu Glu Val Arg Asp Leu Leu Gly Pro Leu Gin Arg 650 655 660 665 CTG GCC CCT AGC ATG GAC GGG GAT GCT GAC AAC TTC TGT GTC CAG ATC 2067 Leu Ala Pro Ser Met Asp Gly Asp Ala Asp Asn Phe Cys Val Gin Ile 670 675 680 ATC GGA GGC TTC TTC ACC TGG ACC CCT GAT GGA ATC CCC ACT CTG TCC 2115 Ile Gly Gly Phe Phe Thr Trp Thr Pro Asp Gly Ile Pro Thr Leu Ser 685 690 695 AAC ATC ACC ATC CGT ATT CCC CGA GGT CAG CTA ACC ATG ATT GTG GGG 2163 Asn Ile Thr Ile Arg Ile Pro Arg Gly Gin Leu Thr Met Ile Val Gly 700 705 710 CAG GTG GGC TGC GGC AAG TCC TCG CTC CTC CTC GCC ACC CTG GGG GAG 2211 Gin Val Gly Cys Gly Lys Ser Ser Leu Leu Leu Ala Thr Leu Gly Glu 715 720 725 ATG CAG AAG GTG TCG GGG GCC GTC TTC TGG AAC AGC AAC CTT CCG GAC 2259 Met Gin Lys Val Ser Gly Ala Val Phe Trp Asn Ser Asn Leu Pro Asp 730 735 740 745 AGC GAG GGG AGA GGA CCC CAG CAG CCC AGA GCG GGA GAC AGC AGC TGG 2307 Ser Glu Gly Arg Gly Pro Gin Gin Pro Arg Ala Gly Asp Ser Ser Trp 750 755 760 CTC GGA TAT CAG GAG CAG AGG CCC CGT GGC TAC GCA TCT CAG AAA CCA 2355 Leu Gly Tyr Gin Glu Gin Arg Pro Arg Gly Tyr Ala Ser Gin Lys Pro 765 770 775 TGG CTG CTA AAC GCC ACC GTG GAA GAG AAC ATC ACC TTC GAG AGT CCC 2403 Trp Leu Leu Asn Ala Thr Val Glu Glu Asn Ile Thr Phe Glu Ser Pro 780 785 790 TTC AAT CCG CAG CGG TAC AAG ATG GTC ATC GAA GCC TGC TCC CTG CAG 2451 Phe Asn Pro Gin Arg Tyr Lys Met Val Ile Glu Ala Cys Ser Leu Gin 795 800 805 CCG GAC ATA GAC ATC CTG CCC CAC GGA GAC CAG ACT CAG ATT GGG GAA 2499 Pro Asp Ile Asp Ile Leu Pro His Gly Asp Gin Thr Gin Ile Gly Glu 810 815 820 825 CGG GGC ATC AAC CTG TCT GGT GGT CAG CGT CCA GAT CAG TGT GGT CCA 2547 Arg Gly Ile Asn Leu Ser Gly Gly Gin Arg Pro Asp Gin Cys Gly Pro 830 835 840 GAG CCC TCT ACC AGC AGA CCA ATG TTC GTC TTC TTG GAT GAC CCC TTC 2595 Glu Pro Ser Thr Ser Arg Pro Met Phe Val Phe Leu Asp Asp Pro Phe 845 850 855 TCA GCT TTG GAT GTC CAT CTG AGT GAC CAC CTG ATG CAG GCC GGC ATC 2643 Ser Ala Leu Asp Val His Leu Ser Asp His Leu Met Gin Ala Gly Ile 860 865 870 CTT GAG CTG CTC CGG GAT GAC AAG AGG ACA GTG GTC TTG GTG ACC CAC 2691 Leu Glu Leu Leu Arg Asp Asp Lys Arg Thr Val Val Leu Val Thr His 875 880 885 AAG CTA CAG TAT CTG CCT CAT GCA GAC TGG ATC ATT GCC ATG AAG GAT 2739 Lys Leu Gin Tyr Leu Pro His Ala Asp Trp Ile Ile Ala Met Lys Asp 890 895 900 905 GGG ACC ATT CAG AGG GAA GGG ACG CTC AAG GAC TTC CAG AGG TCC GAG 2787 Gly Thr Ile Gin Arg Glu Gly Thr Leu Lys Asp Phe Gin Arg Ser Glu 910 915 920 TGC CAG CTC TTT GAG CAC TGG AAG ACC CTC ATG AAC CGG CAG GAC CAA 2835 Cys Gin Leu Phe Glu His Trp Lys Thr Leu Met Asn Arg Gin Asp Gin 925 930 935 GAG CTG GAG AAG GAG ACA GTC ATG GAG AGG AAA GCC TCA GAG CCA TCT 2883 Glii Leu Glu Lys Glu Thr Val Met Glu Arg Lys Ala Ser Glu Pro Ser .940 945 950 CAG GGC CTG CCC CGT GCC ATG TCC TCC AGA GAC GGC CTT CTG CTG GAT 2931 Gin Gly Leu Pro Arg Ala Met Ser Ser Arg Asp Gly Leu Leu Leu Asp 955 960 965 GAG GAA GAG GAG GAA GAG GAG GCA GCC GAA AGC GAG GAA GAT GAC AAC 2979 Glu Glu Glu Glu Glu Glu Glu Ala Ala Glu Ser Glu Glu Asp Asp Asn 970 975 980 985 TTA TCT TCA GTG CTG CAT CAG CGA GCT AAG ATC CCC TGG CGA GCC TGC 3027 Leu Ser Ser Val Leu His Gin Arg Ala Lys Ile Pro Trp Arg Ala Cys 990 995 1000 ACT AAG TAT CTG TCC TCT GCT GGC ATT CTG CTC CTG TCC CTG CTT GTC 3075 Thr Lys Tyr Leu Ser Ser Ala Gly Ile Leu Leu Leu Ser Leu Leu Val 1005 1010 1015 TTC TCC CAG CTG CTC AAG CAC ATG GTC TTG GTG GCC ATT GAT TAT TGG 3123 Phe Ser Gin Leu Leu Lys His Met Val Leu Val Ala Ile Asp Tyr Trp 1020 1025 1030 CTG GCC AAG TGG ACG GAC AGT GCC CTG GTC CTG AGC CCC GCT GCC AGG 3171 Leu Ala Lys Trp Thr Asp Ser Ala Leu Val Leu Ser Pro Ala Ala Arg 1035 1040 1045 AAC TGT TCG CTC AGC CAG GAA TGT GAC CTG GAC CAG TCT GTC TAT GCC 3219 Asn Cys Ser Leu Ser Gin Glu Cys Asp Leu Asp Gin Ser Val Tyr Ala 1050 1055 1060 1065 ATG GTA TTC ACC TTG CTC TGC AGC CTG GGT ATC GTG CTG TGC CTG GTC 3267 Met Val Phe Thr Leu Leu Cys Ser Leu Gly Ile Val Leu Cys Leu Val 1070 1075 1080 ACC TCT GTC ACT GTG GAG TGG ACG GGA CTG AAG GTG GCC AAG AGG CTA 3315 Thr Ser Val Thr Val Glu Trp Thr Gly Leu Lys Val Ala Lys Arg Leu 1085 1090 1095 CAC CGC AGC CTG CTC AAC CGC ATC ATC CTG GCC CCC ATG AGG TTC TTT 3363 His Arg Ser Leu Leu Asn Arg Ile Ile Leu Ala Pro Met Arg Phe Phe 1100 1105 1110 GAG ACC ACA CCC CTC GGG AGT ATC CTG AAC AGA TTT TCA TCC GAC TGT 3411 Glu Thr Thr Pro Leu Gly Ser Ile Leu Asn Arg Phe Ser Ser Asp Cys 1115 1120 1125 AAC ACC ATT GAC CAG CAC ATC CCA TCC ACG CTG GAG TGT CTG AGC CGG 3459 Asn Thr lie Asp Gin His Ile Pro Ser Thr Leu Glu Cys Leu Ser Arg 1130 1135 1140 1145 TCC ACC CTG CTG TGT GTC TCC GCC CTG ACT GTC ATC TCC TAT GTC ACA 3507 Ser Thr Leu Leu Cys Val Ser Ala Leu Thr Val Ile Ser Tyr Val Thr 1150 1155 1160 CCC GTG TTC CTC GTG GCC CTC TTA CCC CTA GCT GTT GTG TGC TAC TTC 3555 Pro Val Phe Leu Val Ala Leu Leu Pro Leu Ala Val Val Cys Tyr Phe 1165 1170 1175 ATT CAG AAG TAC TTC CGA GTG GCA TCC AGG GAC CTG CAG CAG CTG GAC 3603 Ile Gin Lys Tyr Phe Arg Val Ala Ser Arg Asp Leu Gin Gin Leu Asp 1180 1185 1190 GAC ACG ACG CAG CTC CCG CTC GTC TCA CAC TTT GCT GAA ACT GTG GAG 3651 Asp Thr Thr Gin Leu Pro Leu Val Ser His Phe Ala Glu Thr Val Glu 1195 1200 1205 GGA CTC ACC ACC ATC CGT GCC TTC AGG TAC GAG GCC CGG TTC CAG CAG 3699 Gly Leu Thr Thr Ile Arg Ala Phe Arg Tyr Glu Ala Arg Phe Gin Gin 1210 1215 1220 1225 AAG CTT CTA GAA TAT ACC GAC TCC AAC AAC ATC GCC TCC CTC TTC CTC 3747 Lys Leu Leu Glu Tyr Thr Asp Ser Asn Asn Ile Ala Ser Leu Phe Leu 1230 1235 1240 ACG GCA GCC AAC AGA TGG CTG GAA GTC TGC ATG GAG TAC ATC GGA GCG 3795 Thr Ala Ala Asn Arg Trp Leu Glu Val Cys Met Glu Tyr Ile Gly Ala 1245 1250 1255 TGC GTG GTA CTC ATT GCG GCT GCC ACC TCC ATC TCC AAC TCC CTG CAC 3843 Cys Val Val Leu Ile Ala Ala Ala Thr Ser Ile Ser Asn Ser Leu His 1260 1265 1270 AGG GAA CTT TCT GCT GGC CTG GTG GGC CTG GGC CTC ACC TAT GCC TTG 3891 Arg Glu Leu Ser Ala Gly Leu Val Gly Leu Gly Leu Thr Tyr Ala Leu 1275 1280 1285 ATG GTC TCC AAC TAC CTC AAC TGG ATG GTG AGG AAC CTG GCG GAC ATG 3939 Met Val Ser Asn Tyr Leu Asn Trp Met Val Arg Asn Leu Ala Asp Met 1290 1295 1300 1305 GAG ATC CAG CTG GGG GCT GTG AAG AGG ATC CAC GCA CTC CTG AAA ACC 3987 Glu Ile Gin Leu Gly Ala Val Lys Arg Ile His Ala Leu Leu Lys Thr 1310 1315 1320 GAG GCG GAG AGC TAT GAG GGG CTC CTG GCG CCG TCG TTG ATC CCC AAG 4035 Glu Ala Glu Ser Tyr Glu Gly Leu Leu Ala Pro Ser Leu Ile Pro Lys 1325 1330 1335 AAC TGG CCA GAC CAA GGG AAG ATC CAA ATT CAG AAC CTG AGC GTG CGC 4083 Asn Trp Pro Asp Gin Gly Lys Ile Gin Ile Gin Asn Leu Ser Val Arg 1340 1345 1350 TAT GAC AGC TCC CTG AAG CCA GTG CTG AAG CAT GTC AAC ACC CTC ATC 4131 Tyr Asp Ser Ser Leu Lys Pro Val Leu Lys His Val Asn Thr Leu Ile 1355 1360 1365 TCC CCG GGG CAG AAG ATC GGG ATC TGC GGC CGC ACA GGC AGC GGG AAG 4179 Ser Pro Gly Gin Lys Ile Gly Ile Cys Gly Arg Thr Gly Ser Gly Lys 1370 1375 1380 1385 TCC TCC TTC TCC CTG GCC TTT TTC CGA ATG GTG GAC ATG TTT GAA GGA 4227 Ser Ser Phe Ser Leu Ala Phe Phe Arg Met Val Asp Met Phe Glu Gly 1390 1395 1400 CGC ATC ATC ATT GAT GGC ATC GAC ATC GCC AAG CTG CCA CTT CAC ACG 4275 Arg Ile Ile Ile Asp Gly Ile Asp Ile Ala Lys Leu Pro Leu His Thr 1405 1410 1415 CTG CGC TCA CGC CTG TCC ATC ATC CTA CAG GAC CCC GTC CTC TTC AGC 4323 Leu Arg Ser Arg Leu Ser Ile Ile Leu Gin Asp Pro Val Leu Phe Ser 1420 1425 1430 GGC ACG ATC AGA TTC AAC CTG GAC CCC GAG AAG AAA TGC TCA GAC AGC 4371 Gly Thr Ile Arg Phe Asn Leu Asp Pro Glu Lys Lys Cys Ser Asp Ser 1435 1440 1445 ACA CTG TGG GAG GCC CTG GAG ATC GCC CAG CTG AAG CTG GTA GTG AAG 4419 Thr Leu Trp Glu Ala Leu Glu Ile Ala Gin Leu Lys Leu Val Val Lys 1450 1455 1460 1465 GCA CTG CCA GGA GGC CTA GAT GCC ATC ATC ACA GAA GGA GGG GAG AAT 4467 Ala Leu Pro Gly Gly Leu Asp Ala Ile Ile Thr Glu Gly Gly Glu Asn 1470 1475 1480 TTT AGC CAG GGC CAG AGG CAG CTG TTC TGC CTG GCC CGG GCC TTC GTG 4515 Phe Ser Gin Gly Gin Arg Gin Leu Phe Cys Leu Ala Arg Ala Phe Val 1485 1490 1495 AGG AAG ACC AGC ATC TTC ATC ATG GPΥ GAA GCA ACC GCC TCC ATC GAC 4563 Arg Lys Thr Ser Ile Phe Ile Met Asp Glu Ala Thr Ala Ser Ile Asp 1500 1505 1510 ATG GCT ACG GAG AAC ATC CTC CAG AAG GTG GTG ATG ACA GCC TTC GCA 4611 Met Ala Thr Glu Asn Ile Leu Gin Lys Val Val Met Thr Ala Phe Ala 1515 1520 1525 GAC CGC ACG GTG GTC ACC ATC GCG CAT CGT GTG CAC ACC ATC CTG AGT 4659 Asp Arg Thr Val Val Thr Ile Ala His Arg Val His Thr Ile Leu Ser 1530 1535 1540 1545 GCA GAC CTG GTG ATG GTC CTC AAG AGG GGT GCT ATC CTG GAG TTT GAC 4707 Ala Asp Leu Val Met Val Leu Lys Arg Gly Ala Ile Leu Glu Phe Asp 1550 1555 1560 AAG CCA GAG ACG CTC CTC AGC CAG AAG GAC AGC GTG TTC GCC TCC TTT 4755 Lys Pro Glu Thr Leu Leu Ser Gin Lys Asp Ser Val Phe Ala Ser Phe 1565 1570 1575 GTC CGT GCG GAC AAG TGACTTACCG GAGCCAAAGT GCCACCCCGC GCCTCGCTTG 4810 Val Arg Ala Asp Lys 1580 CTTGCCTAGG ATTTCTAACT GCAAATCACT TGTAAATAAA TTAATTCTTT GCTAAAAAAA 4870 AAAAAAA 4877 (36) INFORMATION FOR SEQ ID NO:37: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1582 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37: Met Pro Leu Ala Phe Cys Gly Thr Glu Asn His Ser Ala Ala Tyr Arg 1 5 10 15 Val Asp Gin Gly Val Leu Asn Asn Gly Cys Phe Val Asp Ala Leu Asn 20 25 30 Val Val Pro His Val Phe Leu Leu Phe Ile Thr Phe Pro Ile Leu Phe 35 40 45 Ile Gly Trp Gly Ser Gin Ser Ser Lys Val His Ile His His Ser Thr 50 55 60 Trp Leu His Phe Pro Gly His Asn Leu Arg Trp Ile Leu Thr Phe Ile 65 70 75 80 Leu Leu Phe Val Leu Val Cys Glu Ile Ala Glu Gly Ile Leu Ser Asp 85 90 95 Gly Val Thr Glu Ser Arg His Leu His Leu Tyr Met Pro Ala Gly Met 100 105 110 Ala Phe Met Ala Ala Ile Thr Ser Val Val Tyr Tyr His Asn Ile Glu 115 120 125 Thr Ser Asn Phe Pro Lys Leu Leu Ile Ala Leu Leu Ile Tyr Trp Thr 130 135 140 Leu Ala Phe Ile Thr Lys Thr Ile Lys Phe Val Lys Phe Tyr Asp His 145 150 155 160 Ala Ile Gly Phe Ser Gin Leu Arg Phe Cys Leu Thr Gly Leu Leu Val 165 170 175 Ile Leu Tyr Gly Met Leu Leu Leu Val Glu Val Asn Val Ile Arg Val 180 185 190 Arg Arg Tyr Ile Phe Phe Lys Thr Pro Arg Glu Val Lys Pro Pro Glu 195 200 205 Asp Leu Gin Asp Leu Gly Val Arg Phe Leu Gin Pro Phe Val Asn Leu 210 215 220 Leu Ser Lys Gly Thr Tyr Trp Trp Met Asn Ala Phe Ile Lys Thr Ala 225 230 235 240 His Lys Lys Pro Ile Asp Leu Arg Ala Ile Ala Lys Leu Pro Ile Ala 245 250 255 Met Arg Ala Leu Thr Asn Tyr Gin Arg Leu Cys Val Ala Phe Asp Ala 260 265 270 Gin Ala Arg Lys Asp Thr Gin Ser Pro Gin Gly Ala Arg Ala Ile Trp 275 280 285 Arg Ala Leu Cys His Ala Phe Gly Arg Arg Leu Ile Leu Ser Ser Thr 290 295 300 Phe Arg Ile Leu Ala Asp Leu Leu Gly Phe Ala Gly Pro Leu Cys Ile 305 310 315 320 Phe Gly Ile Val Asp His Leu Gly Lys Glu Asn His Val Phe Gin Pro 325 330 335 Lys Thr Gin Phe Leu Gly Val Tyr Phe Val Ser Ser Gin Glu Phe Leu 340 345 350 Gly Asn Ala Tyr Val Leu Ala Val Lea Leu Phe Leu Ala Leu Leu Leu 355 360 365 Gin Arg Thr Phe Leu Gin Ala Ser Tyr Tyr Val Ala Ile Glu Thr Gly 370 375 380 Ile Asn Leu Arg Gly Ala Ile Gin Thr Lys Ile Tyr Asn Lys Ile Met 385 390 395 400 His Met Ser Thr Ser Asn Leu Ser Met Gly Glu Met Thr Ala Gly Gin 405 410 415 Ile Cys Asn Leu Val Ala Ile Asp Thr Asn Gin Leu Met Trp Phe Phe 420 425 430 Phe Leu Cys Pro Asn Leu Trp Thr Met Pro Val Gin Ile Ile Val Gly 435 440 445 Val Ile Leu Leu Tyr Tyr Ile Leu Gly Val Ser Ala Leu Ile Gly Ala 450 455 460 Ala Val Ile Ile Leu Leu Ala Pro Val Gin Tyr Phe Val Ala Thr Lys 465 470 475 480 Leu Ser Gin Ala Gin Arg Thr Thr Leu Glu His Ser Asn Glu Arg Leu 485 490 495 Lys Gin Thr Asn Glu Met Leu Arg Gly Met Lys Leu Leu Lys Leu Tyr 500 505 510 Ala Trp Glu Ser Ile Phe Cys Ser Arg Val Glu Val Thr Arg Arg Lys 515 520 525 Glu Met Thr Ser Leu Arg Ala Phe Ala Val Tyr Thr Ser Ile Ser Ile 530 535 540 Phe Met Asn Thr Ala Ile Pro Ile Ala Ala Val Leu Ile Thr Phe Val 545 550 555 560 Gly His Val Ser Phe Phe Lys Glu Ser Asp Leu Ser Pro Ser Val Ala 565 570 575 Phe Ala Ser Leu Ser Leu Phe His Ile Leu Val Thr Pro Leu Phe Leu 580 585 590 Leu Ser Ser Val Val Arg Ser Thr Val Lys Ala Leu Val Ser Val Gin 595 600 605 Lys Leu Ser Glu Phe Leu Ser Ser Ala Glu Ile Arg Glu Glu Gin Cys 610 615 620 Ala Pro Arg Glu Pro Ala Pro Gin Gly Gin Ala Gly Lys Tyr Gin Ala 625 630 635 640 Val Pro Leu Lys Val Val Asn Arg Lys Arg Pro Ala Arg Glu Glu Val 645 650 655 Arg Asp Leu Leu Gly Pro Leu Gin Arg Leu Ala Pro Ser Met Asp Gly 660 665 670 Asp Ala Asp Asn Phe Cys Val Gin Ile Ile Gly Gly Phe Phe Thr Trp 675 680 685 Thr Pro Asp Gly Ile Pro Thr Leu Ser Asn Ile Thr Ile Arg Ile Pro 690 695 700 Arg Gly Gin Leu Thr Met Ile Val Gly Gin Val Gly Cys Gly Lys Ser 705 710 715 720 Ser Leu Leu Leu Ala Thr Leu Gly Glu Met Gin Lys Val Ser Gly Ala 725 730 735 Val Phe Trp Asn Ser Asn Leu Pro Asp Ser Glu Gly Arg Gly Pro Gin 740 745 750 Gin Pro Arg Ala Gly Asp Ser Ser Trp Leu Gly Tyr Gin Glu Gin Arg 755 760 765 Pro Arg Gly Tyr Ala Ser Gin Lys Pro Trp Leu Leu Asn Ala Thr Val 770 775 780 Glu Glu Asn Ile Thr Phe Glu Ser Pro Phe Asn Pro Gin Arg Tyr Lys 785 790 795 800 Met Val Ile Glu Ala Cys Ser Leu Gin Pro Asp Ile Asp Ile Leu Pro 805 810 815 His Gly Asp Gin Thr Gin Ile Gly Glu Arg Gly Ile Asn Leu Ser Gly 820 825 830 Gly Gin Arg Pro Asp Gin Cys Gly Pro Glu Pro Ser Thr Ser Arg Pro 835 840 845 Met Phe Val Phe Leu Asp Asp Pro Phe Ser Ala Leu Asp Val His Leu 850 855 860 Ser Asp His Leu Met Gin Ala Gly Ile Leu Glu Leu Leu Arg Asp Asp 865 870 875 880 Lys Arg Thr Val Val Leu Val Thr His Lys Leu Gin Tyr Leu Pro His 885 890 895 Ala Asp Trp Ile Ile Ala Met Lys Asp Gly Thr Ile Gin Arg Glu Gly 900 905 910 Thr Leu Lys Asp Phe Gin Arg Ser Glu Cys Gin Leu Phe Glu His Trp 915 920 925 Lys Thr Leu Met Asn Arg Gin Asp Gin Glu Leu Glu Lys Glu Thr Val 930 935 940 Met Glu Arg Lys Ala Ser Glu Pro Ser Gin Gly Leu Pro Arg Ala Met 945 950 955 960 Ser Ser Arg Asp Gly Leu Leu Leu Asp Glu Glu Glu Glu Glu Glu Glu 965 970 975 Ala Ala Glu Ser Glu Glu Asp Asp Asn Leu Ser Ser Val Leu His Gin 980 985 990 Arg Ala Lys Ile Pro Trp Arg Ala Cys Thr Lys Tyr Leu Ser Ser Ala 995 1000 1005 Gly Ile Leu Leu Leu Ser Leu Leu Val Phe Ser Gin Leu Leu Lys His 1010 1015 1020 Met Val Leu Val Ala Ile Asp Tyr Trp Leu Ala Lys Trp Thr Asp Ser 1025 1030 1035 1040 Ala Leu Val Leu Ser Pro Ala Ala Arg Asn Cys Ser Leu Ser Gin Glu 1045 1050 1055 Cys Asp Leu Asp Gin Ser Val Tyr Ala Met Val Phe Thr Leu Leu Cys 1060 1065 1070 Ser Leu Gly Ile Val Leu Cys Leu Val Thr Ser Val Thr Val Glu Trp 1075 1080 1085 Thr Gly Leu Lys Val Ala Lys Arg Leu His Arg Ser Leu Leu Asn Arg 1090 1095 1100 Ile Ile Leu Ala Pro Met Arg Phe Phe Glu Thr Thr Pro Leu Gly Ser 1105 1110 1115 1120 Ile Leu Asn Arg Phe Ser Ser Asp Cys Asn Thr Ile Asp Gin His Ile 1125 1130 1135 Pro Ser Thr Leu Glu Cys Leu Ser Arg Ser Thr Leu Leu Cys Val Ser 1140 1145 1150 Ala Leu Thr Val Ile Ser Tyr Val Thr Pro Val Phe Leu Val Ala Leu 1155 1160 1165 Leu Pro Leu Ala Val Val Cys Tyr Phe Ile Gin Lys Tyr Phe Arg Val 1170 1175 1180 Ala Ser Arg Asp Leu Gin Gin Leu Asp Asp Thr Thr Gin Leu Pro Leu 1185 1190 1195 1200 Val Ser His Phe Ala Glu Thr Val Glu Gly Leu Thr Thr Ile Arg Ala 1205 1210 1215 Phe Arg Tyr Glu Ala Arg Phe Gin Gin Lys Leu Leu Glu Tyr Thr Asp 1220 1225 1230 Ser Asn Asn Ile Ala Ser Leu Phe Leu Thr Ala Ala Asn Arg Trp Leu 1235 1240 1245 Glu Val Cys Met Glu Tyr Ile Gly Ala Cys Val Val Leu Ile Ala Ala 1250 1255 1260 Ala Thr Ser Ile Ser Asn Ser Leu His Arg Glu Leu Ser Ala Gly Leu 1265 1270 1275 1280 Val Gly Leu Gly Leu Thr Tyr Ala Leu Met Val Ser Asn Tyr Leu Asn 1285 1290 1295 Trp Met Val Arg Asn Leu Ala Asp Met Glu Ile Gin Leu Gly Ala Val 1300 1305 1310 Lys Arg Ile His Ala Leu Leu Lys Thr Glu Ala Glu Ser Tyr Glu Gly 1315 1320 1325 Leu Leu Ala Pro Ser Leu Ile Pro Lys Asn Trp Pro Asp Gin Gly Lys 1330 1335 1340 Ile Gin Ile Gin Asn Leu Ser Val Arg Tyr Asp Ser Ser Leu Lys Pro 1345 1350 1355 1360 Val Leu Lys His Val Asn Thr Leu Ile Ser Pro Gly Gin Lys Ile Gly 1365 1370 1375 Ile Cys Gly Arg Thr Gly Ser Gly Lys Ser Ser Phe Ser Leu Ala Phe 1380 1385 1390 Phe Arg Met Val Asp Met Phe Glu Gly Arg Ile Ile Ile Asp Gly Ile 1395 1400 1405 Asp Ile Ala Lys Leu Pro Leu His Thr Leu Arg Ser Arg Leu Ser Ile 1410 1415 1420 Ile Leu Gin Asp Pro Val Leu Phe Ser Gly Thr Ile Arg Phe Asn Leu 1425 1430 1435 1440 Asp Pro Glu Lys Lys Cys Ser Asp Ser Thr Leu Trp Glu Ala Leu Glu 1445 1450 1455 Ile Ala Gin Leu Lys Leu Val Val Lys Ala Leu Pro Gly Gly Leu Asp 1460 1465 1470 Ala Ile Ile Thr Glu Gly Gly Glu Asn Phe Ser Gin Gly Gin Arg Gin 1475 1480 1485 Leu Phe Cys Leu Ala Arg Ala Phe Val Arg Lys Thr Ser Ile Phe Ile 1490 1495 1500 Met Asp Glu Ala Thr Ala Ser Ile Asp Met Ala Thr Glu Asn Ile Leu 1505 1510 1515 1520 Gin Lys Val Val Met Thr Ala Phe Ala Asp Arg Thr Val Val Thr Ile 1525 1530 1535 Ala His Arg Val His Thr Ile Leu Ser Ala Asp Leu Val Met Val Leu 1540 1545 1550 Lys Arg Gly Ala Ile Leu Glu Phe Asp Lys Pro Glu Thr Leu Leu Ser 1555 1560 1565 Gin Lys Asp Ser Val Phe Ala Ser Phe Val Arg Ala Asp Lys 1570 1575 1580

Claims: WHAT IS CLAIMED IS: 1. A sulfonylurea receptor encoded by the nucleic acid sequence of SEQ ID NO: 1. 2. The sulfonylurea receptor of claim 1 selected from the group consisting of mouse, rat, and hamster sulfonylurea receptor. 3. A sulfonylurea receptor encoded by the nucleic acid sequence selected from the group consisting of SEQ ID NO: 4 and SEQ ID NO: 6. 4. The sulfonylurea receptor of claim 3 encoded by the nucleic acid sequence of SEQ ID NO: 4. 5. The sulfonylurea receptor of claim 4 further comprising SEQ ID NO: 2. 6. The sulfonylurea receptor of claim 3 encoded by the nucleic acid sequence of SEQ ID NO: 6. 7. The sulfonylurea receptor of claim 4 further comprising SEQ ID NO: 3. 8. A sulfonylurea receptor encoded by the amino acid sequence selected from the group consisting of SEQ ID NO: 5 and SEQ ID NO: 7. 9. A purified nucleic acid sequence encoding a sulfonylurea receptor selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 4, and SEQ ID NO: 6. 10. A purified amino acid sequence encoding a sulfonylurea receptor selected from the group consisting of SEQ ID NO: 5 and SEQ ID NO: 7. 11. An expression vector comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 4, and SEQ ID NO: 6. 12. A host cell capable of expressing the nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 4, and SEQ ID NO: 6. 13. A cell culture capable of expressing a sulfonylurea receptor encoded by the amino acid sequence selected from the group consisting of SEQ ID NO: 5 and SEQ ID NO: 7. 14. A protein preparation comprising a sulfonylurea receptor encoded by the amino acid sequence selected from the group consisting of SEQ ID NO: 5 and SEQ ID NO: 7. 15. A transgenic non-human mammal all of whose germ cells and somatic sells contain a recombinant sequence encoding a sulfonylurea receptor introduced into said mammal, or an ancestor of said mammal. 16. The mammal of claim 15 wherein said sequence encoding a sulfonylurea receptor is selected from the group consisting of SEQ ID NO: 1, 4, and 6. 17. A monoclonal antibody capable of binding to a sequence encoding a sulfonylurea receptor. 18. The monoclonal antibody of claim 17 wherein said sequence encoding a sulfonylurea receptor is selected from the group consisting of SEQ ID NO: 5 and 7. 19. A method of detecting persistent hyperinsulinemic hypoglycemia of infancy comprising obtaining a sample comprising patient nucleic acids from a patient tissue sample; amplifying sulfonylurea receptor specific nucleic acids from said patient nucleic acids to produce a test 5 fragment; obtaining a sample comprising control nucleic acids from a control tissue sample; amplifying control nucleic acids encoding wild type sulfonylurea receptor to produce a control fragment; 10 comparing the test fragment with the control fragment to detect the presence of a sequence difference in the test fragment, wherein a difference in said test fragment indicates persistent hyperinsulinemic hypoglycemia of infancy. 15 20. The method of claim 19 wherein a sequence difference is selected from the group consisting of a nucleic acid transition and a restriction digest pattern alteration. 21. The method of claim 19 wherein a sequence difference is a nucleic acid transition. 20 22. The method of claim 21 wherein said nucleic acid transition is a G to A transition at nucleic acid position 750 of SEQ ID NO: 26. 23. The method of claim 21 wherein a nucleic acid transition results at position 27 of SEQ ID NO: 29. 25. 24. The method of claim 19 wherein a sequence difference is a restriction digest pattern alteration. 25. The method of claim 24 wherein said restriction digest pattern alteration comprises test fragments of about 304 base pairs and about 123 base pairs 30 upon digestion with Mspl . 26. The method of claim 24 wherein said restriction digest pattern alteration comprises a test fragment of about 146 base pairs upon digestion with Neil. 27. The method of claim 19 wherein said amplification step comprises performing the polymerase chain reaction. 28. The method of claim 27 wherein the polymerase chain reaction comprises using a pair of primers, wherein on primer within said pair is selected from the group consistin of SEQ ID NOS: 16-24. 29. The method of claim 27 wherein said polymerase chain reaction comprises the use of two primers, a first primer selected from the group consisting of SEQUENCE ID NOS: 17, 18, 21, and 23, and a second primer selected from the group consisting of SEQUENCE ID NOS: 16, 19, 20, 22, and 24. 30. The method of claim 19 wherein said tissue sample is selected from the group consisting of pancreatic tissue, blood, serum, saliva, sputum, mucus, bone marrow, urine, lymph, and a tear. 31. A method of detecting persistent hyperinsulinemic hypoglycemia of infancy comprising obtaining a sample comprising patient mRNA from a patient tissue sample; reverse transcribing said mRNA into cDNA to produce patient cDNA; amplifying sulfonylurea receptor specific cDNA from said patient cDNA to produce a test fragment; obtaining a sample comprising control nucleic acids from a control tissue sample; amplifying control DNA encoding wild type sulfonylurea receptor to produce a control fragment; digesting said test fragment and said control fragment with Mspl; comparing the test fragment with the control fragment to detect test fragments having about 304 base pairs and about 123 base pairs, wherein said test fragments indicate persistent hyperinsulinemic hypoglycemia of infancy. 32. A method of detecting persistent hyperinsulinemic hypoglycemia of infancy comprising obtaining a sample comprising patient genomic DNA from a patient tissue sample; amplifying sulfonylurea receptor specific DNA from said patient genomic DNA to produce a test fragment; obtaining a sample comprising control nucleic acids from a control tissue sample; amplifying control DNA encoding wild type sulfonylurea receptor to produce a control fragment; comparing the test fragment with the control fragment to detect a test fragment having G to A transition at nucleic acid position 750 of SEQ ID NO: 26, wherein said test fragment indicates persistent hyperinsulinemic hypoglycemia of infancy. 33. A method of detecting persistent hyperinsulinemic hypoglycemia of infancy comprising obtaining a sample comprising patient mRNA from a patient tissue sample; reverse transcribing said mRNA into cDNA to produce patient cDNA; amplifying sulfonylurea receptor specific cDNA from said patient cDNA to produce a test fragment; obtaining a sample comprising control nucleic acids from a control tissue sample; amplifying control DNA encoding wild type sulfonylurea receptor to produce a control fragment; digesting said test fragment and said control fragment with Neil; and comparing the test fragment with the control fragment to detect a test fragment of about 146 base pairs wherein said test fragment indicates persistent hyperinsulinemic hypoglycemia of infancy. 34. A method of claim 32, 33, or 34, wherein said amplification step comprises performing the polymerase chain reaction. 35. A sulfonylurea receptor encoded by the nucleic acid sequence of SEQ ID NO: 26. 36. The sulfonylurea receptor of claim 35 which is a human sulfonylurea receptor. 37. A sulfonylurea receptor encoded by the amino acid sequence of SEQ ID NO: 28. 38. A purified nucleic acid sequence encoding a sulfonylurea receptor comprising the sequence of SEQ ID NO: 26. 39. A purified amino acid sequence encoding a sulfonylurea receptor comprising the sequence of SEQ ID NO: 28. 40. An expression vector comprising a nucleic acid sequence of SEQ ID NO: 26. 41. A host cell capable of expressing the nucleic acid sequence of SEQ ID NO: 26. 42. A cell culture capable of expressing a sulfonylurea receptor encoded by the amino acid sequence of SEQ ID NO: 28. 43. A protein preparation comprising a sulfonylurea receptor encoded by the amino acid sequence of SEQ ID NO: 28. 44. A transgenic non-human mammal having all or part of its own sulfonylurea receptor sequence suppressed. 45. A transgenic non-human mammal comprising a recombinant wild type sequence for all or part of the sulfonylurea receptor sequence. 46. The transgenic non-human mammal of claim 45 wherein said sulfonylurea receptor sequence is SEQ ID NO: 26. 47. A monoclonal antibody capable of binding to a sequence encoding a sulfonylurea receptor, wherein said sequence encoding a sulfonylurea receptor is SEQ ID NO: 28. 48. A diagnostic kit for detecting persistent hyperinsulinemic hypoglycemia of infancy comprising in one or more containers a pair of primers, wherein one primer within said pair is complementary to a region of the sulfonylurea receptor, wherein one of said pair of primers is selected from the group consisting of SEQ ID NOS: 16-24, a probe specific to the amplified product, and a means for visualizing amplified DNA, and optionally including one or more size markers, and positive and negative controls. 49. The diagnostic kit of claim 48 wherein said means for visualizing amplified DNA is selected from the group consisting of fluorescent stain, 32P, and biotin. 50. The sequence encoded by a SEQ ID NO selected from the group consisting of SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 24.

Inventors: BRYAN JOSEPH, BRYAN LYDIA AGUILAR, COTE GILBERT J, GAGEL ROBERT F, NELSON DANIEL A, THOMAS PAMELA M, BRYAN, JOSEPH, BRYAN, LYDIA, AGUILAR, COTE, GILBERT, J., GAGEL, ROBERT, F., NELSON, DANIEL, A., THOMAS, PAMELA, M.
Applicants: BAYLOR COLLEGE MEDICINE, UNIV TEXAS, BAYLOR COLLEGE OF MEDICINE, THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYST
Application year: 1995
Main classification: C07H15
IPC codes: A01K67, A61K38, C07H21, C07K14, C07K16, C12N5, C12N15, C12P21, C12Q1, C12R1, G01N33